Combinations of bile acids and phenylbutyrate compounds for the treatment of neurodegenerative diseases - Patents.com
A combination of TURSO and sodium phenylbutyrate addresses the limitations of current neurodegenerative disease treatments by reducing tau and amyloid-beta levels and slowing disease progression through targeted administration based on biomarker profiles, effectively improving cognitive function in patients.
Patent Information
- Application Number
- JP2024527177
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-07
- Filing Date
- 2022-11-07
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for neurodegenerative diseases such as Alzheimer's disease and progressive supranuclear palsy are inadequate, particularly for patients who do not respond to amyloid-targeted therapies, as they fail to address neuronal cell death and inflammation pathways that drive disease progression beyond mild cognitive impairment.
Administration of a combination of TURSO and sodium phenylbutyrate to patients, tailored to specific biomarker profiles such as elevated tau levels in cerebrospinal fluid, to target neuronal cell death and inflammation, thereby reducing tau and amyloid-beta levels and slowing disease progression.
The combination therapy effectively reduces tau and amyloid-beta levels, slows disease progression, and improves cognitive function in patients with neurodegenerative diseases, including Alzheimer's and progressive supranuclear palsy, by targeting neuronal cell death and inflammation pathways.
Smart Images

Figure 2024543053000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Patent Application Publication Nos. 63 / 277,007 and 63 / 404,516, filed November 8, 2021 and September 7, 2022, respectively.
[0002] Technical Field This disclosure relates generally to compositions and methods for treating a variety of disorders. [Background technology]
[0003] Neurodegenerative diseases of the central nervous system (CNS) cause progressive loss of neuronal structure and function and are devastating to patients and their families. These neurodegenerative diseases include, for example, multiple sclerosis (MS), various types of tauopathies (e.g. Alzheimer's disease), Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and stroke. Due to the complexity of the CNS, many of these diseases are so far poorly understood.
[0004] Alzheimer's disease is characterized by loss of neurons and synapses in the cerebral cortex and atrophy of the temporal and parietal lobes. Abnormal aggregation of amyloid plaques and neurofibrillary tangles are the major histopathological findings of AD and are the target of many clinical trials. However, recent studies suggest that reducing amyloid may not halt the progression of the disease after AD has progressed beyond the mild cognitive impairment (MCI) stage. At this stage, neuronal cell death and inflammatory pathways may contribute more to disease progression than amyloid or tau. This suggests that there may be a group of patients who do not respond to amyloid-targeted therapies but would benefit from treatments that target cell death and inflammation. Summary of the Invention
[0005] In some aspects, the disclosure provides a method of treating at least one symptom of progressive supranuclear palsy (PSP), comprising administering to a subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate.
[0006] In another aspect, also provided herein is a method of treating at least one symptom of Alzheimer's disease (AD) in a human subject, comprising administering to the human subject a pharma- cerebrospinal fluid (CSF) pharma- cerebrospinal fluid (CSF) pharma- ceutical of a ...
[0007] In another aspect, provided herein is a method of slowing the progression of Alzheimer's disease (AD) in a human subject having one or more symptoms of AD, comprising administering to the subject a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
[0008] In another aspect, provided herein is a method of increasing survival time of a human subject having one or more symptoms of Alzheimer's disease, comprising administering to the subject a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
[0009] In another aspect, the present invention provides a method for reducing CSF total tau levels, reducing CSF phosphorylated tau levels, and reducing CSF Aβ levels in a human subject having one or more symptoms of Alzheimer's disease. 1-42 / Aβ 1-40Provided herein are methods of increasing CSF 8-OHDG levels or increasing CSF 8-OHDG levels comprising administering to a subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate. In some embodiments, the phosphorylated tau species is phosphorylated tau 181.
[0010] In another aspect, provided herein is a method for treating and / or preventing a tauopathy in a human subject, comprising administering to the human subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate. In some embodiments, the subject has a baseline CSF total tau level of about 300 pg / mL or greater. In some embodiments, the tauopathy is progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD-TAU), corticobasal degeneration, Pick's disease, argyrophilic grain disease, postencephalitic parkinsonism, chronic traumatic encephalopathy, primary age-related tauopathy, stroke, traumatic brain injury, or Alzheimer's disease. In some embodiments, the tauopathy is progressive supranuclear palsy.
[0011] In another aspect, there is also provided herein a method for treating and / or preventing a condition associated with amyloidosis in a human subject, the method comprising administering to the human subject a pharma- ceutical effective amount of a combination of TURSO and sodium phenylbutyrate.
[0012] In another aspect, a method is provided herein comprising administering a pharma- ceutically effective amount of a combination of TURSO and sodium phenylbutyrate to a human subject at risk of developing Alzheimer's disease. In some embodiments, the subject is determined to be at risk of developing Alzheimer's disease by assessing the level of a biomarker in a biological sample obtained from the subject. In some embodiments, the biomarker is total tau or phosphorylated tau. In some embodiments, the biological sample is CSF. In some embodiments, the subject carries one or more copies of the APOE ε4 allele. In some embodiments, the subject carries one or more mutations in at least one gene selected from the group consisting of APP, PSEN1, and PSEN2.
[0013] In another aspect, provided herein is a method of reducing CSF FABP3, neurogranin, YKL-40 or IL-15 levels in a human subject having one or more symptoms of Alzheimer's disease, comprising administering to the subject a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
[0014] In another aspect, provided herein is a method for treating at least one symptom of a neurodegenerative disease characterized by elevated levels of total tau or phosphorylated tau, comprising administering to a subject a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
[0015] In another aspect, provided herein is a method of treating at least one symptom of a neurodegenerative disease characterized by elevated levels of YKL-40, comprising administering to a subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate. In some embodiments, the neurodegenerative disease is Alzheimer's disease. In some embodiments, the neurodegenerative disease is PSP. In some embodiments, the neurodegenerative disease is cerebral amyloid angiopathy, corticobasal degeneration, Creutzfeldt-Jakob disease, dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17, frontotemporal lobar degeneration (FTLD-TAU), corticobasal degeneration, Pick's disease, argyrophilic grain disease, postencephalitic parkinsonism, chronic traumatic encephalopathy, primary age-related tauoma. The following conditions are considered to be associated with myocardial infarction, including myocardial infarction, stroke, traumatic brain injury, Gerstmann-Sträussler-Scheinker disease, Hallervorden-Spatz disease, inclusion body myositis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C, non-Guam motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, subacute sclerosing panencephalitis, dementia with isolated neurofibrillary tangles, multi-infarct dementia, or ischemic stroke.
[0016] In another aspect, provided herein is a method of decreasing CSF YKL-40 levels, decreasing Ptpn1 levels, or increasing CSF 33 kDa tau / 55 kDa tau in a human subject having one or more symptoms of PSP, comprising administering to the subject a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
[0017] In some embodiments of the methods described herein, TURSO and sodium phenylbutyrate are administered once a day or twice a day. In some embodiments of the methods described herein, TURSO is administered to the subject at a dose of about 5 mg / kg to about 100 mg / kg. In some embodiments of the methods described herein, sodium phenylbutyrate is administered to the subject at a dose of about 10 mg / kg to about 400 mg / kg. In some embodiments of the methods described herein, TURSO is administered at about 0.5 to about 5 g per day. In some embodiments of the methods described herein, sodium phenylbutyrate is administered at about 0.5 g to about 10 g per day. In some embodiments of the methods described herein, the methods include administering 1 g of TURSO and 3 g of sodium phenylbutyrate to the subject once a day or twice a day. In some embodiments of the methods described herein, the methods include administering to the subject 1 g of TURSO once per day and 3 g of sodium phenylbutyrate once per day for about 14 days or more, followed by administering to the subject about 1 g of TURSO twice per day and 3 g of sodium phenylbutyrate twice per day. In some embodiments of the methods described herein, the TURSO and sodium phenylbutyrate are administered orally. In some embodiments of the methods described herein, the TURSO and sodium phenylbutyrate are formulated as a single powder.
[0018] In some embodiments of the methods described herein, the methods further comprise administering to the subject one or more additional therapeutic agents, hi some embodiments, the therapeutic agent is tacrine, rivastigmine, galantamine, donepezil, or memantine.
[0019] In some embodiments of the methods described herein, the methods further include administering to the human subject a plurality of foods, including solid foods or liquid foods. In some embodiments of the methods described herein, the human subject is about 18 years of age or older.
[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.
[0021] It is recognized that some features of this disclosure, which are described in the context of separate embodiments for clarity, may also be provided in combination in a single embodiment. Conversely, various features of this disclosure, which are described in the context of a single embodiment for brevity, may also be provided separately or in any suitable subcombination. All combinations of the embodiments related to this disclosure are specifically embraced in this disclosure and disclosed in this specification as if each combination was individually and explicitly disclosed in this specification. Furthermore, all subcombinations of the various embodiments and elements thereof are specifically embraced in this disclosure and disclosed in this specification as if each such subcombination was individually and explicitly disclosed in this specification.
[0022] All publications, patent applications, patents, and other references mentioned in this specification are incorporated by reference in their entirety. In case of conflict, this specification, including definitions, will control. Furthermore, the materials, methods, and examples are illustrative only and not limiting. Other features and advantages of the invention will be apparent from the following detailed description and claims. [Brief description of the drawings]
[0023] [Figure 1] FIG. 1 is a bar graph showing hippocampal Aβ42 levels upon treatment with vehicle or AMX0035. [Diagram 2] Figure 2 is a diagram of the overall study workflow. [Diagram 3] FIG. 3 is a chart summarizing the levels of various biomarkers of AD. [Figure 4A-4B] 4A and 4B are schematics of the enrolled participants. [Diagram 5] Figure 5 is a chart of baseline characteristics. [Figure 6] Figure 6 is a chart of baseline characteristics for various cognitive tests. [Figure 7] FIG. 7 is a chart showing baseline levels of CSF biomarkers. [Figure 8] FIG. 8 shows ApoEε4 status. [Figure 9] FIG. 9 is a graph showing an overview of subjects who were excluded, withdrawn or discontinued early. [Figure 10] Figure 10 shows an overview of adverse events in the intention-to-treat population. [Figure 11] FIG. 11 is a chart of the calculated GST for the intent-to-treat LZCF population. [Figure 12A-12B] Figures 12A and 12B show data for secondary efficacy endpoints in the intent-to-treat (LZCF) population. [Figure 13] FIG. 13 shows tau and phosphorylated tau levels in the intent-to-treat (LZCF) population. [Figure 14] FIG. 14 shows data on Aβ1-40, Aβ1-42 and Aβ1-42 / Aβ1-40 levels in the intent-to-treat (LZCF) population. [Figure 15] FIG. 15 is a bar graph showing CSF 8-OHdG levels in the intent-to-treat (LZCF) population. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] Detailed Description Provided herein are compositions and methods for treating neurodegenerative diseases, such as multiple sclerosis (MS), various types of tauopathies (e.g., Alzheimer's disease), Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and stroke. Age-related neurodegenerative diseases are characterized by specific major protein inclusions accompanied by neuronal loss and gliosis.
[0025] A major class of neurodegenerative diseases, collectively referred to as tauopathies, are characterized at autopsy by intracellular inclusions composed of abnormally modified microtubule-associated protein tau. Tauopathies are disorders characterized by abnormal levels of tau in the cells, tissues, or bodily fluids of an individual. In some cases, tauopathies are characterized by the presence of elevated (higher than normal) levels of tau or tau polypeptides and / or pathological forms of tau in cells, tissues, or bodily fluids. For example, in some cases, tauopathies are characterized by the presence of elevated levels of tau or tau polypeptides and / or pathological forms of tau in brain tissue and / or cerebrospinal fluid. A "higher than normal" level of tau in a cell, tissue, or bodily fluid indicates that the level of tau in the tissue or fluid is higher than that of a normal control, e.g., higher than that of a normal control for an individual or a population of individuals of the same age group. In other cases, tauopathies are characterized by the presence of lower than normal levels of tau in cells, tissues, or bodily fluids. A "lower than normal" level of tau in a tissue or bodily fluid indicates that the level of tau in the cell, tissue or bodily fluid is lower than that of a normal control, e.g., lower than that of a normal control for an individual or a population of individuals of the same age group. In some cases, an individual suffering from a tauopathy exhibits one or more additional symptoms of the tauopathy (e.g., cognitive decline).
[0026] Examples of tauopathies include progressive supranuclear palsy (PSP), cerebral amyloid angiopathy, corticobasal degeneration, Creutzfeldt-Jakob disease, dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down syndrome, frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17, frontotemporal lobar degeneration (FTLD-TAU), corticobasal degeneration, Pick's disease, argyrophilic grain disease, postencephalitic parkinsonism, chronic traumatic encephalopathy, primary age-related tauopathy, and cerebral These include, but are not limited to, stroke, traumatic brain injury, Gerstmann-Sträussler-Scheinker disease, Hallervorden-Spatz disease, inclusion body myositis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C, non-Guam motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, subacute sclerosing panencephalitis, neurofibrillary tangle-isolated dementia, multi-infarct dementia, ischemic stroke, and Alzheimer's disease (e.g. Irwin DJ. Tauopathies as clinicopathological entities. Parkinsonism Relat Disord. 2016;22 Suppl 1(0 1):S29-S33. doi:10.1016 / j.parkreldis.2015.09.020).
[0027] Alzheimer's disease (AD) results in a progressive decline in cognitive function, including loss of declarative and procedural memory, diminished learning ability, reduced attention span, and severe impairment of thinking ability, judgment, and decision-making. Alzheimer's disease is characterized by loss of neurons and synapses in the cerebral cortex and atrophy of the temporal and parietal lobes. Abnormal aggregation of amyloid plaques and neurofibrillary tangles are the two major histopathological findings of AD and have been the targets of many recent clinical trials. However, recent studies suggest that once AD has progressed beyond the mild cognitive impairment (MCI) stage, reducing amyloid is less likely to halt the pathology. By this point, neuronal cell death and inflammatory pathways may be contributing factors in disease progression beyond either amyloid or tau. This suggests that there is a significant patient population that cannot respond to amyloid-targeted therapy alone, but could benefit from treatments that target cell death and inflammation.
[0028] The terms "Alzheimer's disease" and "AD" are used interchangeably herein and include all classifications of Alzheimer's disease known in the art. This disclosure provides methods of treating at least one symptom of AD, methods of reducing AD disease progression; and methods of reducing the deterioration of, maintaining, or improving one or more physical functions affected by AD. Also provided are methods of improving one or more biomarkers affected in AD patients (e.g., reducing levels of total tau and phosphorylated tau, both of which are elevated in AD). The method includes administering a bile acid or a pharmaceutically acceptable salt thereof, and a phenylbutyrate compound.
[0029] The term "progressive supranuclear palsy" or "PSP" refers to a neurological disorder of unknown cause that progressively destroys cells in many regions of the brain, including the accumulation of abnormal aggregates of the microtubule-associated protein tau that give rise to insoluble paired helical filaments, including the gradual deterioration of neurons and glial cells in the midbrain and frontal cortex that exhibit insoluble helical filaments of tau protein.
[0030] PSP begins with a prodromal phase during which neuropathological abnormalities increase. The patient then develops a sporadic symptom suggestive of PSP (soPSP). In any of the methods described herein, the PSP may be classical PSP-Richardson syndrome (PSP-RS), PSP-parkinsonism (PSP-P), PSP-corticobasal syndrome (PSP-CBS), PSP-progressive non-fluent aphasia (PSP-PNFA), or PSP-pure akinesia with freezing of gait (PSP-PAGF) (Ling et al., J. Mov. Discord. 9(1):3-13, 2016). In some embodiments of the methods described herein, the subject may have previously been diagnosed or identified as suffering from PSP (e.g., PSP-RS, PSP-P, PSP-PNFA, or PSP-PAGF). In some embodiments of the methods described herein, the subject may have previously been identified as being at high risk for developing PSP (e.g., a subject who has a genetically related family member (e.g., a parent, grandparent, aunt, uncle, or sibling) identified or diagnosed as having PSP). In some embodiments of the methods described herein, the subject may have previously been identified or diagnosed as having prodromal PSP or an indication of PSP.
[0031] After onset, symptoms of PSP rapidly and progressively worsen, and subjects diagnosed with PSP can become severely disabled within five years and die within six years.
[0032] Additionally, compositions and methods are provided herein for treating conditions associated with amyloidosis, in some cases. Amyloid fibrils are protein polymers containing identical monomeric units (homopolymers). Functional amyloids play beneficial roles in various physiological processes (e.g. long-term memory formation, gradual release of stored peptide hormones). Amyloidosis is a clinical disorder caused by the extracellular and / or intracellular deposition of insoluble abnormal amyloid fibrils that alter the normal function of tissues. Only 10% of amyloidosis deposits are components such as glycosaminoglycans (GAGs), apolipoprotein E (apoE) and serum amyloid P component (SAP), while almost 90% of the deposits consist of amyloid fibrils formed by the aggregation of misfolded proteins. These proteins either arise from proteins expressed by cells at the site of deposition (localized) or are precipitated systemically after production at local sites (systemic). In humans, approximately 23 different related proteins are known to form amyloid fibrils in vivo.
[0033] Many mechanisms of protein function contribute to amyloid formation, including "non-physiological proteolysis, defective or absent physiological proteolysis, mutations and uncharacterized pathways involving altered thermodynamic or kinetic properties."
[0034] Where ranges are described, it is understood that, to the first decimal place of the unit of the lower limit unless otherwise clear from the context, each intervening value between the upper and lower limits of that range, and any other stated or intervening value in that stated range, is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the scope of this disclosure, provided that any limit in a stated range is specifically excluded. Where a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure.
[0035] Certain ranges provided in this specification are preceded by the term "about." The term "about" is used in this specification to literally support the exact number that is followed by it, as well as a number that is close to or approximately the number that is followed by the term. In determining whether a number is close to or approximately a specifically recited number, the unrecited near or approximate number may be a number that provides a substantially equivalent number to the specifically recited number in the context provided.
[0036] Unless otherwise defined, all technical terms, symbols, and other scientific or technical terms used in this specification are intended to have the meanings commonly understood by those of ordinary skill in the art to which this application pertains. In some cases, terms with commonly understood meanings are defined in this specification for clarity and / or ease of reference, and the inclusion of such definitions in this specification should not necessarily be construed as representing a substantial difference with respect to what is commonly understood in the art.
[0037] Diagnosis and Target Selection Alzheimer's disease In one aspect, the disclosure provides a method of treating at least one symptom of AD in a human subject. Also provided herein are methods of slowing AD disease progression (e.g., reducing the rate of AD disease progression); treating dementia or mild cognitive impairment (MCI) (e.g., AD dementia or MIC); and reducing the progressive decline in cognitive function, including loss of declarative and procedural memory, diminished learning ability, reduced attention span, and severe impairment of thinking ability, judgment, and decision-making. Also provided are methods of increasing the survival time of a human subject having one or more symptoms of AD. Also provided are methods of improving one or more affected biomarkers in a human subject with AD (e.g., reducing levels of total tau and phosphorylated tau, both of which may be elevated in AD). Any of the methods described herein can include administering to the subject a bile acid or a pharma- ceutically acceptable salt thereof (e.g., any of the bile acids or pharma- ceutically acceptable salts thereof described herein or known in the art) and a phenylbutyrate compound (e.g., any of the phenylbutyrate compounds described herein or known in the art).
[0038] Any of the human subjects in the methods described herein may exhibit one or more symptoms associated with AD or may have been diagnosed with AD. In some embodiments, the subject may be suspected of having and / or at risk for developing AD.
[0039] Some embodiments of the methods described herein can further include determining that the human subject has or is at risk for developing AD, diagnosing the human subject as having or at risk for developing AD, or selecting a human subject as having or at risk for developing AD.
[0040] In some embodiments of the methods described herein, the human subject has been exhibiting one or more symptoms of AD for about 24 months or less (e.g., about 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 month or week or less). In some embodiments, the subject has been exhibiting one or more symptoms of AD for about 36 months or less (e.g., about 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, or 25 months or less).
[0041] In some cases, the human subject has been diagnosed with AD. For example, the subject may have been diagnosed with AD for about 24 months or less (e.g., about 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 month or less). For example, the subject may have been diagnosed with AD for 1 week or less, or on the same day that the treatment of the disclosure is administered. The subject may have been diagnosed with AD for more than about 24 months (e.g., more than about 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, or 80 months). Methods for diagnosing AD are known in the art. For example, the subject may be diagnosed based on clinical history, family history, physical or neurological examination. The subject may be confirmed or identified as suffering from AD, for example, by a medical professional. More than one person may be involved in a diagnosis. For example, if a sample is obtained from a subject as part of a diagnosis, a first person may obtain the sample from the subject and a second person may test the sample. In some embodiments of human subjects described herein, the subject is diagnosed, selected, or referred by a physician (e.g., a general practitioner).
[0042] In general, the diagnosis of AD is well known in the art (see, e.g., Alzheimer's Disease Diagnostic Guidelines published by the NIH's National Institute on Aging, https: / / www.nia.nih.gov / health / alzheimers-disease-diagnostic-guidelines, incorporated herein by reference). In some embodiments, the subject has a diagnosis of "probable Alzheimer's Disease" or "mild cognitive impairment" with major amnesic symptoms (lack of learning and recall of recently learned information). In some cases, the diagnosis of "probable Alzheimer's Disease" or "mild cognitive impairment" is based on a score received from a cognitive test (e.g., ADAS-Cog, MoCA, DSRS, MADCOMS, FAQ, or NPI-Q) accompanied by the presence of one or more biomarkers supporting the syndrome being likely due to AD pathology (amyloid PET (i.e., presence of amyloid plaques), AD biomarkers in CSF (described in more detail below and in Example 1), FDG-PET, or vMRI).
[0043] ADAS-Cog The ADAS-Cog has been validated and is widely used as the primary cognitive outcome measure in AD pharmacotherapy studies. It is a psychometric instrument that assesses memory (immediate and delayed word recall, word recognition), attention (digit cancellation), reasoning (following commands), language (naming, comprehension), orientation, ideational (placing a letter in an envelope) and constructional (copying a geometric structure), as well as executive function (completion of a maze). Scoring ranges from 0 to 90, with higher scores indicating greater impairment.
[0044] MoCA The Montreal Cognitive Assessment (MoCA) is a questionnaire commonly used in clinical trials and research settings to measure the level of cognitive impairment. The MoCA measures five areas of cognitive function: orientation, visuospatial, attention and calculation, recall, and language. The MoCA takes about 10 minutes to complete. In some cases, AD patients have a baseline MoCA score of 8-30, e.g., greater than 8.
[0045] DSRS The DSRS is a brief, 12-item informant-administered questionnaire that assesses the functional ability of subjects. 44The DSRS comprehensively characterizes daily activities that may be affected by neurodegenerative diseases. The DSRS has strong concurrent validity and is designed in a multiple choice format that includes parallel material covered in the Clinical Dementia Rating Scale (CDR), a commonly used dementia staging instrument (Moelter, ST, Glenn, MA, Xie, SX, Chittams, J., Clark, CM, Watson, M., & Arnold, SE (2015). The Dementia Severity Rating Scale predicts clinical dementia rating sum of boxes scores. Alzheimer Dis Assoc Disord, 29(2), 158-160. doi:10.1097 / WAD.0000000000000031).The DSRS is an extremely reliable scale with interrater reliability of >90% and internal consistency of Cronbach's alpha >0.70 (Rikkert, MG, Tona, KD, Janssen, L., Burns, A., Lobo, A., Robert, P., . . . Waldemar, G. (2011). Validity, reliability, and feasibility of clinical staging scales in dementia: a systematic review. Am J Alzheimers Dis Other Demen, 26(5), 357-365. doi:10.1177 / 1533317511418954) and has been shown to accurately distinguish cognitively normal individuals from subjects with dementia of various severities (Clark, CM, & Ewbank, DC (1996). Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord, 10(1), 31-39;Mitchell, JC, Dick, MB, Wood, AE, Tapp, AM, & Ziegler, R. (2015). The utility of the Dementia Severity Rating Scale in differentiating mild cognitive impairment and Alzheimer disease from controls. Alzheimer Dis Assoc Disord, 29(3), 222-228. doi:10.1097 / WAD.0000000000000057).Furthermore, the DSRS allows for a wide range of scores (total score 0-54) that enhances sensitivity for detecting incremental changes in functional ability over time, making it suitable for quantifying a wide range of functional impairments without being hindered by floor effects seen in more advanced disease (Xie, SX, Ewbank, DC, Chittams, J., Karlawish, JH, Arnold, SE, & Clark, CM (2009). Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale. Alzheimer Dis Assoc Disord, 23(3), 268-274. doi:10.1097 / WAD.0b013e318194a324). The DSRS takes approximately 5 minutes to administer, requires minimal rater training, and can be administered over the phone to subjects if necessary.
[0046] MADCOMS ADAS-Cog14 does not specifically target mild / moderate stages of AD. The Mild / Moderate AD Composite Scale (MADCOMS) was pre-optimized for two separate groups: mild AD (baseline MMSE 20-26) and moderate AD (baseline MMSE 14-19). A weighted composite value was derived from the individual items of ADAS-Cog, MMSE and CDR using PLS regression (S. Hendrix ADPD 2021).
[0047] Moderate MADCOM= Comprehension x 0.36390157 + Paraphrasing x 0.10931155 + Ideation x 0.42535667 + Object Naming x 0.65626894 + Word Recognition x 0.05159097 + Word Recall x 1.0698506 + Oral Language x 0.3019936 + Home Life and Hobbies x 0.66529282 + Memory x 0.12277257 - Place Orientation x 0.23001218 - Spelling Backwards x 0.07980965 - Language and Performance x 0.18954955 Mild MADCOM= Paraphrasing x 0.39065568 + Word Recall x 1.14084544 + Oral Language x 1.09895590 + Personal Care x 0.60865765 + Community Activities x 0.15706995 + Judgment x 1.40920029 - Time Orientation x 0.27596627
[0048] FAQ The FAQ is a brief informant-administered rating scale used to determine a subject's level of functional independence in performing instrumental activities of daily living (IADLs); repeated assessments are useful for monitoring performance in these areas over time. 47(See below for scale). The FAQ total score (0-30) reflects the sum of 10 ordinal ratings (0=fully independent, 1=doing it on my own, with some difficulty, 2=needing assistance, 3=dependence) assessing a range of functional activities (i.e., preparing a balanced meal, money management skills, and shopping), with higher scores indicating greater levels of dependency. For activities that an individual would not normally perform, a score of 1 was assigned if the informant believed the subject would not be able to complete the task upon request, or a score of 0 was assigned if the informant believed the subject could perform the task as required. Overall, the FAQ is a sensitive marker of functional impairment among individuals with a range of dementia severity (see, e.g., Castilla-Rilo, J., Lopez-Arrieta, J., Bermejo-Pareja, F., Ruiz, M., Sanchez-Sanchez, F., & Trincado, R. (2007). Instrumental activities of daily living in the screening of dementia in population studies: a systematic review and meta-analysis. Int J Geriatr Psychiatry, 22(9), 829-836. doi:10.1002 / gps.1747) and has been shown to distinguish mild cognitive impairment from early Alzheimer's disease with 80% sensitivity and 87% specificity (see, e.g., Teng, E., Becker, BW, Woo, E., Knopman, DS, Cummings, JL, & Lu, PH (2010). Utility of the functional activities questionnaire for distinguishing Mild cognitive impairment from very mild Alzheimer disease. Alzheimer Dis Assoc Disord, 24(4), 348-353. See doi:10.1097 / WAD.0b013e3181e2fc84.The FAQ has demonstrated high reliability (greater than 0.90), takes approximately 5 minutes to complete, and requires limited rater training to administer (see, e.g., Pfeffer, RI, Kurosaki, TT, Harrah, CH, Jr., Chance, JM, & Filos, S. (1982). Measurement of functional activities in older adults in the community. J Gerontol, 37(3), 323-329).
[0049] NPI-Q The Neuropsychiatric Inventory (NPI) measures behavioral symptoms associated with dementia and was used to assess changes in psychological status. There are several versions of the NPI, including the NPI-Questionnaire (NPI-Q), NPI-Clinician (NPI-C) and NPI-Nursing Home (NPI-NH). All test 12 subdomains of behavioral functioning, including hallucinations, delusions, agitation, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, abnormal motor activity, feeding disorders and changes in nocturnal behavior.
[0050] A / T / N system In some cases, the "A / T / N" system is used to classify patients with AD based on biomarkers. In this system, the seven major AD biomarkers are divided into three binary categories based on the nature of the pathophysiology they each measure. "A" refers to the value of the β-amyloid biomarker (amyloid PET or CSF Aβ42); "T" refers to the value of the tau biomarker (CSF phospho-tau or tau PET); "N" refers to the value of the neurodegeneration or neuronal injury biomarker ( 18FA / T / N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016 Aug 2;87(5):539-47 and Kalmady et al. 2014.
[0051] Neuroimaging Neuroimaging studies may be used to diagnose subjects at risk for or afflicted with AD. Methods for measuring hippocampal volume, gray matter, mean cortical thickness, number of white matter lesions, white matter lesion volume, ventricular volume, medial temporal lobe atrophy as assessed by magnetic resonance imaging (MRI), and 18 Functional neuroimaging using F-fluorodeoxyglucose-positron emission tomography (FDG-PET), single photon emission computed tomography (SPECT), diffusion tensor imaging (DIT), amyloid imaging, and computed tomography (CT) has demonstrated reduced glucose metabolism in the temporoparietal regions. See, e.g., Ferreira LK, Busatto GF. Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. Clinics (Sao Paulo). 2011;66 Suppl 1(Suppl 1):19-24. doi:10.1590 / s1807-59322011001300003.
[0052] CSF AD biomarkers In some embodiments, subjects may be selected based on the level of certain CSF biomarkers. The concentration of one or more biomarkers, such as total tau (t-tau), phosphorylated tau 181 (p-tau 181), neurofilament light chain (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1) / PGP9.5, glial fibrillary acidic protein (GFAP), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and soluble insulin receptor (sIR), may be elevated in the CSF of AD patients. Aβ 1-42 , Aβ 1-42 / Aβ 1-40 and leptin may be decreased in the CSF of AD patients. 24-hydroxycholesterol (24-OHC) may be elevated in early AD and decreased in advanced AD.
[0053] Any of the above biomarkers can be detected, for example, in cerebrospinal fluid, plasma and / or serum using methods known in the art (see, e.g., Blennow K, Mattsson N, Schoell M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015;36:297-309. https: / / doi.org / https: / / doi.org / 10.1016 / j.tips.2015.03.002;Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med 2016;8:1184-96. https: / / doi.org / https: / / doi.org / 10.15252 / emmm.201606540;Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90:870 LP - 881. https: / / doi.org / 10.1136 / jnnp-2018-320106;Constantinescu R, Krysl D, Bergquist F, Andren K, Malmestroem C, Asztely F, et al. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.Eur J Neurol 2016;23:796-806. https: / / doi.org / https: / / doi.org / 10.1111 / ene.12942;Hall S, Oehrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and / or Parkinsonian Disorders. Arch Neurol 2012;69:1445-52. https: / / doi.org / 10.1001 / archneurol.2012.1654;Petersen A, Gerges NZ. Neurogranin regulates CaM dynamics at dendritic spines. Sci Rep 2015;5:11135. https: / / doi.org / 10.1038 / srep11135;Portelius E, Zetterberg H, Skillbaeck T, Toernqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain 2015;138:3373-85. https: / / doi.org / 10.1093 / brain / awv267;Liu W, Lin H, He X, Chen L, Dai Y, Jia W, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment. Transl Psychiatry 2020;10:125. https: / / doi.org / 10.1038 / s41398-020-0801-2;Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and / or oxidative DNA damage contributes to the neurodegenerative process. J Neurol 2010;257:399-404. https: / / doi.org / 10.1007 / s00415-009-5333-x;Gerena Y, Menendez-Delmestre R, Skolasky RL, Hechavarria RM, Perez S, Hilera C, et al. Soluble insulin receptor as a source of insulin resistance and cognitive impairment in HIV-seropositive women. J Neurovirol 2015;21:113-9. https: / / doi.org / 10.1007 / s13365-014-0310-2;Gerena Y, Menendez-Delmestre R, Delgado-Nieves A, Velez J, Mendez-Alvarez J, Sierra-Pagan JE, et al. Release of Soluble Insulin Receptor From Neurons by Cerebrospinal Fluid From Patients With Neurocognitive Dysfunction and HIV Infection. Front Neurol 2019;10:285. https: / / doi.org / 10.3389 / fneur.2019.00285;Hughes TM, Rosano C, Evans RW, Kuller LH.Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimers Dis 2013;33:891–911. https: / / doi.org / 10.3233 / JAD-2012-121585;Papassotiropoulos A, Luetjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000;11:1959-62. Cuadrado E, Rosell A, Penalba A, Slevin M, Alvarez-Sabin J, Ortega-Aznar A, et al. Up-regulation of vascular MMP-9 / TIMP-2 and neuronal MMP-10 in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res 2009;8:3191–7. https: / / doi.org / 10.1021 / pr801012x;Duits FH, Hernandez-Guillamon M, Montaner J, Goos JDC, Montanola A, Wattjes MP, et al. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. J Alzheimers Dis 2015;48:711–20. https: / / doi.org / 10.3233 / JAD-143186 , Google Scholar
[0054] In some cases, the ratio of a subject in any of the methods described herein is obtained and (as measured in CSF) Aβ 1-42 / Aβ 1-40 The Aβ may be determined by measuring the ratio. 1-42 / Aβ 1-40 The ratio is an important marker in Alzheimer's disease and is decreased in CSF in patients with Alzheimer's disease. 1-42 / Aβ 1-40 The researchers showed that the ratio is a more reliable indicator of AD than other representative AD biomarkers, and suggested that the ratio could be used to distinguish types of dementia. For example, Hansson, O., Lehmann, S., Otto, M. et al. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42 / 40 ratio in the diagnosis of Alzheimer's Disease. Alz Res Therapy 11, 34 (2019). https: / / doi.org / 10.1186 / s13195-019-0485-0 and James D. Doecke, Virginia Perez-Grijalba, Noelia Fandos, Christopher Fowler, Victor L. Villemagne, Colin L. Masters, Pedro Pesini, Manuel Sarasa, for the AIBL Research Group, “Total Aβ42 / Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis,” Neurology Apr 2020, 94 (15) e1580-e1591;DOI: See 10.1212 / WNL.0000000000009240, incorporated herein by reference.
[0055] The subject in the methods described herein may have a total CSF tau level of about 100 pg / mL or more. In some embodiments, the subject has a total CSF tau level of about 300 pg / mL or more (e.g., about 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 170 0, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 3000, 3200, 3500, 3800 or 4000 pg / mL or more).
[0056] In the methods described herein, the subject's CSF may have a phosphorylated tau (e.g., phosphorylated tau 181, phosphorylated tau 199 and / or phosphorylated tau 231) level of about 30 pg / mL or more. In some embodiments, the subject's CSF has a phosphorylated tau (e.g., phosphorylated tau 181) level of about 70 pg / mL or more (e.g., about 75, 100, 125, 150, 175, or 200 pg / mL or more).
[0057] Aβ in the CSF of a subject in the methods described herein 1-42 The level may be about 1000 pg / mL or less (e.g., about 500 pg / mL or less). In some embodiments, the Aβ level in the CSF of the subject is 1-42 The level is about 500 pg / mL or less (e.g., about 450, 400, 350, 300, 250, 200, 150, 100, 50, or 25 pg / mL or less).
[0058] The method described herein is directed to determining whether total CSF tau and CSF Aβ are present in the subject. 1-42 (i.e., total tau / Aβ 1-42) may be about 0.5 or greater. In some embodiments, the ratio is about 0.9 or greater (e.g., 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 or 7.0 or more).
[0059] A subject may be identified as suffering from or at risk for developing AD based on genetic analysis. Researchers have not found a specific gene that directly causes late-onset Alzheimer's disease. However, having a genetic variant of the Apolipoprotein E (APOE) gene on chromosome 19 may increase a person's risk. The APOE gene is involved in making proteins that help keep cholesterol and other types of fats in the bloodstream. APOEε4 increases the risk of Alzheimer's disease and is also associated with an earlier age of onset of the disease. Having one or two APOEε4 alleles increases the risk of developing Alzheimer's disease. About 25% of people carry one copy of APOEε4 and 2-3% carry two copies. APOEε4 is called a risk factor gene because it increases a person's risk of developing the disease. APOEε2 is relatively rare (leading to an amino acid change of arginine to cysteine at position 158) and may confer some protection against the disease. The most common allele, APOEε3, neither lowers nor increases risk and appears to play a neutral role in the disease.For example, Chu LW. Hong Kong Med J. 2012;18:228-237;Belloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron. 2019 Mar 6;101(5):820-838;Reiman, EM, Arboleda-Velasquez, JF, Quiroz, YT et al. Exceptionally low likelihood of Alzheimer's dementia in APOEε2 homozygotes from a 5,000-person neuropathological study. Nat Commun 11, 667 (2020);Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, Fryer JD, Heckman See MG, Bu G. APOEε2 is associated with longevity independent of Alzheimer's disease. Elife. 2020 Oct 19;9:e62199, which are incorporated by reference herein.
[0060] Early-onset Alzheimer's disease is rare, accounting for less than 10% of all people with Alzheimer's disease. It usually occurs in people in their 30s to mid-60s. Some cases are caused by inherited changes in one of three genes. The three single gene mutations associated with early-onset Alzheimer's disease are (1) amyloid precursor protein (APP) on chromosome 21; (2) presenilin 1 (PSEN1) on chromosome 14; or (3) presenilin 2 (PSEN2) on chromosome 1. Mutations in these genes result in the production of abnormal proteins associated with the disease. Each of these mutations plays a role in the degradation of APP. This degradation is part of the process that produces the harmful form of amyloid plaques that are the hallmark of Alzheimer's disease. Genetic variants associated with AD may affect the rate of AD progression in a subject, the pharmacokinetics of an administered compound in a subject, and / or the efficacy of an administered compound to a subject.
[0061] The effects of AD on the anti-inflammatory drug are slightly higher than those of Mintun MA, Donanemab in Early View Article PubMed Google Scholar Belloy ME, Napolioni V, Greicius MD 6;101(5):820-838;Reiman, EM, Arboleda-Velasquez, JF, Quiroz, YT et al [ PMC free article ] [ PubMed ] [ Cross Ref ] 2020 Oct 19;9:e62199;Trombetta BA, Carlyle BC, Koenig AM, Shaw LM, Trojanowski JQ, Wolk DA, Locascio JJ, Arnold SE.2018;and Vasunilashorn SM, Ngo LH, Dillon ST, Fong TG, Carlyle BC, Kivisaekk P, Trombetta BA, Vlassakov KV, Kunze LJ, Arnold SE, Xie Z, Inouye SK, Libermann TA, Marcantonio ER;RISE Study Group. Plasma and cerebrospinal fluid inflammation and the blood-brain barrier in older surgical patients: the Role of Inflammation after Surgery for Elders (RISE) study. J Neuroinflammation. 2021 Apr 30;18(1):103 (these documents are incorporated by reference).
[0062] inflammation Neuroinflammation also participates in a complex cascade that leads to AD pathology and symptoms. Considerable pathological and clinical evidence supports immunological changes associated with AD, including elevated concentrations of pro-inflammatory cytokines in the blood and cerebrospinal fluid. Whether these changes may be a cause or a consequence of AD is not yet fully understood, but inflammation in the brain has been implicated in the pathogenesis and progression of AD, including increased reactivity of resident microglia to amyloid deposits. Subjects may be identified as suffering from or at risk of developing AD based on the presence of neuroinflammation (see, e.g., Chu LW. Hong Kong Med J. 2012;18:228-237. 2. Newcombe EA, et al. Neuroinflammation.2018;15(1):276. doi: 10.1186 / s12974-018-1313-3).
[0063] Misfolded Proteins AD is considered a protein misfolding disease due to the accumulation of abnormally folded amyloid beta (Aβ) protein in the brain. Amyloid beta is a short peptide that is an abnormal proteolytic by-product of the transmembrane protein amyloid beta precursor protein (APP), whose function is unclear but is thought to be involved in neurodevelopment. Presenilins are components of proteolytic complexes involved in APP processing and degradation.
[0064] Amyloid-β monomers are soluble and contain short regions of β-sheet and polyproline II helical secondary structure in solution, but are predominantly α-helical in membranes; however, at sufficiently high concentrations, they undergo dramatic conformational changes to form β-sheet-rich tertiary structures, which aggregate to form amyloid fibrils. These fibrils and oligomeric forms of Aβ are deposited on the outside of neurons as formations known as senile plaques. There are different types of plaques, including diffuse, compact, core-type or neuritic types, as well as Aβ deposits in the walls of brain microvessels, called cerebral amyloid angiopathy (see, for example, Chu LW. Hong Kong Med J. 2012;18:228-237. 2. Newcombe EA, et al. Neuroinflammation.2018;15(1):276. doi: 10.1186 / s12974-018-1313-3). In view of the above, misfolded proteins may be useful in identifying subjects who may be suffering from or at risk of developing AD.
[0065] Mitochondrial / metabolic dysfunction and oxidative stress Mitochondrial dysfunction is prevalent in neurodegenerative diseases. In Alzheimer's disease, mitochondrial membrane potential of cells is significantly reduced, mitochondrial glucose metabolism is impaired, and mitochondrial permeability is increased. Mitochondria have been observed to mediate multiple apoptotic pathways leading to neuronal cell death in Alzheimer's disease (see, e.g., Swerdlow RH. J Alzheimers Dis. 2018;62(3):1403-1416 and Chu LW. Hong Kong Med J. 2012;18:228-237; Tonnies E and Trushina E. J Alzheimers Dis.2017;57(4):1105-1121).
[0066] Both PINK1 and Parkin are mitochondrial quality control proteins. Mutations or absence of these proteins are strongly associated with Parkinson's disease. MPTP, the molecule used to induce permanent symptoms of Parkinson's disease, acts through the disruption of mitochondrial complex I, causing mitochondrial dysfunction, alteration of the redox state of the cell, and apoptosis.
[0067] Mutant huntingtin genes and the resulting proteins, believed to be the primary mediators of Huntington's disease, have been shown directly in cell culture to result in loss of mitochondrial membrane potential and reduced expression of critical oxidative phosphorylation genes. Huntington's disease pathology has also been associated with a reduction in the number of mitochondria present in the central nervous system.
[0068] Mitochondrial mislocalization, impaired energy metabolism, and apoptotic pathways are thought to mediate amyotrophic lateral sclerosis. Mitochondria from diseased tissues have also been shown to overproduce reactive oxygen metabolites and leak them into the cytosol.
[0069] In many neurodegenerative diseases, mitochondria overproduce free radicals, cause the decline of energy metabolism, increase permeability, decrease membrane potential, decrease antioxidants, leak metal ions into cells, change the redox state of cells, and lead cells to pro-apoptotic pathways.Therefore, there is a need for agents that can change and reduce mitochondrial dysfunction mechanisms.In some cases, the symptoms of mitochondrial / metabolic dysfunction and oxidative stress can be useful in diagnosing and selecting subjects who may suffer from AD or are at risk of developing AD.
[0070] Other factors useful in diagnosing / selecting AD Vascular disease (e.g., Sweeny MD, et al. Alzheimers Dement. 2019;15(1):158-167), synaptic activity, or neurotransmitter activity (see, e.g., Tonnies E and Trushina E. J Alzheimers Dis. 2017;57(4):1105-1121) may also be useful in diagnosing and selecting subjects who may be suffering from or at risk of developing AD.
[0071] Carrying a mutation in any of the AD-associated genes described herein, carrying one or more copies of the APOE ε4 allele, or exhibiting any of the biomarkers described herein may indicate that a subject is at risk for developing AD, and such subjects may be treated with the methods provided herein for prevention and prophylaxis purposes.
[0072] progressive supranuclear palsy In one aspect, the disclosure provides a method of treating at least one symptom of PSP in a human subject. Also provided herein are methods of slowing PSP disease progression (e.g., reducing the rate of PSP disease progression); and reducing the progressive decline in cognitive function, including loss of declarative and procedural memory, diminished learning ability, reduced attention span, and severe impairment of thinking ability, judgment, and decision-making. Also provided are methods of increasing the survival time of a human subject having one or more symptoms of PSP. Also provided are methods of improving one or more affected biomarkers in a human subject having PSP (e.g., reducing levels of total tau and phosphorylated tau, both of which may be elevated in PSP, or reducing levels of YKL-40, which may also be elevated in PSP). Any of the methods described herein can include administering to the subject a bile acid or a pharma- ceutically acceptable salt thereof (e.g., a bile acid or a pharma- ceutically acceptable salt thereof described herein or known in the art) and a phenylbutyrate compound (e.g., any of the phenylbutyrate compounds described herein or known in the art).
[0073] Any of the human subjects in the methods described herein may exhibit one or more symptoms associated with or be diagnosed with PSP, hi some embodiments, the subject may be suspected of having and / or at risk of developing PSP.
[0074] Some embodiments of the methods described herein can further include determining that the human subject has or is at risk for developing PSP, diagnosing the human subject as having or at risk for developing PSP, or selecting a human subject as having or at risk for developing PSP.
[0075] In some embodiments of the methods described herein, the human subject has been exhibiting one or more symptoms of PSP for about 24 months or less (e.g., about 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 month or week or less). In some embodiments, the subject has been exhibiting one or more symptoms of PSP for about 36 months or less (e.g., about 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, or 25 months or less).
[0076] In some cases, the human subject has been diagnosed with PSP. For example, the subject may have been diagnosed with PSP for about 24 months or less (e.g., about 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 month or less). For example, the subject may have been diagnosed with PSP for one week or less, or on the same day that the treatment of the disclosure is administered. The subject may have been diagnosed with PSP for more than about 24 months (e.g., more than about 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, or 80 months). Methods for diagnosing PSP are known in the art. For example, the subject may be diagnosed based on clinical history, family history, physical or neurological examination. The subject may be confirmed or identified as suffering from PSP, for example, by a medical professional. More than one person may be involved in a diagnosis. For example, if a sample is obtained from a subject as part of a diagnosis, a first person may obtain the sample from the subject and a second person may test the sample. In some embodiments of human subjects described herein, the subject is diagnosed, selected, or referred by a physician (e.g., a general practitioner).
[0077] In general, the diagnosis of PSP is known in the art. Symptoms of PSP usually first appear around age 60 and worsen until death. PSP patients usually die from pneumonia, choking, or other complications caused by loss of functional brain cells that results in loss of autonomy and motor function (e.g., ability to swallow).
[0078] Signs and symptoms of PSP include motor, cognitive and psychiatric disorders. Voluntary movements are impaired in PSP and can include pseudobulbar palsy (i.e., inability to control facial movements), bradykinesia (i.e., slow or abnormal muscle movements), neck and trunk rigidity, impaired gait, impaired balance, postural instability, and difficulty speaking and swallowing. Individuals who are unable to swallow food can be fitted with a feeding tube to provide nutrition. The most obvious outward sign of the disease is the inability to coordinate and move both eyes normally, resulting in vertical gaze paralysis. Cognitive impairments include loss of executive function (e.g., attention control, inhibitory control, working memory, cognitive flexibility, reasoning, problem solving and planning) and reduced fluency. Concomitant psychiatric symptoms include depression, feelings of irritability, sadness or lack of motivation, insomnia, fatigue and loss of energy.
[0079] Progressive supranuclear palsy can be difficult to diagnose because the signs and symptoms are similar to those of Parkinson's disease. One of skill in the art may distinguish between PSP and Parkinson's disease based on the absence of tremor, frequent falls for unknown reasons, little or no response to Parkinson's medications, and / or difficulty moving both eyes, especially downward.
[0080] MDS PSP diagnostic criteria In some embodiments, a subject may be identified as having PSP using the MDS PSP diagnostic criteria (as described in, e.g., Hoglinger et al., Mov. Disord. 31:644-652, 2016). The criteria address four functional domains (oculomotor dysfunction, postural instability, akinesia, and cognitive dysfunction) as clinical predictors of PSP.
[0081] Progressive Supranuclear Palsy Rating Scale Some embodiments of the methods described herein can include monitoring the progression of PSP in a subject, for example, by assessing the severity of PSP in the subject over time, for example, using the Progressive Supranuclear Palsy Rating Scale (PSPRS) (e.g., as described in Golbe et al., Brain 130(6):1552-1565, 2007). The PSPRS assesses a subject according to the subject's ability to perform daily activities, behavior, bulbar function, oculomotor function, limb motor function, and ambulation.
[0082] Genetic mutations In some embodiments, a subject may be identified as being at increased risk of developing PSP or as suffering from PSP (e.g., any of the types of PSP described herein), e.g., at least in part, by detecting a genetic mutation in the gene encoding microtubule-associated protein tau (MAPT) (e.g., an inversion polymorphism in the MAPT gene, a haplotype-specific polymorphism in the MAPT gene, a rare coding MAPT variant (A152T), or a mutation that enhances splicing of exon 10 in the MAPT gene, e.g., as described in Hoglinger et al., Nature Genet. 43:699-705, 2011 and Hinz et al., Cold Spring Harb. Perspect Biol.). Non-limiting examples of genetic mutations in genes encoding MAPT include mutations that result in the production of the MAPT protein, including one or more point mutations of S285R, L284R, P301L, and G303V. Additional specific genetic mutations in the gene encoding the MAPT protein that can be used to identify a subject as being at increased risk for developing PSP or as suffering from PSP (e.g., any of the types of PSP described herein) are described, for example, in Boxer et al., Lancet 16:552-563, 2017.
[0083] Scanning and Neuroimaging In some aspects, a subject may be identified as being at increased risk of developing PSP or as suffering from PSP (e.g., any of the types of PSP described herein), e.g., at least in part, by detection of tau protein deposits (e.g., deposits of four repeat tau protein), detection of atrophy of the midbrain and / or superior cerebellar peduncle (e.g., using any of the imaging techniques described herein or known in the art, e.g., magnetic resonance imaging (MRI) or positron emission tomography (PET) scan), and / or detection of hypometabolism in the subject's frontal cortex, caudate nucleus, and / or thalamus (e.g., using any of the imaging techniques described herein or known in the art, e.g., MRI, CT scan, or PET scan).
[0084] For example, in some embodiments, the subject is assessed for brain atrophy in the subject, e.g., at least in part, using MRI to detect brain atrophy (Min et al., Nat. Med. 21:1154-1162, 2015; Yanamandra et al., Ann. Clin. Transl. Neurol. 2:278-288, 2015), regional gray and white matter volume changes to detect atrophy (see, e.g., Josephs et al., Brain 137:2783-2795, 2014; Santos-Santos et al., JAMA Neurol. 73:733-742, 2016), and midbrain atrophy by detecting midbrain regions and volumes (Josephs et al., Neurobiol. Aging 29:280-289, 2008; Whitwell et al., Eur. J. Neurol. 20:1417-1422, 2013), a person may be identified or diagnosed as having PSP (e.g., any of the types of PSP described herein). In some embodiments, a subject may be identified or diagnosed as suffering from PSP (e.g., any of the types of PSP described herein), e.g., at least in part, by administering to the subject a tau protein tracer (e.g., AV1451 or PBB3) and detecting tau protein in the subject's brain using a PET scan (see, e.g., Marquie et al., Ann. Neurol. 78:787-800, 2015; Cho et al., Mov. Disord. 32:134-140, 2017; Whitwell et al., Mov. Disord. 32:124-133, 2017; and Smith et al., Mov. Disord. 32:108-114, 2017). In some embodiments, a subject can be diagnosed or identified as suffering from PSP (e.g., any of the types of PSP described herein) by detecting binaural masking level differences in the subject, e.g., at least in part, using PET scanning (see, e.g., Hughes et al., J. Neurophysiol. 112:3086-3094, 2014).
[0085] CSF PSP biomarkers In some embodiments, a subject may be identified as being at elevated risk for developing PSP or as suffering from PSP (e.g., any of the types of PSP described herein), e.g., at least in part, by detecting the presence or elevated levels (e.g., compared to levels in healthy control subjects) of one or more biomarkers in the subject.
[0086] Tau and phosphorylated tau A subject in the methods described herein may have a total CSF tau level that is elevated compared to a healthy subject. For example, a subject may have a total CSF tau level of about 100 pg / mL or greater. In some embodiments, a subject may have a total CSF tau level of about 300 pg / mL or greater (e.g., about 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 2000, 2100, 2200, 2300, 2400, 250, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 350, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 450, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 00, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 3000, 3200, 3500, 3800 or 4000 pg / mL or more).
[0087] A subject in the methods described herein may have elevated CSF phosphorylated tau (e.g., phosphorylated tau 181, phosphorylated tau 199, and / or phosphorylated tau 231) compared to a healthy subject. For example, a subject may have a CSF phosphorylated tau level of about 30 pg / mL or greater. In some embodiments, a subject has a CSF phosphorylated tau (e.g., phosphorylated tau 181) level of about 70 pg / mL or greater (e.g., about 75, 100, 125, 150, 175, or 200 pg / mL or greater).
[0088] Neurofilament light chain (NfL) In some embodiments, a subject may be identified or diagnosed, e.g., at least in part, as suffering from PSP (e.g., any of the types of PSP described herein) by detecting the presence of, or elevated levels of, neurofilament light chains in the subject's blood and / or cerebrospinal fluid (e.g., using any of the immunoassays described in Scherling et al., Ann. Neurol. 75:116-126, 2014; Bacioglu et al., Neuron 91:56-66, 2016; and Rojas et al., Ann. Clin. Transl. Neurol. 3:216-255, 2016).
[0089] Methods for detecting NfL (e.g., in cerebrospinal fluid, plasma, or serum) are known in the art and include, but are not limited to, ELISA and Simoa assays (see, e.g., Shaw et al. Biochemical and Biophysical Research Communications 336:1268-1277, 2005; Ganesalingam et al. Amyotroph Lateral Scler Frontotemporal Degener 14(2):146-9, 2013; De Schaepdryver et al. Annals of Clinical and Translational Neurology 6(10): 1971-1979, 2019; Wilke et al. Clin Chem Lab Med 57(10):1556-1564, 2019; Poesen et al. Front Neurol 9:1167, 2018; Pawlitzki et al. Front. Neurol. 9:1037, 2018; Gille (see, e.g., Wilke et al. Neuropathol Appl Neurobiol 45(3):291-304, 2019). Commercially available NfL assay kits based on Simoa technology, such as those produced by Quanterix, can also be used (see, e.g., Thouvenot et al. European Journal of Neurology 27:251-257, 2020). Factors influencing NfL levels or their detection in serum or plasma in relation to disease course may differ from those in CSF. Levels of neurofilaments (e.g., pNF-H and / or NfL) in CSF and serum may be correlated (see, e.g., Wilke et al. Clin Chem Lab Med 57(10):1556-1564, 2019).
[0090] YKL-40 In some embodiments, a subject may be identified or diagnosed as suffering from PSP (e.g., any of the types of PSP described herein), for example, at least in part, by detecting the presence of YKL-40 in cerebrospinal fluid from the subject, or elevated levels thereof (e.g., compared to levels in healthy control subjects) (see, e.g., Magdalinou et al., J. Neurol. Neurosurg. Psychiatry 2014 October; 85(10): 1065-1075; and Magdalinou et al., J. Neurol. Neurosurg. Psychiatry 86:1240-1247, 2015).
[0091] Ratio of 33kDa tau to 55kDa tau In some aspects, a subject may be identified or diagnosed as suffering from PSP (e.g., any of the types of PSP described herein), for example, at least in part, by detecting a decrease in the ratio of 33 kDa tau to 55 kDa tau in the subject's CSF (e.g., compared to the ratio of 33 kDa tau to 55 kDa tau in a healthy subject).
[0092] Ptpn1 In some embodiments, a subject may be identified or diagnosed as having PSP (e.g., any of the types of PSP described herein), for example, at least in part, by detecting the presence of, or elevated levels of, protein tyrosine phosphatase 1 (Ptpn1) (see, e.g., Xiang Y, Xin J, Le W, Yang Y. Neurogranin: A Potential Biomarker of Neurological and Mental Diseases. Front Aging Neurosci. 2020 Oct 6;12:584743. doi: 10.3389 / fnagi.2020.584743).
[0093] Neurogranin In some embodiments, a subject may be identified or diagnosed as suffering from PSP (e.g., any of the types of PSP described herein), for example, at least in part, by detecting the presence of, or elevated levels of, neurogranin (see, e.g., Xiang Y, Xin J, Le W, Yang Y. Neurogranin: A Potential Biomarker of Neurological and Mental Diseases. Front Aging Neurosci. 2020 Oct 6;12:584743. doi: 10.3389 / fnagi.2020.584743).
[0094] Other factors useful in the diagnosis / selection of PSP In some embodiments, a subject may be identified or diagnosed as having PSP (e.g., any of the types of PSP described herein) by detecting, at least in part, reduced saccade velocity and gain in the subject using, for example, infrared oculography (see, e.g., Boxer et al., Arch. Neurol. 69:509-517, 2012; Boxer et al., Lancet Neurol. 132:676-685, 2014). In some embodiments, a subject may be identified or diagnosed as having PSP (e.g., any of the types of PSP described herein) by, for example, at least in part, detecting spontaneous and evoked blink rates associated with PSP in the subject (see, e.g., Bologna et al., Brain 132:502-510, 2009). In some embodiments, a subject may be identified or diagnosed as having PSP (e.g., any of the types of PSP described herein) by detecting, e.g., at least in part, a decrease in retinal thickness in the subject's eye using optical coherence tomography (see, e.g., Schneider et al., J. Neural Transm. 121:41-47, 2014). In some embodiments, a subject may be identified or diagnosed as having PSP (e.g., any of the types of PSP described herein) by detecting, e.g., at least in part, a disturbance in circadian rhythm and sleep in the subject (see, e.g., Walsh et al., Sleep Med. 22; 50-56, 2016).
[0095] General selection of subjects with various neurodegenerative diseases In some embodiments, the subjects described herein have "elevated levels" of a biomarker (e.g., tau, phosphorylated tau, NfL, YKL-40, Ptpn1, or neurogranin) in the CSF or blood compared to healthy subjects not suffering from PSP. In some embodiments, the elevated levels in a PSP subject may be, for example, about 1% to about 500%, about 1% to about 450%, about 1% to about 400%, about 1% to about 350%, about 1% to about 300%, about 1% to about 250%, about 1% to about 200%, about 1% to about 150%, about 1% to about 100%, about 1% to about 50%, about 1% to about 25%, about 1% to about 20%, about 1% to about 15%, about 1% to about 10%, about 1% to about 5%, about 2% to about 500%, about 2% to about 450%, about 2% to about 400%, as compared to a healthy subject not afflicted with PSP. %, about 2% to about 350%, about 2% to about 300%, about 2% to about 250%, about 2% to about 200%, about 2% to about 150%, about 2% to about 100%, about 2% to about 50%, about 2% to about 25%, about 2% to about 20%, about 2% to about 15%, about 2% to about 10%, about 5% to about 500%, about 5% to about 450%, about 5% to about 400%, about 5% to about 350%, about 5% to about 300%, about 5% to about 250%, about 5% to about 200%, about 5% to about 150%, about 5% to about 100%, about 5% to about 50%, about 5% to about 25%, about 5% to about 2 0%, about 5% to about 15%, about 5% to about 10%, about 10% to about 500%, about 10% to about 450%, about 10% to about 400%, about 10% to about 350%, about 10% to about 300%, about 10% to about 250%, about 10% to about 200%, about 10% to about 150%, about 10% to about 100%, about 10% to about 50%, about 10% to about 25%, about 10% to about 20%, about 10% to about 15%, about 15% to about 500%, about 15% to about 450%, about 15% to about 400%, about 15% to about 350%, about 15% to about 300%, about 15% to About 250%, about 15% to about 200%, about 15% to about 150%, about 15% to about 100%, about 15% to about 50%, about 15% to about 25%, about 15% to about 20%, about 20% to about 500%, about 20% to about 450%, about 20% to about 400%, about 20% to about 350%, about 20% to about 300%, about 20% to about 250%, about 20% to about 200%, about 20% to about 150%, about 20% to about 100%, about 20% to about 50%, about 20% to about 25%, about 25% to about 500%, about 25% to about 450%, about 25% to about 400%,About 25% to about 350%, about 25% to about 300%, about 25% to about 250%, about 25% to about 200%, about 25% to about 150%, about 25% to about 100%, about 25% to about 50%, about 50% to about 500%, about 50% to about 450%, about 50% to about 400%, about 50% to about 350%, about 50% to about 300%, about 50% to about 250%, about 50% to about 200%, about 0% to about 150%, about 50% to about 100%, about 100% to about 500%, about 100% to about 450%, about 100% to about 400%, about 100% to about 350%, about 100% to about 300%, about 100% to about 250%, about 100% to about 200%, about 100% to about 150%, about 150% to about 500%, about 150% to about 450%, about 150% to about 400%, about 150 % to about 350%, about 150% to about 300%, about 150% to about 250%, about 150% to about 200%, about 200% to about 500%, about 200% to about 450%, about 200% to about 400%, about 200% to about 350%, about 200% to about 300%, about 200% to about 250%, about 250% to about 500%, about 250% to about 450%, about 250% to about 400%, about 250 There is a possibility of an increase or increase of about 250% to about 300%, about 300% to about 500%, about 300% to about 450%, about 300% to about 400%, about 300% to about 350%, about 350% to about 500%, about 350% to about 450%, about 350% to about 400%, about 400% to about 500%, about 400% to about 450%, or about 450% to about 500%.
[0096] In some embodiments, after administration of any of the compositions described herein (e.g., TURSO and sodium phenylbutyrate), the subject experiences a decrease in the level (in plasma or CSF) of a biomarker (e.g., tau, phosphorylated tau, NfL, YKL-40, or Ptpn1). For example, compared to a first level of a biomarker (e.g., tau, phosphorylated tau, NfL, YKL-40, or Ptpn1) (i.e., before treatment with a composition described herein), a second level of a biomarker (e.g., tau, phosphorylated tau, NfL, YKL-40, or Ptpn1) (i.e., after treatment with a composition described herein) may exhibit, for example, a 1% to about 99% decrease, a 1% to about 95% decrease, a 1% to about 90% decrease, a 1% to about 85% decrease, a 1% to about 80% decrease, or a 1% to about 75% decrease. , 1% to about 70% reduction, 1% to about 65% reduction, 1% to about 60% reduction, 1% to about 55% reduction, 1% to about 50% reduction, 1% to about 45% reduction, 1% to about 40% reduction, 1% to about 35% reduction, 1% to about 30% reduction, 1% to about 25% reduction, 1% to about 20% reduction, 1% to about 15% reduction, 1% to about 10% reduction, 1% to about 5% reduction, about 5% to about 99% reduction, about 5% to about 95% reduction, about 5% to about 90% reduction, about 5% to about 85% reduction, about 5% to about 80% reduction, about 5% to about 75% reduction, about 5% to about 70% reduction, about ~65% reduction, ~5%~60% reduction, ~5%~55% reduction, ~5%~50% reduction, ~5%~45% reduction, ~5%~40% reduction, ~5%~35% reduction, ~5%~30% reduction, ~5%~25% reduction, ~5%~20% reduction, ~5%~15% reduction, ~5%~10% reduction, ~10%~99% reduction, ~10%~95% reduction, ~10%~90% reduction, ~10%~85% reduction, ~10%~80% reduction, ~10%~75% reduction, ~10%~70% reduction, ~10%~6 5% reduction, about 10% to about 60% reduction, about 10% to about 55% reduction, about 10% to about 50% reduction, about 10% to about 45% reduction, about 10% to about 40% reduction, about 10% to about 35% reduction, about 10% to about 30% reduction, about 10% to about 25% reduction, about 10% to about 20% reduction, about 10% to about 15% reduction, about 15% to about 99% reduction, about 15% to about 95% reduction, about 15% to about 90% reduction, about 15% to about 85% reduction, about 15% to about 80% reduction, about 15% to about 75% reduction, about 15% to about 70% reduction, about 15% to about 65% reduction,Approximately 15% to approximately 60% reduction, Approximately 15% to approximately 55% reduction, Approximately 15% to approximately 50% reduction, Approximately 15% to approximately 45% reduction, Approximately 15% to approximately 40% reduction, Approximately 15% to approximately 35% reduction, Approximately 15% to approximately 30% reduction, Approximately 15% to approximately 25% reduction, Approximately 15% to approximately 20% reduction, Approximately 20% to approximately 99% reduction, Approximately 20% to approximately 95% reduction, Approximately 20% to approximately 90% reduction, Approximately 20% to approximately 85% reduction, Approximately 20% to approximately 80% reduction, Approximately 20% to approximately 75% reduction, Approximately 20% to approximately 70% reduction, Approximately 20% to approximately 65% reduction, Approximately 20% to approximately 60% reduction, Approximately 20% to approximately 55% reduction, Approximately 20% to approximately 50% reduction, Approximately 20% to approximately 45% reduction, about 20% to about 40% reduction, about 20% to about 35% reduction, about 20% to about 30% reduction, about 20% to about 25% reduction, about 25% to about 99% reduction, about 25% to about 95% reduction, about 25% to about 90% reduction, about 25% to about 85% reduction, about 25% to about 80% reduction, about 25% to about 75% reduction, about 25% to about 70% reduction, about 25% to about 65% reduction, about 25% to about 60% reduction, about 25% to about 55% reduction, about 25% to about 50% reduction, about 25% to about 45% reduction, about 25% to about 40% reduction, about 25% to about 35% reduction, about 25% to about 30% reduction, about 30% to about 99% reduction, about 30% to about 95% reduction, about 30% to about 90% reduction, about 30% to about 85% reduction, about 30% to about 80% reduction, about 30% to about 75% reduction, about 30% to about 70% reduction, about 30% to about 65% reduction, about 30% to about 60% reduction, about 30% to about 55% reduction, about 30% to about 50% reduction, about 30% to about 45% reduction, about 30% to about 40% reduction, about 30% to about 35% reduction, about 35% to about 99% reduction, about 35% to about 95% reduction, about 35% to about 90% reduction, about 35% to about 85% reduction, about 35% to about 80% reduction, about 35% to about 75% reduction, about 35% to about 70% reduction, about 35% to about 65% reduction, about % to about 60% reduction, about 35% to about 55% reduction, about 35% to about 50% reduction, about 35% to about 45% reduction, about 35% to about 40% reduction, about 40% to about 99% reduction, about 40% to about 95% reduction, about 40% to about 90% reduction, about 40% to about 85% reduction, about 40% to about 80% reduction, about 40% to about 75% reduction, about 40% to about 70% reduction, about 40% to about 65% reduction, about 40% to about 60% reduction, about 40% to about 55% reduction, about 40% to about 50% reduction, about 40% to about 45% reduction, about 45% to about 99% reduction, about 45% to about 95% reduction, about 45% to about 90% reduction, about 45% to about 85% reduction,Approximately 45% to approximately 80% reduction, Approximately 45% to approximately 75% reduction, Approximately 45% to approximately 70% reduction, Approximately 45% to approximately 65% reduction, Approximately 45% to approximately 60% reduction, Approximately 45% to approximately 55% reduction, Approximately 45% to approximately 50% reduction, Approximately 50% to approximately 99% reduction, Approximately 50% to approximately 95% reduction, Approximately 50% to approximately 90% reduction, Approximately 50% to approximately 85% reduction, Approximately 50% to approximately 80% reduction, Approximately 50% to approximately 75% reduction, Approximately 50% to approximately 70% reduction, Approximately 50% to approximately 65% reduction, Approximately 50% to approximately 60% reduction, approximately 50% to approximately 55% reduction, approximately 55% to approximately 99% reduction, approximately 55% to approximately 95% reduction, approximately 55% to approximately 90% reduction, approximately 55% to approximately 85% reduction, approximately 55% to approximately 80% reduction, approximately 55% to approximately 75% reduction, approximately 55% to approximately 70% reduction, approximately 55% to approximately 65% reduction, approximately 55% to approximately 60% reduction, approximately 60% to approximately 99% reduction, approximately 60% to approximately 95% reduction, approximately 60% to approximately 90% reduction, approximately 60% to approximately 85% reduction, approximately 60% to approximately 80% reduction, Approximately 60% to 75% reduction, Approximately 60% to 70% reduction, Approximately 60% to 65% reduction, Approximately 65% to 99% reduction, Approximately 65% to 95% reduction, Approximately 65% to 90% reduction, Approximately 65% to 85% reduction, Approximately 65% to 80% reduction, Approximately 65% to 75% reduction, Approximately 65% to 70% reduction, Approximately 70% to 99% reduction, Approximately 70% to 95% reduction, Approximately 70% to 90% reduction, Approximately 70% to 85% reduction, Approximately 70% to 80% reduction, Approximately 70% to 85% reduction 75% reduction, about 75% to about 99% reduction, about 75% to about 95% reduction, about 75% to about 90% reduction, about 75% to about 85% reduction, about 75% to about 80% reduction, about 80% to about 99% reduction, about 80% to about 95% reduction, about 80% to about 90% reduction, about 80% to about 85% reduction, about 85% to about 99% reduction, about 85% to about 95% reduction, about 85% to about 90% reduction, about 90% to about 99% reduction, about 90% to about 95% reduction, or about 95% to about 99% reduction.
[0097] Bioavailability / Metabolism A skilled physician will recognize that several factors may affect the bioavailability and metabolism of a compound administered to a subject and can make adjustments accordingly. These include, but are not limited to, liver function (e.g., liver enzyme levels), kidney function, and gallbladder function (e.g., ion absorption and secretion, cholesterol transport protein levels). There may be variability in each subject's exposure level to the administered compound (e.g., bile acids and phenylbutyrate compounds), differences in excretion levels and pharmacokinetics of the compound in subjects during treatment. Any of the factors described herein may affect drug exposure by a subject. For example, a decrease in the clearance of a compound may result in increased drug exposure, and improved renal function may reduce actual drug exposure. The degree of drug exposure may correlate with the subject's response to the administered compound and the outcome of the treatment.
[0098] Age range The subject may be, for example, older than 18 years of age (e.g., 18-100, 18-90, 18-80, 18-70, 18-60, 18-50, 18-40, 18-30, 18-25, 25-100, 25-90, 25-80, 25-70, 25-60, 25-50, 25-40, 25-30, 30-100, 30-90, 30-80, 30-70, (30-60, 30-50, 30-40, 40-100, 40-90, 40-80, 40-70, 40-60, 40-50, 50-100, 50-90, 50-80, 50-70, 50-60, 60-100, 60-90, 60-80, 60-70, 70-100, 70-90, 70-80, 80-100, 80-90, or 90-100 years old). 2 (e.g. 18.5~28, 18.5~26, 18.5~24, 18.5~22, 18.5~20, 20~30, 20~28, 20~26, 20~24, 20~22, 22~30, 22~28, 22~26, 22~24, 24~30, 24~28, 24~26, 26~30, 26~28 or 28~30kg / m 2 ) may also be used.
[0099] Treatment method This disclosure provides methods of treating a neurodegenerative disease (e.g., AD or PSP) in a subject, or ameliorating at least one symptom of a neurodegenerative disease (e.g., AD or PSP) in a subject, or prophylactically treating a subject at risk of developing a neurodegenerative disease (e.g., AD or PSP) (e.g., a subject who possesses one or more copies of the APOE ε4 allele) or a subject suspected of developing a neurodegenerative disease (e.g., a subject exhibiting at least one symptom of AD or at least one symptom of PSP).
[0100] Some embodiments of this disclosure provide methods of slowing neurodegenerative disease (e.g., AD or PSP) disease progression (e.g., reducing the rate of AD or PSP disease progression); and methods of reducing and / or preventing the progressive decline in cognitive function, including loss of declarative and procedural memory, diminished learning ability, reduced attention span, and severe impairment of thinking skills, judgment, and decision-making.
[0101] Also provided herein are methods of improving one or more biomarkers affected in patients with a neurodegenerative disease (e.g., AD or PSP), e.g., in some cases, methods are provided herein for reducing total tau and / or phosphorylated tau, such as in CSF, serum or blood.
[0102] Generally, methods of treating a tauopathy in a subject, or improving at least one symptom of a tauopathy in a subject, or prophylactically treating a subject at risk of developing a tauopathy or suspected of developing a tauopathy are also provided in this disclosure. Some aspects of this disclosure provide methods of slowing the progression of a tauopathy disease; as well as methods of reducing and / or preventing the progressive decline of various functions associated with tauopathy (e.g., in some cases, this may be cognitive function). Also provided herein are methods of improving one or more biomarkers affected in tauopathy patients.
[0103] In some embodiments of the methods described herein, the methods include administering to the subject a bile acid or a pharma- ceutically acceptable salt thereof, and a phenylbutyrate compound. In some embodiments, the methods described herein include administering to the subject about 10 mg / kg to about 50 mg / kg (e.g., about 10 mg / kg to about 48 mg / kg, about 10 mg / kg to about 46 mg / kg, about 10 mg / kg to about 44 mg / kg, about 10 mg / kg to about 42 mg / kg, about 10 mg / kg to about 40 mg / kg, about 10 mg / kg to about 38 mg / kg, about 10 mg / kg to about 36 mg / kg, about 10 mg / kg to about 34 mg / kg, about 10 mg / kg to about 32 mg / kg, about 10 mg / kg to about 30 mg / kg, Approximately 10mg / kg to approximately 28mg / kg, approximately 10mg / kg to approximately 26mg / kg, approximately 10mg / kg to approximately 24mg / kg, approximately 10mg / kg to approximately 22mg / kg, approximately 10mg / kg to approximately 20mg / kg, approximately 10mg / kg to approximately 18mg / kg, approximately 10mg / kg kg~about 16mg / kg, about 10mg / kg~about 14mg / kg, about 10mg / kg~about 12mg / kg, about 12mg / kg~about 50mg / kg, about 12mg / kg~about 48mg / kg, about 12mg / kg~about 46mg / kg, about 12mg / kg~about 44 mg / kg, about 12 mg / kg to about 42 mg / kg, about 12 mg / kg to about 40 mg / kg, about 12 mg / kg to about 38 mg / kg, about 12 mg / kg to about 36 mg / kg, about 12 mg / kg to about 34 mg / kg, about 12 mg / kg to about 32 mg / kg, Approximately 12mg / kg to approximately 30mg / kg, approximately 12mg / kg to approximately 28mg / kg, approximately 12mg / kg to approximately 26mg / kg, approximately 12mg / kg to approximately 24mg / kg, approximately 12mg / kg to approximately 22mg / kg, approximately 12mg / kg to approximately 20mg / kg, approximately 12mg / kg kg~about 18mg / kg, about 12mg / kg~about 16mg / kg, about 12mg / kg~about 14mg / kg, about 14mg / kg~about 50mg / kg, about 14mg / kg~about 48mg / kg, about 14mg / kg~about 46mg / kg, about 14mg / kg~about 44 mg / kg, about 14 mg / kg to about 42 mg / kg, about 14 mg / kg to about 40 mg / kg, about 14 mg / kg to about 38 mg / kg, about 14 mg / kg to about 36 mg / kg, about 14 mg / kg to about 34 mg / kg, about 14 mg / kg to about 32 mg / kg,about 14 mg / kg to about 30 mg / kg, about 14 mg / kg to about 28 mg / kg, about 14 mg / kg to about 26 mg / kg, about 14 mg / kg to about 24 mg / kg, about 14 mg / kg to about 22 mg / kg, about 14 mg / kg to about 20 mg / kg, about 14 mg / kg to about 18 mg / kg, about 14 mg / kg to about 16 mg / kg, about 16 mg / kg to about 50 mg / kg, about 16 mg / kg to about 48 mg / kg, about 16 mg / kg to about 46 mg / kg, about 16 mg / kg to about 44 mg / kg, about 16 mg / kg to about 42 mg / kg, about 16 mg / kg to about 40 mg / kg g / kg, about 16 mg / kg to about 38 mg / kg, about 16 mg / kg to about 36 mg / kg, about 16 mg / kg to about 34 mg / kg, about 16 mg / kg to about 32 mg / kg, about 16 mg / kg to about 30 mg / kg, about 16 mg / kg to about 28 mg / kg, about 16 mg / kg to about 26 mg / kg, about 16 mg / kg to about 24 mg / kg, about 16 mg / kg to about 22 mg / kg, about 16 mg / kg to about 20 mg / kg, about 16 mg / kg to about 18 mg / kg, about 18 mg / kg to about 50 mg / kg, about 18 mg / kg to about 48 mg / kg, about 18 mg / kg to About 46mg / kg, about 18mg / kg to about 44mg / kg, about 18mg / kg to about 42mg / kg, about 18mg / kg to about 40mg / kg, about 18mg / kg to about 38mg / kg, about 18mg / kg to about 36mg / kg, about 18mg / kg to about 34mg / kg, about 18mg / kg to about 32mg / kg, about 18mg / kg to about 30mg / kg, about 18mg / kg to about 28mg / kg, about 18mg / kg to about 26mg / kg, about 18mg / kg to about 24mg / kg, about 18mg / kg to about 22mg / kg, about 18mg / kg to about 20mg / kg, about 20m g / kg to about 50mg / kg, about 20mg / kg to about 48mg / kg, about 20mg / kg to about 46mg / kg, about 20mg / kg to about 44mg / kg, about 20mg / kg to about 42mg / kg, about 20mg / kg to about 40mg / kg, about 20mg / kg to about 38mg / kg, about 20mg / kg to about 36mg / kg, about 20mg / kg to about 34mg / kg, about 20mg / kg to about 32mg / kg, about 20mg / kg to about 30mg / kg, about 20mg / kg to about 28mg / kg, about 20mg / kg to about 26mg / kg, about 20mg / kg to about 24mg / kg,about 20mg / kg to about 22mg / kg, about 22mg / kg to about 50mg / kg, about 22mg / kg to about 48mg / kg, about 22mg / kg to about 46mg / kg, about 22mg / kg to about 44mg / kg, about 22mg / kg to about 42mg / kg, about 22mg / kg to about 40mg / kg, about 22mg / kg to about 38mg / kg, about 22mg / kg to about 36mg / kg, about 22mg / kg to about 34mg / kg, about 22mg / kg to about 32mg / kg, about 22mg / kg to about 30mg / kg, about 22mg / kg to about 28mg / kg, about 22mg / kg to about 26mg / kg g / kg, about 22mg / kg to about 24mg / kg, about 24mg / kg to about 50mg / kg, about 24mg / kg to about 48mg / kg, about 24mg / kg to about 46mg / kg, about 24mg / kg to about 44mg / kg, about 24mg / kg to about 42mg / kg, about 24mg / kg to about 40mg / kg, about 24mg / kg to about 38mg / kg, about 24mg / kg to about 36mg / kg, about 24mg / kg to about 34mg / kg, about 24mg / kg to about 32mg / kg, about 24mg / kg to about 30mg / kg, about 24mg / kg to about 28mg / kg, about 24mg / kg to about 26mg / kg, about 26mg / kg to about 50mg / kg, about 26mg / kg to about 48mg / kg, about 26mg / kg to about 46mg / kg, about 26mg / kg to about 44mg / kg, about 26mg / kg to about 42mg / kg, about 26mg / kg to about 40mg / kg, about 26mg / kg to about 38mg / kg, about 26mg / kg to about 36mg / kg, about 26mg / kg to about 34mg / kg, about 26mg / kg to about 32mg / kg, about 26mg / kg to about 30mg / kg, about 26mg / kg to about 28mg / kg, about 28mg / kg to about 50mg / kg, about 28m g / kg to about 48mg / kg, about 28mg / kg to about 46mg / kg, about 28mg / kg to about 44mg / kg, about 28mg / kg to about 42mg / kg, about 28mg / kg to about 40mg / kg, about 28mg / kg to about 38mg / kg, about 28mg / kg to about 36mg / kg, about 28mg / kg to about 34mg / kg, about 28mg / kg to about 32mg / kg, about 28mg / kg to about 30mg / kg, about 30mg / kg to about 50mg / kg, about 30mg / kg to about 48mg / kg, about 30mg / kg to about 46mg / kg, about 30mg / kg to about 44mg / kg,Approximately 30mg / kg to approximately 42mg / kg, approximately 30mg / kg to approximately 40mg / kg, approximately 30mg / kg to approximately 38mg / kg, approximately 30mg / kg to approximately 36mg / kg, approximately 30mg / kg to approximately 34mg / kg, approximately 30mg / kg to approximately 32mg / kg, approximately 32mg / kg to approximately 50mg / kg kg, about 32 mg / kg to about 48 mg / kg, about 32 mg / kg to about 46 mg / kg, about 32 mg / kg to about 44 mg / kg, about 32 mg / kg to about 42 mg / kg, about 32 mg / kg to about 40 mg / kg, about 32 mg / kg to about 38 mg / kg, about 32 mg / kg to about 36 mg / kg, about 32 mg / kg to about 34 mg / kg, about 34 mg / kg to about 50 mg / kg, about 34 mg / kg to about 48 mg / kg, about 34 mg / kg to about 46 mg / kg, about 34 mg / kg to about 44 mg / kg, about 34 mg / kg to about 42 mg / kg, about 34 mg / kg to about About 40mg / kg, about 34mg / kg to about 38mg / kg, about 34mg / kg to about 36mg / kg, about 36mg / kg to about 50mg / kg, about 36mg / kg to about 48mg / kg, about 36mg / kg to about 46mg / kg, about 36mg / kg to about 44mg / kg, about 36mg / kg kg~about 42mg / kg, about 36mg / kg~about 40mg / kg, about 36mg / kg~about 38mg / kg, about 38mg / kg~about 50mg / kg, about 38mg / kg~about 48mg / kg, about 38mg / kg~about 46mg / kg, about 38mg / kg~about 44mg / kg, about 38 mg / kg~about 42mg / kg, about 38mg / kg~about 40mg / kg, about 40mg / kg~about 50mg / kg, about 40mg / kg~about 48mg / kg, about 40mg / kg~about 46mg / kg, about 40mg / kg~about 44mg / kg, about 40mg / kg~about 42mg / kg, about 42 mg / kg to about 50 mg / kg, about 42 mg / kg to about 48 mg / kg, about 42 mg / kg to about 46 mg / kg, about 42 mg / kg to about 44 mg / kg, about 44 mg / kg to about 50 mg / kg, about 44 mg / kg to about 48 mg / kg, about 44 mg / kg to about 46 mg / kg, about 46 mg / kg to about 50 mg / kg, about 46 mg / kg to about 48 mg / kg, or about 46 mg / kg to about 50 mg / kg) body weight of a bile acid (e.g., any of the bile acids described herein or known in the art, e.g., TURSO) or a pharma- ceutical acceptable salt thereof,and about 10 mg / kg to about 400 mg / kg (e.g., about 10 mg / kg to about 380 mg / kg, about 10 mg / kg to about 360 mg / kg, about 10 mg / kg to about 340 mg / kg, about 10 mg / kg to about 320 mg / kg, about 10 mg / kg to about 300 mg / kg, about 10 mg / kg to about 280 mg / kg, about 10 mg / kg to about 260 mg / kg, about 10 mg / kg to about 240 mg / kg, about 10 mg / kg to about 220 mg / kg, about 10 mg / kg to about 200 mg / kg, about 10 mg / kg to about 180 mg / kg, about 10 mg / kg to about 160 mg / kg, and g / kg, about 10 mg / kg to about 140 mg / kg, about 10 mg / kg to about 120 mg / kg, about 10 mg / kg to about 100 mg / kg, about 10 mg / kg to about 80 mg / kg, about 10 mg / kg to about 60 mg / kg, about 10 mg / kg to about 40 mg / kg, about 10 mg / k g ~ about 20mg / kg, about 20mg / kg - about 400mg / kg, about 20mg / kg - about 380mg / kg, about 20mg / kg - about 360mg / kg, about 20mg / kg - about 340mg / kg, about 20mg / kg - about 320mg / kg, about 20mg / kg - about 300mg / k g, about 20mg / kg to about 280mg / kg, about 20mg / kg to about 260mg / kg, about 20mg / kg to about 240mg / kg, about 20mg / kg to about 220mg / kg, about 20mg / kg to about 200mg / kg, about 20mg / kg to about 180mg / kg, about 20mg / k g~about 160mg / kg, about 20mg / kg~about 140mg / kg, about 20mg / kg~about 120mg / kg, about 20mg / kg~about 100mg / kg, about 20mg / kg~about 80mg / kg, about 20mg / kg~about 60mg / kg, about 20mg / kg~about 40mg / kg, Approximately 40mg / kg to approximately 400mg / kg, approximately 40mg / kg to approximately 380mg / kg, approximately 40mg / kg to approximately 360mg / kg, approximately 40mg / kg to approximately 340mg / kg, approximately 40mg / kg to approximately 320mg / kg, approximately 40mg / kg to approximately 300mg / kg, approximately 40mg / kg to Approximately 280mg / kg, approximately 40mg / kg to approximately 260mg / kg, approximately 40mg / kg to approximately 240mg / kg, approximately 40mg / kg to approximately 220mg / kg, approximately 40mg / kg to approximately 200mg / kg, approximately 40mg / kg to approximately 180mg / kg, approximately 40mg / kg to approximately 160mg / kg,about 40 mg / kg to about 140 mg / kg, about 40 mg / kg to about 120 mg / kg, about 40 mg / kg to about 100 mg / kg, about 40 mg / kg to about 80 mg / kg, about 40 mg / kg to about 60 mg / kg, about 60 mg / kg to about 400 mg / kg, about 60 mg / kg to about 380 mg / kg, about 60 mg / kg to about 360 mg / kg, about 60 mg / kg to about 340 mg / kg, about 60 mg / kg to about 320 mg / kg, , about 60 mg / kg to about 300 mg / kg, about 60 mg / kg to about 280 mg / kg, about 60 mg / kg to about 260 mg / kg, about 60 mg / kg to about 240 mg / kg, about 60 mg / kg to about 220 mg / kg, about 60 mg / kg to about 200 mg / kg, about 60 mg / kg to about 180 mg / kg, about 60 mg / kg to about 160 mg / kg, about 60 mg / kg to about 140 mg / kg, about 60 mg / kg to about 120 mg / kg, about 60 mg / kg to about 100 mg / kg, about 60 mg / kg to about 80 mg / kg, about 80 mg / kg to about 400 mg / kg, about 80 mg / kg to about 380mg / kg, about 80mg / kg to about 360mg / kg, about 80mg / kg to about 340mg / kg, about 80mg / kg to about 320mg / kg, about 80mg / kg to about 300mg / kg, about 80mg / kg to about 280mg / kg, about 80mg / kg to about 260mg / kg, about 80mg / kg to about 240mg / kg, about 80mg / kg to about 220mg / kg, about 80mg / kg to about 200mg / kg, about 80mg / kg to about 180mg / kg, about 80mg / kg to about 160mg / kg, about 80mg / kg to About 140mg / kg, about 80mg / kg to about 120mg / kg, about 80mg / kg to about 100mg / kg, about 100mg / kg to about 400mg / kg, about 100mg / kg to about 380mg / kg, about 100mg / kg to about 360mg / kg, about 100mg / kg to about 340mg / kg, about 100mg / kg to about 320mg / kg, about 100mg / kg to about 300mg / kg, about 100mg / kg to about 280mg / kg, about 100mg / kg to about 260mg / kg, about 100mg / kg to about 240mg / kg, about 100mg / kg to about 220mg / kg, about 100 mg / kg to about 200 mg / kg, about 100 mg / kg to about 180 mg / kg, about 100 mg / kg to about 160 mg / kg, about 100 mg / kg to about 140 mg / kg, about 100 mg / kg to about 120 mg / kg, about 120 mg / kg to about 400 mg / kg, about 120 mg / kg to about 380 mg / kg, about 120 mg / kg to about 360 mg / kg, about 120 mg / kg to about 340 mg / kg, about 120 mg / kg to about 320 mg / kg, about 120 mg / kg to about 300 mg / kg, about 120 mg / kg to about 280 mg / kg, about 120 mg / kg to about 260 mg / kg,about 120mg / kg to about 240mg / kg, about 120mg / kg to about 220mg / kg, about 120mg / kg to about 200mg / kg, about 120mg / kg to about 180mg / kg, about 120mg / kg to about 160mg / kg, about 120mg / kg to about 140mg / kg, about 140mg / kg to about 400mg / kg, about 140mg / kg to about 380mg / kg, about 140mg / kg to about 360mg / kg, about 140mg / kg to about 340mg / kg, about 140mg / kg to about 320mg / kg, about 140mg / kg to about 300mg / kg, about 140mg / kg to about 280mg / kg, about 140mg / kg to about 260mg / kg, about 140mg / kg to about 240mg / kg, about 140mg / kg to about 220mg / kg, about 140mg / kg to about 200mg / kg, about 140mg / kg to about 180mg / kg, about 140mg / kg to about 160mg / kg, about 160mg / kg to about 400mg / kg, about 160mg / kg to about 380mg / kg, about 160mg / kg to about 360mg / kg, about 160mg / kg to about 340mg / kg, about 160mg / kg to about 320mg / kg, about 160mg / kg to about 300mg / kg, About 160mg / kg to about 280mg / kg, about 160mg / kg to about 260mg / kg, about 160mg / kg to about 240mg / kg, about 160mg / kg to about 220mg / kg, about 160mg / kg to about 200mg / kg, about 160mg / kg to about 180mg / kg, about 180mg / kg to about 400mg / kg, about 180mg / kg to about 380mg / kg, about 180mg / kg to about 360mg / kg, about 180mg / kg to about 340mg / kg, about 180mg / kg to about 320mg / kg, about 180mg / kg to about 300mg / kg, about 180mg / kg to about 280 mg / kg, about 180 mg / kg to about 260 mg / kg, about 180 mg / kg to about 240 mg / kg, about 180 mg / kg to about 220 mg / kg, about 180 mg / kg to about 200 mg / kg, about 200 mg / kg to about 400 mg / kg, about 200 mg / kg to about 380 mg / kg, about 200 mg / kg to about 360 mg / kg, about 200 mg / kg to about 340 mg / kg, about 200 mg / kg to about 320 mg / kg, about 200 mg / kg to about 300 mg / kg, about 200 mg / kg to about 280 mg / kg, about 200 mg / kg to about 260 mg / kg,Approximately 200mg / kg to approximately 240mg / kg, approximately 200mg / kg to approximately 220mg / kg, approximately 220mg / kg to approximately 400mg / kg, approximately 220mg / kg to approximately 380mg / kg, approximately 220mg / kg to approximately 360mg / kg, approximately 220mg / kg to approximately 340mg / kg, approximately 220m g / kg~about 320mg / kg, about 220mg / kg~about 300mg / kg, about 220mg / kg~about 280mg / kg, about 220mg / kg~about 260mg / kg, about 220mg / kg~about 240mg / kg, about 240mg / kg~about 400mg / kg, about 240mg / kg~ Approx. 380mg / kg, Approx. 240mg / kg~Approx. 360mg / kg, Approx. 240mg / kg~Approx. 340mg / kg, Approx. 240mg / kg~Approx. 320mg / kg, Approx. 240mg / kg~Approx. 300mg / kg, Approx. 240mg / kg~Approx. 280mg / kg, Approx. 240mg / kg~Approx. 260m g / kg, about 260 mg / kg to about 400 mg / kg, about 260 mg / kg to about 380 mg / kg, about 260 mg / kg to about 360 mg / kg, about 260 mg / kg to about 340 mg / kg, about 260 mg / kg to about 320 mg / kg, about 260 mg / kg to about 300 mg / kg, Approximately 260mg / kg to approximately 280mg / kg, approximately 280mg / kg to approximately 400mg / kg, approximately 280mg / kg to approximately 380mg / kg, approximately 280mg / kg to approximately 360mg / kg, approximately 280mg / kg to approximately 340mg / kg, approximately 280mg / kg to approximately 320mg / kg, approximately 280m g / kg~about 300mg / kg, about 300mg / kg~about 400mg / kg, about 300mg / kg~about 380mg / kg, about 300mg / kg~about 360mg / kg, about 300mg / kg~about 340mg / kg, about 300mg / kg~about 320mg / kg, about 320mg / kg~ about 400 mg / kg, about 320 mg / kg to about 380 mg / kg, about 320 mg / kg to about 360 mg / kg, about 320 mg / kg to about 340 mg / kg, about 340 mg / kg to about 400 mg / kg, about 340 mg / kg to about 380 mg / kg, about 340 mg / kg to about 360 mg / kg, about 360 mg / kg to about 400 mg / kg, about 360 mg / kg to about 380 mg / kg, or about 380 mg / kg to about 400 mg / kg) of body weight of a phenylbutyrate compound (e.g., any of the phenylbutyrate compounds described herein or known in the art,e.g. sodium phenylbutyrate).
[0104] In some embodiments, a bile acid (e.g., TURSO) is administered at about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 55 mg / kg, about 60 mg / kg, about 65 mg / kg, or about 70 mg / kg body weight. In some embodiments, the phenylbutyrate compound (e.g., sodium phenylbutyrate) is administered at about 10 mg / kg, about 20 mg / kg, about 30 mg / kg, about 40 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg, about 100 mg / kg, about 120 mg / kg, about 140 mg / kg, about 160 mg / kg, about 180 mg / kg, about 200 mg / kg, about 220 mg / kg, about 240 mg / kg, about 260 mg / kg, about 280 mg / kg, about 300 mg / kg, about 320 mg / kg, about 340 mg / kg, about 360 mg / kg, about 380 mg / kg, or about 400 mg / kg of body weight.
[0105] The bile acid or its pharma- ceutically acceptable salt and the phenylbutyrate compound can be included as part of a treatment regimen and administered separately or simultaneously. The compound can be administered daily, weekly, monthly, or quarterly. In some embodiments, the compound is administered once a day, twice a day, or three times a day or more. The compound can be administered for weeks, months, or years. For example, the compound can be administered for at least or about 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, or at least or about 5 years or more. The bile acid and the phenylbutyrate compound can be administered, for example, once a day or twice a day for 60 days or less (e.g., 55 days, 50 days, 45 days, 40 days, 35 days, 30 days or less). Alternatively, the bile acid and phenylbutyrate compounds can be administered once daily or twice daily for more than 60 days (e.g., more than 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 130, 140, 150, 160, 180, 200, 250, 300, 400, 500, 600 days).
[0106] In some embodiments of the methods described herein, the bile acid is TURSO. TURSO can be administered to a subject at a dose of about 0.5 g to about 10 g daily (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, or 9 g daily). For example, TURSO is administered in a dose of about 0.5 to about 5 g (e.g., about 0.5 to about 4.5, about 0.5 to about 4, about 0.5 to about 3.5, about 0.5 to about 3, about 0.5 to about 2.5, about 0.5 to about 2, about 0.5 to about 1.5, about 0.5 to about 1, about 1 to about 5, about 1 to about 4.5, about 1 to about 4, about 1 to about 3.5, about 1 to about 3, about 1 to about 2.5, about 1 to about 2, about 1 to about 1.5, about 1.5 to about 5, about 1.5 to about 4.5, about 1.5 to about 4, about 1.5 to about 3.5, about 1 About 1.5 to about 3, about 1.5 to about 2.5, about 1.5 to about 2, about 2 to about 5, about 2 to about 4.5, about 2 to about 4, about 2 to about 3.5, about 2 to about 3, about 2 to about 2.5, about 2.5 to about 5, about 2.5 to about 4.5, about 2.5 to about 4, about 2.5 to about 3.5, about 2.5 to about 3, about 3 to about 5, about 3 to about 4.5, about 3 to about 4, about 3 to about 3.5, about 3.5 to about 5, about 3.5 to about 4.5, about 3.5 to about 4, about 4 to about 5, about 4 to about 4.5, or about 4.5 to about 5 g). In some embodiments, about 1 g of TURSO is administered to the subject per day. In some embodiments, about 2 g of TURSO is administered to the subject per day. For example, TURSO can be administered at about 1 g twice daily.
[0107] In some embodiments of the methods described herein, the phenylbutyrate compound is sodium phenylbutyrate, which can be administered at about 1 g to about 30 g per day (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 g daily). For example, sodium phenylbutyrate is administered in a dose of about 0.5 to about 10 g (e.g., about 0.5 to about 9.5, about 0.5 to about 9, about 0.5 to about 8.5, about 0.5 to about 8, about 0.5 to about 7.5, about 0.5 to about 7, about 0.5 to about 6.5, about 0.5 to about 6, about 0.5 to about 5.5, about 0.5 to about 5, about 0.5 to about 4.5, about 0.5 to about 4, about 0.5 to about 3.5, about 0.5 to about 3, about 0.5 to about 2.5, about 0.5 to about 2, about 0.5 to about 1.5, about 0.5 to about 1, about 1 to about 10, about 1 ... about 9.5, about 1 to about 9, about 1 to about 8.5, about 1 to about 8, about 1 to about 7.5, about 1 to about 7, about 1 to about 6.5, about 1 to about 6, about 1 to about 5.5, about 1 to about 5, about 1 to about 4.5, about 1 to about 4, about 1 to about 3.5, about 1 to about 3, about 1 to about 2.5, about 1 to about 2, about 1 to about 1.5, about 1.5 to about 10, about 1.5 to about 9.5, about 1.5 to about 9, about 1.5 to about 8.5, about 1.5 to about 8, about 1.5 to about 7.5, about 1.5 to about 7, about 1.5 to about 6.5, about 1.5 to about 6, about 1.5 to about 5.5 , about 1.5 to about 5, about 1.5 to about 4.5, about 1.5 to about 4, about 1.5 to about 3.5, about 1.5 to about 3, about 1.5 to about 2.5, about 1.5 to about 2, about 2 to about 10, about 2 to about 9.5, about 2 to about 9, about 2 to about 8.5, about 2 to about 8, about 2 to about 7.5, about 2 to about 7, about 2 to about 6.5, about 2 to about 6, about 2 to about 5.5, about 2 to about 5, about 2 to about 4.5, about 2 to about 4, about 2 to about 3.5, about 2 to about 3, about 2 to about 2.5, about 2.5 to about 10, about 2.5 to about 9.5, about 2.5 to about 9, about 2. 5 to about 8.5, about 2.5 to about 8, about 2.5 to about 7.5, about 2.5 to about 7, about 2.5 to about 6.5, about 2.5 to about 6, about 2.5 to about 5.5, about 2.5 to about 5, about 2.5 to about 4.5, about 2.5 to about 4, about 2.5 to about 3.5, about 2.5 to about 3, about 3 to about 10, about 3 to about 9.5, about 3 to about 9, about 3 to about 8.5, about 3 to about 8, about 3 to about 7.5, about 3 to about 7, about 3 to about 6.5, about 3 to about 6, about 3 to about 5.5, about 3 to about 5, about 3 to about 4.5, about 3 to about 4, about 3 to about 3.5, about 3.5 to about 10, about 3.5 to about 9.5, about 3.5 to about 9, about 3.5 to about 8.5, about 3.5 to about 8, about 3.5 to about 7.5, about 3.5 to about 7, about 3.5 to about 6.5, about 3.5 to about 6, about 3.5 to about 5.5, about 3.5 to about 5, about 3.5 to about 4.5, about 3.5 to about 4, about 4 to about 10, about 4 to about 9.5, about 4 to about 9, about 4 to about 8.5, about 4 to about 8, about 4 to about 7.5, about 4 to about 7, about 4 to about 6.5, about 4 to about 6, about 4 to about 5.5, about 4 to about 5, about 4 to about 4.5, about 4.5 to about 10, about 4.5 to about 9.5, about 4.5 to about 9, about 4.5 to about 8.5, about 4.5 to about 8, about 4.5 to about 7.5, about 4.5 to about 7, about 4.5 to about 6.5, about 4.5 to about 6, about 4.5 to about 5.5, about 4.5 to about 5, about 5 to about 10, about 5 to about 9.5, about 5 to about 9, about 5 to about 8.5, about 5 to about 8, about 5 to about 7.5, about 5 to about 7, about 5 to about 6.5, about 5 to about 6, about 5 to about 5.5, about 5.5 ~ about 10, about 5.5 to about 9.5, about 5.5 to about 9, about 5.5 to about 8.5, about 5.5 to about 8, about 5.5 to about 7.5, about 5.5 to about 7, about 5.5 to about 6.5, about 5.5 to about 6, about 6 to about 10, about 6 to about 9.5, about 6 to about 9, about 6 to about 8.5, about 6 to about 8, about 6 to about 7.5, about 6 to about 7, about 6 to about 6.5, about 6.5 to about 10, about 6.5 to about 9.5, about 6.5 to about 9, about 6.5 to about 8.5, about 6.5 to about 8, about 6.5 to about 7 .5, about 6.5 to about 7, about 7 to about 10, about 7 to about 9.5, about 7 to about 9, about 7 to about 8.5, about 7 to about 8, about 7 to about 7.5, about 7.5 to about 10, about 7.5 to about 9.5, about 7.5 to about 9, about 7.5 to about 8.5, about 7.5 to about 8, about 8 to about 10, about 8 to about 9.5, about 8 to about 9, about 8 to about 8.5, about 8.5 to about 10, about 8.5 to about 9.5, about 8.5 to about 9, about 9 to about 10, about 9 to about 9.5, or about 9.5 to about 10 g). In some embodiments, sodium phenylbutyrate is administered about 3 g per day. In some embodiments, sodium phenylbutyrate is administered about 6 g per day. For example, sodium phenylbutyrate can be administered about 3 g twice a day. In some embodiments, the bile acid and the phenylbutyrate compound are administered in a weight ratio of about 2.5:1 to about 3.5:1 (e.g., about 3:1).
[0108] In some embodiments of the methods described herein, the methods include administering TURSO and sodium phenylbutyrate to a subject according to a first regimen followed by a second regimen, where the first regimen includes administering about 1 gram of TURSO once per day and about 3 grams of sodium phenylbutyrate once per day for at least 14 days (e.g., at least 16, 18, 21, 24, 27, 30, 35, or 40 days) and the second regimen includes administering about 1 gram of TURSO twice per day and about 3 grams of sodium phenylbutyrate twice per day for at least 30 days (e.g., at least 35, 40, 45, 50, 60, 80, 100, 120, 150, 180, 250, 300, or 400 days).
[0109] In some aspects of the methods described herein, the subject is diagnosed with AD, at risk of developing AD, or suspected of having AD. The subject may, for example, have been diagnosed with AD for 24 months or less (e.g., any of the subranges within this range described herein). For example, the subject may be diagnosed with AD for one week or less, or on the same day that the treatment of the disclosure is administered. The subject may have exhibited one or more symptoms of AD for 24 months or less (e.g., any of the subranges within this range described herein) and have elevated levels of total tau, phosphorylated tau, neurofilament light chain (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1) / PGP9.5, glial fibrillary acidic protein (GFAP), 8-hydroxy-2'-deoxyguanosine (8-OHdG), soluble insulin receptor (sIR); and reduced CSF Aβ. 1-42 levels; and carrying a mutation in one or more genes selected from the group consisting of APOE (e.g., carrying one or more copies of the APOE ε4 allele), APP, PSEN1, and PSEN2.
[0110] In some aspects of the methods described herein, the subject is diagnosed with a neurodegenerative disease (e.g., a tauopathy such as PSP), is at risk for developing a neurodegenerative disease (e.g., a tauopathy such as PSP), or is suspected of having a neurodegenerative disease (e.g., a tauopathy such as PSP). The subject may, for example, have been diagnosed with a neurodegenerative disease (e.g., a tauopathy such as PSP) for 24 months or less (e.g., any of the subranges within this range described herein). For example, the subject may be diagnosed with a neurodegenerative disease (e.g., a tauopathy such as PSP) for one week or less, or on the same day that the treatment of the disclosure is administered. The subject may have been exhibiting one or more symptoms of a neurodegenerative disease (e.g., a tauopathy such as PSP) for 24 months or less (e.g., any of the subranges within this range described herein) and have elevated levels of total tau, phosphorylated tau, neurofilament light chain (NfL), or YKL-40.
[0111] In some embodiments, prior to treatment, the subject has a baseline CSF tau total level of about 300 pg / mL or greater (e.g., about 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 3000, 3200, 3500, 3800 or 4000 pg / mL or more). In some aspects, administration of bile acids (e.g., TURSO) and phenylbutyrate compounds (e.g., sodium phenylbutyrate) reduces total CSF tau levels by about 35 pg / mL or more (e.g., about 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 pg / mL or more).
[0112] In some embodiments, prior to treatment, the subject has a baseline CSF phosphorylated tau (e.g., phosphorylated tau 181, phosphorylated tau 199, and / or phosphorylated tau 231) level of about 30 pg / mL or more. In some embodiments, prior to treatment, the subject has a baseline CSF phosphorylated tau (e.g., phosphorylated tau 181) level of about 70 pg / mL or more (e.g., about 75, 100, 125, 150, 175, or 200 pg / mL or more). In some embodiments, administration of a bile acid (e.g., TURSO) and a phenylbutyrate compound (e.g., sodium phenylbutyrate) reduces CSF phosphorylated tau levels by about 5 pg / mL or more (e.g., about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 pg / mL or more). In some embodiments, prior to treatment, the subject has a baseline CSF fatty acid binding protein 3 (FABP3) level of about 2000 pg / mL or more (e.g., about 2200, 2500, 2800, 3200, 3500, 3800, 3900, 4000, 4100, or 4200 pg / mL or more). In some aspects, administration of a bile acid (e.g., TURSO) and a phenylbutyrate compound (e.g., sodium phenylbutyrate) reduces CSF levels of FABP3 by about 200 pg / mL or more (e.g., about 250, 280, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500 pg / mL or more).
[0113] In some embodiments, prior to treatment, the subject has a baseline CSF neurogranin level of 200 pg / mL or more (e.g., about 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 pg / mL or more). In some embodiments, administration of a bile acid (e.g., TURSO) and a phenylbutyrate compound (e.g., sodium phenylbutyrate) reduces CSF neurogranin levels by about 30 pg / mL or more (e.g., about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 200 pg / mL or more).
[0114] In some embodiments, prior to treatment, the subject has a baseline CSF YKL-40 level of 140,000 pg / mL or more (e.g., about 160,000, 180,000, 210,000, 220,000, 230,000, 240,000, 250,000, 300,000 pg / mL or more). In some embodiments, administration of a bile acid (e.g., TURSO) and a phenylbutyrate compound (e.g., sodium phenylbutyrate) reduces CSF YKL-40 levels by about 5,000 pg / mL or more (e.g., about 7,000, 9,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 18,000, 20,000, 25,000 pg / mL or more).
[0115] In some embodiments, prior to treatment, the subject has a baseline CSF IL-15 level of about 1 to about 5 pg / mL (e.g., about 1.5, 2, 2.5, 3, 3.5, 4, or 4.5 pg / mL). In some embodiments, administration of a bile acid (e.g., TURSO) and a phenylbutyrate compound (e.g., sodium phenylbutyrate) reduces CSF IL-15 levels by about 0.01 pg / mL or more (e.g., about 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5 pg / mL or more).
[0116] In some embodiments, the Aβ in the CSF 1-42 The level is about 500 pg / mL or less (e.g., about 450, 400, 350, 300, 250, 200, 150, 100, 50, or 25 pg / mL or less). 1-42 Levels of about 150 to about 550 pg / mL and / or baseline CSF Aβ 1-40 The level may be about 3500 to about 9500 pg / mL. Administration of bile acids (e.g., TURSO) and phenylbutyrate compounds (e.g., sodium phenylbutyrate) may reduce Aβ levels. 1-42 / Aβ 1-40 The ratio can be increased by about 0.001 to about 0.02 (e.g., about 0.002 to about 0.015 or about 0.009).
[0117] A subject may have a baseline 8-OHdG level of about 2 to about 5 pg / mL (e.g., about 2.5, 3, 3.5, 4, or 4.5 pg / mL). Administration of bile acids (e.g., TURSO) and phenylbutyrate compounds (e.g., sodium phenylbutyrate) can increase 8-OHdG levels by about 0.1 pg / mL or more (e.g., about 0.2, 0.3, 0.4, 0.5, 0.6, or 0.7 pg / mL or more).
[0118] The methods described in this disclosure can include treatment of AD itself as well as treatment of one or more symptoms of AD. "Treating" AD does not require 100% disappearance of the disease or disease symptoms in the subject. Any alleviation or reduction in the severity of the symptoms or characteristics of the disease is contemplated. "Treating" AD can also refer to delaying the onset of symptoms (e.g., prophylactic treatment) or delaying the progression of symptoms or loss of function associated with the disease. "Treating" AD can also refer to eliminating or reducing one or more side effects of the treatment (e.g., caused by any of the therapeutic agents disclosed herein or known in the art for treating AD). "Treating" AD can also refer to eliminating or reducing one or more direct or indirect effects of AD disease progression. A subject may not exhibit signs of AD, but may be at risk for AD. For example, a subject may possess a mutation in a gene associated with AD (e.g., possess one or more copies of the APOE ε4 allele), have elevated levels of biomarkers indicative of risk for developing AD (e.g., including but not limited to, total tau, phosphorylated tau), or have elevated levels of biomarkers indicative of risk for developing AD (e.g., Aβ 1-42 The subject may exhibit early signs of disease or may exhibit symptoms of established or progressing disease. This disclosure contemplates any degree of delay in onset of symptoms, alleviation of one or more symptoms of disease, or slowing the progression of any one or more disease symptoms.
[0119] The treatments provided in this disclosure can be initiated at any stage during the progression of the disease. For example, treatment can be initiated pre-symptomatically (e.g., for subjects at risk of developing AD, e.g., with elevated total tau or phosphorylated tau), at symptom onset or immediately after detection of AD symptoms, or following observation of any one or more symptoms (e.g., cognitive decline, memory loss, reduced attention span) that lead a medical expert to suspect that the subject may be developing AD. Treatment can also be initiated at a later stage.
[0120] Treatment methods can include single doses, multiple doses, and repeated doses as needed to prevent or treat AD or at least one symptom of AD. The duration of preventative treatment can be a single dose, or treatment can continue for the duration of a subject's life, for example, for several years or indefinitely (e.g., multiple doses). For example, a subject at risk for AD can be treated with the methods provided herein for days, weeks, months, or even years to prevent the disease from developing or becoming apparent. In some embodiments, treatment methods can include assessing the level of disease in the subject before, during, and / or after treatment. Treatments provided herein can be administered one or more times daily, or can be administered weekly or monthly. In some embodiments, treatment can be continued until a reduction in the level of disease in the subject is detected. The methods provided herein, in some embodiments, may begin to demonstrate efficacy (e.g., reducing one or more symptoms of AD, improving as measured by a cognitive test such as the MOCA, ADAS-Cog, DSRS, MADCOMS, FAQ, or NPI-Q) in less than 60 days (e.g., less than 50, 45, 40, 35, 30, 25, 20, 15, or 10 days) after the first dose, or after less than 60 doses (e.g., less than 50, 45, 40, 35, 30, 25, 20, 15, or 10 doses).
[0121] The methods described in this disclosure can include treatment of the neurodegenerative disease (e.g., a tauopathy such as PSP) itself, as well as treatment of one or more symptoms of the neurodegenerative disease (e.g., a tauopathy such as PSP). "Treating" a neurodegenerative disease (e.g., a tauopathy such as PSP) does not require 100% elimination of the disease or disease symptoms in a subject. Any alleviation or reduction in the severity of the symptoms or characteristics of the disease is contemplated. "Treating" a neurodegenerative disease (e.g., a tauopathy such as PSP) can also refer to delaying the onset of symptoms (e.g., prophylactic treatment) or slowing the progression of symptoms or loss of function associated with the disease. "Treating" a neurodegenerative disease (e.g., a tauopathy such as PSP) can also refer to eliminating or reducing one or more side effects of the treatment (e.g., caused by any of the therapeutic agents for treating a neurodegenerative disease (e.g., a tauopathy such as PSP) disclosed herein or known in the art). "Treating" a neurodegenerative disease (e.g., a tauopathy such as PSP) also refers to eliminating or reducing one or more direct or indirect effects of the progression of a neurodegenerative disease (e.g., a tauopathy such as PSP). A subject may not show symptoms of a neurodegenerative disease (e.g., a tauopathy such as PSP), but may be at risk for a neurodegenerative disease (e.g., a tauopathy such as PSP). For example, a subject may carry a mutation in a gene associated with a neurodegenerative disease (e.g., a tauopathy such as PSP) and have elevated biomarker levels (e.g., including but not limited to, total tau, phosphorylated tau, or YKL-40) indicative of a risk of developing a neurodegenerative disease (e.g., a tauopathy such as PSP). A subject may show early signs of disease or may exhibit symptoms of established or progressive disease. This disclosure contemplates any degree of delaying the onset of symptoms, alleviating one or more symptoms of the disease, or slowing the progression of any one or more disease symptoms.
[0122] Treatments provided in this disclosure can be initiated at any stage during the progression of the disease. For example, treatment can be initiated pre-symptomatically (e.g., for subjects at risk of developing a neurodegenerative disease (e.g., a tauopathy such as PSP), e.g., those with elevated total tau or phosphorylated tau), at symptom onset or immediately after detection of symptoms of a neurodegenerative disease (e.g., a tauopathy such as PSP), or following observation of any one or more symptoms (e.g., cognitive decline) that lead a medical expert to suspect that a subject may be developing a neurodegenerative disease (e.g., a tauopathy such as PSP). Treatment can also be initiated at a later stage.
[0123] The treatment methods can include single doses, multiple doses, and repeated doses as required to prevent or treat a neurodegenerative disease (e.g., a tauopathy such as PSP) or at least one symptom of a neurodegenerative disease (e.g., a tauopathy such as PSP). The duration of the preventative treatment can be a single dose, or the treatment can continue (e.g., multiple doses) for the duration of the subject's life, for example, for several years or indefinitely. For example, a subject at risk for a neurodegenerative disease (e.g., a tauopathy such as PSP) can be treated with the methods provided herein for days, weeks, months, or even years to prevent the disease from developing or becoming apparent. In some embodiments, the treatment methods can include assessing the level of disease in the subject before, during, and / or after treatment. The treatments provided herein can be administered one or more times daily, or can be administered weekly or monthly. In some embodiments, the treatment can be continued until a reduction in the level of disease in the subject is detected. The methods provided herein, in some embodiments, may begin to demonstrate efficacy (e.g., reducing one or more symptoms of a neurodegenerative disease (e.g., a tauopathy such as PSP) and improving as measured by a cognitive function test) in less than 60 days (e.g., less than 50, 45, 40, 35, 30, 25, 20, 15, or 10 days) after the first dose or after less than 60 doses (e.g., less than 50, 45, 40, 35, 30, 25, 20, 15, or 10 doses).
[0124] As used herein, the terms "administer", "administering" or "administration" refer to administering a drug described herein to a subject using any method known in the art, for example, by ingesting, injecting, implanting, absorbing or inhaling the drug, regardless of form. In some embodiments, one or more of the compounds disclosed herein can be administered to a subject by oral and / or topical (e.g., intranasal) ingestion. For example, the methods herein include administering an effective amount of a compound or compound composition to achieve a desired or stated effect. The specific dosage and treatment regimen for any particular subject will depend on a variety of factors, including the activity of the specific compound employed, age, weight, general health, sex, diet, timing of administration, rate of excretion, drug combination, severity and course of disease, condition or symptoms, predisposition of the subject to disease, condition or symptoms, and the judgment of the treating physician.
[0125] After administration, the subject can be evaluated to detect, assess, or determine the level of disease, hi some embodiments, treatment can be continued until a change (e.g., a decrease) in the level of disease in the subject is detected.
[0126] Upon improvement of a patient's condition (e.g., a change (e.g., a decrease) in the level of disease in a subject), a maintenance dose of a compound, composition, or combination of this disclosure may be administered, if necessary. Thereafter, the dosage or frequency of administration, or both, may be reduced, depending on the symptoms, to a level at which the improved condition is maintained. However, the patient may require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
[0127] Symptoms and outcome measures Described herein are methods for assessing symptoms, monitoring the progression of a neurodegenerative disease, such as AD or PSP, and / or assessing a subject's response to a treatment method. Non-limiting examples include a physical evaluation by a physician, cognitive function testing (e.g., ADAS-Cog, MoCA, DSRS, MADCOMS, FAQ, NPI-Q, MDS PSP diagnostic criteria, PSP rating scale, or other appropriate test depending on the neurodegenerative disease), one or more CSF biomarkers (e.g., total tau (t-tau), phosphorylated tau 181 (e.g., p-tau 181 or another phosphorylated tau), neurofilament light chain (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1) / PGP9.5, glial fibrillary acidic protein (GFAP), 8-hydroxy-2'-deoxyguanosine (8-OHdG), soluble insulin receptor (sIR), Aβ 1-42 , Aβ 1-40 , Aβ 1-42 / Aβ 1-40 These methods may include measurements of cognitive function, such as cognitive function tests and one or more CSF biomarker levels, such as measuring the levels of one or more CSF biomarkers (e.g., cognitive function tests, CSF biomarker levels ...
[0128] In some embodiments, the methods described herein result in an improvement in the score received on one or more cognitive tests. In other embodiments, the methods described herein result in a significant reduction in t-tau, phosphorylated tau, or YKL-40 (e.g., as measured in CSF). In another example, the methods described herein result in a significant reduction in Aβ 1-42 / Aβ 1-40(e.g., measured in CSF; see Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J. Amyloid-β 42 / 40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. J Alzheimers Dis. 2015;43(1):183-91. doi: 10.3233 / JAD-140771. PMID: 25079805;Hansson, O., Lehmann, S., Otto, M. et al. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42 / 40 ratio in the diagnosis of Alzheimer's Disease. Alz Res Therapy 11, 34 (2019). https: / / doi.org / 10.1186 / s13195-019-0485-0; and James D. Doecke, Virginia Perez-Grijalba, Noelia Fandos, Christopher Fowler, Victor L. Villemagne, Colin L. Masters, Pedro Pesini, Manuel Sarasa, for the AIBL Research Group, “Total Aβ42 / Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis,” Neurology Apr 2020, 94 (15) e1580-e1591; DOI: 10.1212 / WNL.0000000000009240, which are incorporated by reference. In some embodiments, the methods described herein result in a significant increase in ventricular volume (e.g., as measured by imaging such as MRI).In some aspects, the methods described herein result in an increase in hippocampal volume, gray matter, average cortical thickness, and / or a decrease in the number of white matter lesions (e.g., as measured by imaging methods such as MRI).
[0129] composition The disclosure provides a method of treating at least one symptom of a neurodegenerative disease (such as AD or PSP) in a subject, the method comprising administering to the subject a bile acid or a pharma- ceutically acceptable salt thereof and a phenylbutyrate compound. In some embodiments, the method comprises administering to the subject a composition comprising TURSO and sodium phenylbutyrate.
[0130] bile acids As used herein, "bile acid" refers to naturally occurring surfactants having a nucleus derived from cholanic acid, typically substituted at the C6, C7, or C12 positions of the sterol nucleus with a 3α-hydroxyl group, as well as other hydroxyl groups. Bile acid derivatives (e.g., aqueous soluble bile acid derivatives) and amine-conjugated bile acids are also encompassed by the term "bile acid". Bile acid derivatives include, but are not limited to, derivatives formed at the carbon atoms where the hydroxyl and carboxylic acid groups of the bile acid are bonded to other functional groups, including, but not limited to, halogens and amino groups. Soluble bile acids may include aqueous preparations of the free acid form of the bile acid in combination with one of HCl, phosphoric acid, citric acid, acetic acid, ammonia, or arginine. Suitable bile acids include, but are not limited to, taurursodiol (TURSO), ursodeoxycholic acid (UDCA), chenodeoxycholic acid (sometimes referred to as "chenodiol" or "enoic acid"), cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursodeoxycholic acid, taurocholic acid, glycocholic acid, or analogues, derivatives, or prodrugs thereof.
[0131] In some embodiments, the bile acids of this disclosure are hydrophilic bile acids, including, but not limited to, TURSO, UDCA, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, lithocholic acid, and glycoursodeoxycholic acid. Pharmaceutically acceptable salts or solvates of any of the bile acids disclosed herein are also contemplated. In some embodiments, bases commonly employed to form pharma- ceutically acceptable salts of the bile acids of this disclosure include hydroxides of alkali metals, including sodium, potassium, and lithium; hydroxides of alkaline earth metals, such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; organic amines, such as ammonia, unsubstituted or hydroxyl-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributylamine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-(C1-C6)-alkylamines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-D-glucamine; morpholine; thiomorpholine; piperidine; pyrrolidine; and amino acids, such as arginine, lysine, and the like.
[0132] The terms "tauroursodeoxycholic acid" (TUDCA) and "taurursodiol" (TURSO) are used interchangeably in this specification.
[0133] The bile acids described herein may be TURSO as shown in Formula I (with carbons labeled to aid in understanding where substitutions may be made). In some embodiments, the TURSO is a hydrate, such as TURSO dihydrate.
[0134] [ka]
[0135] The bile acids described herein are represented by the formula II (with carbons labeled to aid in understanding where substitutions may be made): [ka] The UDCA may be UDCA as shown in Figure 1 or a pharma- ceutically acceptable salt thereof.
[0136] The bile acid derivatives of the disclosure may be physiologically relevant bile acid derivatives, for example, TURSO or UDCA, in which the stereochemistry of the hydroxyl group at the 3 or 7 position is changed in any combination with the substitution of hydrogen at the 3 or 7 position, are suitable for use in the present compositions.
[0137] A "bile acid" may be a bile acid conjugated with an amino acid. The amino acid in the conjugate may be, but is not limited to, taurine, glycine, glutamine, asparagine, methionine, or carbocysteine. Other amino acids that may be conjugated to the bile acids of this disclosure include arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, cysteine, proline, alanine, valine, isoleucine, leucine, phenylalanine, tyrosine, and tryptophan, as well as β-alanine and γ-aminobutyric acid. One example of such a bile acid is the compound of formula III: [ka] (In the formula, R is -H or C1-C4 alkyl; R1 is -CH2-SO3R3, CH2COOH, or CH2CH2COOH and R2 is -H; or R1 is -COOH and R2 is -CH2-CH2-CONH2, -CH2-CONH2, -CH2-CH2-SCH3, CH2CH2CH2NH(C=NH)NH2, CH2(imidazolyl), CH2CH2CH2CH2NH2, CH2COOH, CH2CH2COOH, CH2OH, CH(OH)CH3, CH2SH, pyrrolidin-2-yl, CH3, 2-propyl, 2-butyl, 2-methylbutyl, CH2(phenyl), CH2(4-OH-phenyl) or -CH2-S-CH2-COOH; R3 is -H or a residue of an amino acid, or a pharma- ceutically acceptable analog, derivative, prodrug, or mixture thereof. An example of an amino acid is a basic amino acid. Other examples of amino acids include glycine, glutamine, asparagine, methionine, carbocysteine, arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, cysteine, proline, alanine, valine, isoleucine, leucine, phenylalanine, tyrosine, and tryptophan, as well as β-alanine and γ-aminobutyric acid.
[0138] Another example of a bile acid of the disclosure is represented by formula IV [ka] (In the formula, R is -H or C1-C4 alkyl; R1 is -CH2-SO3R3 and R2 is -H; or R1 is -COOH and R2 is -CH2-CH2-CONH2, -CH2-CONH2, -CH2-CH2-SCH3, or -CH2-S-CH2-COOH; R3 is -H or a residue of a basic amino acid, or a pharma- ceutically acceptable analog, derivative, prodrug, or mixture thereof. Examples of basic amino acids include lysine, histidine and arginine.
[0139] In some embodiments, the bile acid is TURSO. TURSO is an amphoteric bile acid, a taurine-conjugated form of UDCA. TURSO compensates for mitochondrial bioenergetic deficits by incorporating into mitochondrial membranes, reduces Bax translocation to the mitochondrial membrane, reduces mitochondrial permeability, and raises the apoptotic threshold of cells (Rodrigues et al. Biochemistry 42, 10: 3070-3080, 2003). It is used to treat cholesterol gallstones, and long-term treatment (e.g., 1-2 years) is generally required to obtain complete dissolution. It has been used to treat cholestatic liver disease, including primary cirrhosis, pediatric familial intrahepatic cholestasis, and primary sclerosing cholangitis, as well as cystic fibrosis cholestasis. TURSO is contraindicated for subjects with biliary tract infections, frequent biliary colic, or problems absorbing bile acids (e.g., ileal disease or resection). Drug interactions may include interactions with substances that inhibit the absorption of bile acids, such as cholestyramine, and with drugs that increase the excretion of cholesterol in the bile (TURSO reduces biliary cholesterol content). Based on similar physicochemical properties, there are similarities in drug toxicity and interactions between TURSO and UDCA. The most common adverse reactions reported with the use of TURSO (≥1%) are abdominal discomfort, abdominal pain, diarrhea, nausea, pruritus, and rash. There have been some cases of pruritus and a limited number of cases of liver enzyme elevations.
[0140] In some embodiments, the bile acid is UDCA. UDCA or ursodiol, which have been used to treat gallstones, are endogenously produced and secreted by the liver as taurine (TURSO) or glycine (GUDCA) conjugates. Taurine conjugation increases the solubility of UDCA by increasing its hydrophilicity. TURSO is taken up in the distal ileum under active transport, and therefore likely has a slightly longer residence time in the intestine than UDCA, which is taken up more proximally in the ileum. Ursodiol therapy has not been associated with liver damage. Liver enzyme abnormalities have not been associated with Actigall® (Ursodiol USP Capsules) therapy, and Actigall® has been shown to reduce liver enzyme levels in liver disease. However, subjects receiving Actigall® should have SGOT (AST) and SGPT (ALT) measured at the start of treatment and subsequently indicated by specific clinical conditions. Previous studies have shown that bile acid ion sequestering agents such as cholestyramine and colestipol may interfere with the action of ursodiol by reducing its absorption. Aluminum-based antacids have been shown to adsorb bile acids in vitro and may be expected to interfere with ursodiol in a similar manner as bile acid ion sequestering agents. Estrogens, oral contraceptives, and clofibrate (and possibly other lipid-lowering drugs) may increase hepatic cholesterol secretion and promote cholesterol gallstone formation, thus counteracting the effectiveness of ursodiol.
[0141] Phenylbutyrate Compounds Phenylbutyrate compounds are defined herein as generic phenylbutyrates (low molecular weight aromatic carboxylic acids) including the free acid (4-phenylbutyrate (4-PBA), 4-phenylbutyric acid or phenylbutyric acid), and pharma- ceutically acceptable salts, co-crystals, polymorphs, hydrates, solvates, conjugates, derivatives or prodrugs thereof. The phenylbutyrate compounds described herein also encompass analogs of 4-PBA, including, but not limited to, glyceryl tri-(4-phenylbutyrate), phenylacetic acid (the active metabolite of PBA), 2-(4-methoxyphenoxy)acetic acid (2-POAA-OMe), 2-(4-nitrophenoxy)acetic acid (2-POAA-NO2), and 2-(2-naphthyloxy)acetic acid (2-NOAA), and pharma- ceutically acceptable salts thereof. Phenylbutyrate compounds include physiologically relevant 4-PBA species, such as, but not limited to, any substitution of deuterium in place of hydrogen in the structure of 4-PBA. Other HDAC2 inhibitors are contemplated herein as substitutes for phenylbutyrate compounds.
[0142] Physiologically acceptable salts of phenylbutyrate include, for example, the sodium, potassium, magnesium or calcium salts. Other examples of salts include the ammonium, zinc or lithium salts of phenylbutyrate, or salts with organic amines such as lysine or arginine.
[0143] In some embodiments of the methods described herein, the phenylbutyrate compound is sodium phenylbutyrate, which has the formula:
[0144] [ka]
[0145] Phenylbutyrate is a pan-HDAC inhibitor that can ameliorate ER stress through upregulation of the master chaperone regulator DJ-1 and through recruitment of other chaperone proteins (see, e.g., Zhou et al. J Biol Chem. 286: 14941-14951, 2011 and Suaud et al. JBC. 286:21239-21253, 2011). A large increase in chaperone production has been shown to reduce activation of the canonical ER stress pathway, fold misfolded proteins, and enhance survival in in vivo models, including the G93A SOD1 mouse model of ALS (see, e.g., Ryu, H et al. J Neurochem. 93:1087-1098, 2005).
[0146] formulation The bile acid and phenylbutyrate compounds described herein can be formulated for use as or in a pharmaceutical composition. For example, the methods described herein can include administering an effective amount of a composition comprising TURSO and sodium phenylbutyrate. As used herein, the term "effective amount" refers to an amount or concentration of one or more drugs administered for a period of time (including acute or chronic administration and periodic or continuous administration) effective in relation to that administration to cause a desired effect or physiological outcome. The composition can include about 5% to about 15% (w / w) (e.g., about 6% to about 14%, about 7% to about 13%, about 8% to about 12%, about 8% to about 11%, about 9% to about 10%, or about 9.7% (w / w)) TURSO and about 15% to about 45% (w / w) (e.g., about 20% to about 40%, about 25% to about 35%, about 28% to about 32%, or about 29% to about 30%, e.g., about 29.2% (w / w)) sodium phenylbutyrate. In some embodiments, the composition includes about 9.7% (w / w) TURSO and 29.2% (w / w) sodium phenylbutyrate.
[0147] Sodium phenylbutyrate and TURSO can be present in the composition in a weight ratio of about 1:1 to about 4:1 (e.g., about 2:1 or about 3:1). In some embodiments, the ratio of sodium phenylbutyrate to TURSO is about 3:1.
[0148] The compositions described herein may include any pharma- ceutically acceptable carrier, adjuvant, and / or vehicle. The term "pharma- ceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that may be administered to a patient together with a compound disclosed herein, which does not destroy its pharmacological activity, and is non-toxic when administered in a dose sufficient to deliver a therapeutic amount of the compound. In this specification, the term "pharma- ceutically acceptable carrier" includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The pharmaceutical composition may include any conventional non-toxic pharma- ceutical acceptable carrier, adjuvant, or vehicle. In some cases, the pH of the formulation may be adjusted with a pharma- ceutical acceptable acid, base, or buffer to enhance the stability of the formulated compound or its delivery form.
[0149] The compositions of this disclosure can include about 8% to about 24% (w / w) dextrates (e.g., about 9% to about 23%, about 10% to about 22%, about 10% to about 20%, about 11% to about 21%, about 12% to about 20%, about 13% to about 19%, about 14% to about 18%, about 14% to about 17%, about 15% to about 16%, or about 15.6% (w / w) dextrates). Anhydrous and hydrated dextrates are contemplated herein. Dextrates of this disclosure can include a mixture of sugars developed from the controlled enzymatic hydrolysis of starch. Some embodiments of the compositions described herein include hydrated dextrates (e.g., NF grades obtained from JRS Pharma, Colonial Scientific, or Co.).
[0150] The compositions of the disclosure can include about 1% to about 6% (w / w) sugar alcohol (e.g., about 2% to about 5%, about 3% to about 4%, or about 3.9% (w / w) sugar alcohol). Sugar alcohols can be derived from sugars and contain one hydroxyl group (-OH) attached to each carbon atom. Both disaccharides and monosaccharides can form sugar alcohols. Sugar alcohols can be natural or can be produced by hydrogenation of sugars. Exemplary sugar alcohols include, but are not limited to, sorbitol, xylitol, and mannitol. In some embodiments, the compositions include about 1% to about 6% (w / w) sorbitol (e.g., about 2% to about 5%, about 3% to about 4%, or about 3.9% (w / w)).
[0151] The compositions of the disclosure can include about 22% to about 35% (w / w) maltodextrin (e.g., about 22% to about 33%, about 24% to about 31%, about 25% to about 32%, about 26% to about 30%, or about 28% to about 29% (w / w), e.g., about 28.3% (w / w) maltodextrin). Maltodextrin can form a flexible helix that allows for entrapment of active ingredients (e.g., any of the phenylbutyrate compounds and bile acids described herein) when solubilized in solution, thereby masking the flavor of the active ingredients. Maltodextrin produced from any suitable source is contemplated herein, including, but not limited to, pea, rice, tapioca, corn, and potato. In some embodiments, the maltodextrin is pea maltodextrin. In some embodiments, the composition comprises about 28.3% (w / w) pea maltodextrin. For example, pea maltodextrin obtained from Roquette (KLEPTOSE® LINECAPS) can be used.
[0152] The compositions described herein can further include a sugar substitute (e.g., sucralose). For example, the compositions can include about 0.5% to about 5% (w / w) sucralose (e.g., about 1% to about 4%, about 1% to about 3%, or about 1% to about 2%, e.g., about 1.9% (w / w) sucralose). Other sugar substitutes contemplated herein include, but are not limited to, aspartame, neotame, acesulfame potassium, saccharin, and advantame.
[0153] In some embodiments, the composition includes one or more flavoring agents. The composition can include about 2% to about 15% (w / w) of the flavoring agent (e.g., about 3% to about 13%, about 3% to about 12%, about 4% to about 9%, about 5% to about 10%, or about 5% to about 8%, e.g., about 7.3% (w / w)). The flavoring agent can include a substance that imparts a different substance flavor or changes the characteristics of the composition by affecting its flavor. The flavoring agent can be used to mask unpleasant flavors without affecting the physical and chemical stability, and can be selected based on the flavor of the drug to be incorporated. Suitable flavoring agents include, but are not limited to, natural flavors, artificial flavors, and imitation flavors. Blends of flavoring agents can also be used. For example, the compositions described herein can include two or more (e.g., 2, 3, 4, 5 or more) flavoring agents. The flavoring agent may be soluble and stable in water. Selection of a suitable flavoring agent can be based on flavor testing. For example, different flavoring agents can be added separately to the composition and subjected to flavor testing. Exemplary flavoring agents include any fruit flavor powder (e.g., peach, strawberry, mango, orange, apple, grape, raspberry, cherry, or mixed berry flavor powder). The compositions described herein can include about 0.5% to about 1.5% (w / w) (e.g., about 1% (w / w)) mixed berry flavor powder and / or about 5% to about 7% (w / w) (e.g., about 6.3% (w / w)) masking flavor. Suitable masking flavors can be obtained, for example, from Firmenich.
[0154] The compositions described herein may further comprise silicon dioxide (or silica). The addition of silica to the composition may prevent or reduce aggregation of the components of the composition. Silica may serve as an anti-caking agent, adsorbent, disintegrant, or flow agent. In some embodiments, the compositions described herein comprise about 0.1% to about 2% (w / w) of porous silica (e.g., about 0.3% to about 1.5%, about 0.5% to about 1.2%, or about 0.8% to about 1%, e.g., 0.9% (w / w)). The porous silica may have a higher H2O absorption capacity and / or a higher porosity compared to fumed silica at a relative humidity of about 20% or more (e.g., about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or more). The HO absorption capacity of the porous silica may be about 5% to about 40% by weight (e.g., about 20% to about 40% by weight or about 30% to about 40% by weight) at a relative humidity of about 50%. The porosity of the porous silica may be higher than that of fumed silica at a relative humidity of about 20% or more (e.g., about 30%, 40%, 50%, 60%, 70%, 80%, 90% or more). In some embodiments, the porous silica has an average particle size of about 2 μm to about 10 μm (e.g., about 3 μm to about 9 μm, about 4 μm to about 8 μm, about 5 μm to about 8 μm, or about 7.5 μm). In some embodiments, the porous silica has an average pore volume of about 0.1 cc / gm to about 2.0 cc / gm (e.g., about 0.1 cc / gm to about 1.5 cc / gm, about 0.1 cc / gm to about 1 cc / gm, about 0.2 cc / gm to about 0.8 cc / gm, about 0.3 cc / gm to about 0.6 cc / gm, or about 0.4 cc / gm). In some embodiments, the porous silica has a bulk density of about 50 g / L to about 700 g / L (e.g., about 100 g / L to about 600 g / L, about 200 g / L to about 600 g / L, about 400 g / L to about 600 g / L, about 500 g / L to about 600 g / L, about 540 g / L to about 580 g / L, or about 560 g / L). In some embodiments, the compositions described herein include about 0.05% to about 2% (w / w) Syloid® 63FP (WR Grace) (e.g., any subrange of this range described herein).
[0155] The compositions described herein may further comprise one or more buffering agents. For example, the compositions may comprise about 0.5% to about 5% (w / w) of a buffering agent (e.g., about 1% to about 4% (w / w), about 1.5% to about 3.5% (w / w), or about 2% to about 3% (w / w), e.g., about 2.7% (w / w) of a buffering agent). The buffering agent may comprise a weak acid or base, which maintains the acidity or pH of the composition at about a selected value after the addition of another acid or base. Suitable buffering agents are known in the art. In some embodiments, the buffering agent in the compositions provided herein is a phosphate salt, such as sodium phosphate (e.g., sodium phosphate dibasic anhydrous). For example, the composition may comprise about 2.7% (w / w) of sodium phosphate dibasic.
[0156] The composition may also include one or more lubricants. For example, the composition may include about 0.05% to about 1% (w / w) of a lubricant (e.g., about 0.1% to about 0.9%, about 0.2% to about 0.8%, about 0.3% to about 0.7%, or about 0.4% to about 0.6%, e.g., about 0.5% (w / w) of a lubricant). Representative lubricants include, but are not limited to, sodium stearyl fumarate, magnesium stearate, stearic acid, metal stearates, talc, high melting temperature waxes and glycerides, colloidal silica, polyethylene glycol, alkyl sulfates, glyceryl behenate, and hydrogenated oils. Additional lubricants are known in the art. In some embodiments, the composition includes about 0.05% to about 1% (w / w) of sodium stearyl fumarate (e.g., any of the subranges of this range described herein). For example, the composition may contain about 0.5% (w / w) sodium stearyl fumarate.
[0157] In some embodiments, the composition comprises about 29.2% (w / w) sodium phenylbutyrate, about 9.7% (w / w) TURSO, about 15.6% (w / w) dextrates, about 3.9% (w / w) sorbitol, about 1.9% (w / w) sucralose, about 28.3% (w / w) maltodextrin, about 7.3% (w / w) flavorings, about 0.9% (w / w) silicon dioxide, about 2.7% (w / w) sodium phosphate (e.g., sodium phosphate dibasic), and about 0.5% (w / w) sodium stearyl fumarate.
[0158] The composition can include about 3000 mg sodium phenylbutyrate, about 1000 mg TURSO, about 1600 mg dextrates, about 400 mg sorbitol, about 200 mg sucralose, about 97.2 mg silicon dioxide, about 2916 mg maltodextrin, about 746 mg flavorings (e.g., about 102 mg mixed berry flavor and about 644 mg masking flavor), about 280 mg sodium phosphate (e.g., sodium phosphate dibasic), and about 48.6 mg sodium stearyl fumarate.
[0159] Additional suitable sweeteners or flavor masking agents may also be included in the composition, such as, but not limited to, xylose, ribose, glucose, mannose, galactose, fructose, dextrose, sucrose, maltose, steviol glycosides, partially hydrolyzed starch, and corn syrup solids. Water-soluble artificial sweeteners, such as soluble saccharin salts (e.g., sodium or calcium saccharin salts), cyclamates, acesulfame potassium (acesulfame K) and the free acid form of saccharin, as well as L-aspartyl-phenylalanine methyl ester, aspartame-based sweeteners such as Alitame® or Neotame®, are contemplated herein. The amount of sweetener or flavor masking agent may vary depending on the desired amount of sweetener or flavor masking agent selected for a particular final composition.
[0160] Pharmaceutically acceptable binders in addition to those mentioned above are also contemplated. Examples include cellulose derivatives including microcrystalline cellulose, low-substituted hydroxypropyl cellulose (e.g., LH 22, LH 21, LH 20, LH 32, LH 31, LH30); starches including potato starch; croscarmellose sodium (i.e., cross-linked carboxymethylcellulose sodium salt; e.g., Ac-Di-Sol®); alginic acid or alginates; insoluble polyvinylpyrrolidones (e.g., Polyvidon® CL, Polyvidon® CL-M, Kollidon® CL, Polyplasdone® XL, Polyplasdone® XL-10); and sodium carboxymethyl starch (e.g., Primogel® and Explotab®).
[0161] Polyols, sucrose, sorbitol, mannitol, erythritol®, tagatose®, lactose (e.g. spray dried lactose, α-lactose, β-lactose, Tabletose®, various grades of Pharmatose®, Microtose or Fast-Floc®), microcrystalline cellulose (e.g. various grades of Avicel® like Avicel® PH101, Avicel® PH102 or Avicel® PH105, Elcema® P100, Emcocel®, Vivacel®, Ming Tai® and Solka-Floc®), hydroxypropylcellulose, L-hydroxypropylcellulose (low substituted) (e.g. L-HPC-CH31, L-HPC-LH11, LH 22, LH 21, LH 20, LH 32, LH Additional fillers, diluents or binders such as dextrins, maltodextrins (e.g. Lodex® 5 and Lodex® 10), starches or modified starches (including potato starch, corn starch and rice starch), sodium chloride, sodium phosphate, calcium sulfate and calcium carbonate may be incorporated.
[0162] The compositions described herein can be formulated or adapted for administration to a subject via any route, e.g., any route approved by the U.S. Food and Drug Administration (FDA). Exemplary methods are described in FDA's CDER Data Standards Manual, version number 004, available at fda.give / cder / dsm / DRG / drg00301.html.
[0163] Pharmaceutical compositions are typically formulated to be compatible with its intended route of administration, which include parenteral (subcutaneous, intradermal, intravenous, intradermal, intramuscular, intra-articular, intra-arterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques), oral (e.g., via inhalation or feeding tube), transdermal (topical), transmucosal and rectal administration.
[0164] The pharmaceutical composition may take the form of a liquid or powder for inhalation and / or nasal administration. In some embodiments, the pharmaceutical composition is formulated as a powder-filled sachet. Suitable powders may include those that are substantially soluble in water. The pharmaceutical composition may be formulated using suitable dispersing or wetting agents and suspending agents (such as, for example, Tween® 80) according to techniques known in the art. The sterile injectable preparation may be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any non-irritating fixed oil may be employed, including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are pharmaceutically acceptable natural oils such as olive oil or castor oil, particularly in their polyoxyethylated forms. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, or carboxymethylcellulose or similar dispersants commonly used in the preparation of pharmaceutically acceptable dosage forms such as emulsions and / or suspensions. Other commonly used surfactants such as Tween® or Span® and / or other similar emulsifiers or bioavailability enhancers commonly used in the manufacture of pharmaceutically acceptable solid, liquid or other dosage forms may also be used for formulation.
[0165] The composition can be orally administered in any orally acceptable dosage form, including but not limited to powders, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of powders for oral administration, the powders can be substantially dissolved in water before administration. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate may also be added. When administered orally in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and / or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase, combined with emulsifying and / or suspending agents. If desired, some sweeteners and / or flavorings and / or colorings may be added.
[0166] Alternatively, or additionally, the compositions may be administered by nasal aerosol or inhalation.Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption enhancers which enhance bioavailability, fluorocarbons, and / or other solubilizing or dispersing agents known in the art.
[0167] In some embodiments, the therapeutic compositions disclosed herein can be formulated for sale in the United States, imported into the United States, and / or exported from the United States. The pharmaceutical compositions can be included in a container, pack, or dispenser, along with instructions for administration. In some embodiments, the present invention provides kits comprising a bile acid and a phenylbutyrate compound. The kits can also include instructions for the physician and / or patient, syringes, needles, boxes, bottles, vials, and the like.
[0168] Additional Therapeutic Agents and Further Combination Therapies Any of the pharmaceutical compositions or methods described herein may further comprise one or more additional therapeutic agents in an amount effective to treat or achieve modulation of at least one symptom of AD. Any AD therapeutic agent known in the art may be used as the additional therapeutic agent. Exemplary therapeutic agents may also include acetylcholinesterase inhibitors. Exemplary therapeutic agents include tacrine (Cognex®), rivastigmine (Exelon®), galantamine (Nivalin® and Razadyne®), donepezil (Aricept®) and memantine (Namenda®). Any known antidepressant is contemplated herein, including, but not limited to, selective serotonin inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin modulators and stimulants, serotonin antagonists and reuptake inhibitors, norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, tricyclic antidepressants, tetracyclic antidepressants, monoamine oxidase inhibitors, and NMDA receptor antagonists.
[0169] The methods of this disclosure can include administering to the subject one or more additional therapeutic agents (e.g., any of the additional therapeutic agents disclosed herein or known in the art) in combination with a bile acid (e.g., any of the suitable bile acids described herein) or a pharma- ceutically acceptable salt thereof and a phenylbutyrate compound (e.g., any of the suitable phenylbutyrate compounds described herein). The additional therapeutic agents can be administered for a period of time prior to the first administration of a composition comprising a bile acid or a pharma- ceutically acceptable salt thereof (e.g., TURSO) and a phenylbutyrate compound (e.g., sodium phenylbutyrate) and / or for a period of time after the last administration of the composition. In some embodiments, the subject in the methods described herein has previously been treated with one or more additional therapeutic agents (e.g., any of the additional therapeutic agents described herein, such as donepezil, galantamine, rivastigmine, memantine). In some embodiments, the subject has been receiving a stable dosage of a therapeutic agent (e.g., donepezil, galantamine, rivastigmine, and / or memantine) for at least 30 days (e.g., at least 40, 50, 60, 90, or 120 days) prior to administration of a composition of this disclosure. In some embodiments, treatment with a composition comprising a bile acid or a pharma- ceutically acceptable salt thereof (e.g., TURSO) and a phenylbutyrate compound (e.g., sodium phenylbutyrate) as described herein may aid in reducing the need for treatment with one or more additional therapeutic agents (e.g., donepezil, galantamine, rivastigmine, memantine).
[0170] Any of the pharmaceutical compositions or methods described herein may further comprise one or more additional therapeutic agents in an amount effective to treat or achieve regulation of at least one symptom of PSP. These therapies include those approved for treating progressive supranuclear palsy and those in development for treating progressive supranuclear palsy. These therapies include, but are not limited to, medications for treating movement disorders, medications for treating psychiatric disorders, psychotherapy, speech therapy, physical therapy, and occupational therapy. Medications for treating movement disorders include, but are not limited to, antipsychotics such as tetrabenazine, haloperidol, chlorpromazine, risperidone, and quetiapine, and other medications such as amantadine, levetiracetam, and clonazepam. Medications for treating mental disorders include, but are not limited to, antidepressants such as citalopram, fluoxetine and sertraline, antipsychotics such as quetiapine, risperidone and olanzapine, and mood stabilizers including anticonvulsants such as valproate, carbamazepine and lamotrigine.Psychotherapy includes, but is not limited to, talk therapy to help subjects manage behavioral problems, depression and suicidal thoughts.Speech therapy includes, but is not limited to, improving the subject's ability to speak clearly and improving the function and control of the muscles used in eating and swallowing.Physical therapy includes, but is not limited to, improving strength, flexibility, balance and coordination, reducing the risk of falling, improving posture, and reducing the severity of movement disorders.Occupational therapy includes, but is not limited to, the use of assistive devices to improve functional ability, such as handrails, and eating and drinking equipment for subjects with reduced motor skills.
[0171] The combination of a bile acid or a pharmaceutically acceptable salt thereof, a phenylbutyrate compound, and one or more additional therapeutic agents may exert a synergistic effect in treating a neurodegenerative disease (e.g., PSP or AD). A reduction in the dosage of the additional therapeutic agent may be required to obtain the same pharmacological effect when administered in combination with a bile acid or a pharmaceutically acceptable salt thereof, and a phenylbutyrate compound. In some embodiments, the amount of the additional therapeutic agent administered in combination with a bile acid or a pharmaceutically acceptable salt thereof, and a phenylbutyrate compound can be reduced by at least about 10% (e.g., at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or 55%) compared to the dosage used when the additional therapeutic agent is administered alone. Additionally or alternatively, the method of the disclosure can reduce the frequency of administration of other therapeutic agents (e.g., other AD therapeutic agents) required to obtain the same pharmacological effect.
[0172] Some embodiments of this disclosure provide methods of treating at least one symptom of AD or preventing the onset of AD in a human subject, the method comprising administering to the human subject an effective amount of (a) a bile acid or a pharma- ceutically acceptable salt thereof (e.g., any of the bile acids or pharma- ceutically acceptable salts thereof described herein); (b) a phenylbutyrate compound (e.g., any of the phenylbutyrate compounds described herein); and (c) one of the additional therapeutic AD agents listed above, thereby treating at least one symptom of AD or preventing the onset of AD in the human subject.
[0173] The bile acid or its pharmaceutically acceptable salt and the phenylbutyrate compound can be administered immediately after a meal (e.g., within 2 hours of a meal) or under fasting conditions. The subject may have consumed food (e.g., solid or liquid food) less than 2 hours prior to administration of the bile acid or its pharmaceutically acceptable salt and / or the phenylbutyrate compound; or consume food less than 2 hours after administration of one or both of the compounds. Food may affect the rate and extent of absorption of the bile acid or its pharmaceutically acceptable salt and / or the phenylbutyrate compound. For example, food may alter the bioavailability of a compound by delaying gastric emptying, stimulating bile flow, altering gastrointestinal pH, increasing splanchnic blood flow, altering the intestinal metabolism of a substance, or physically or chemically interacting with a dosage form or substance. The nutritional and caloric content of the meal, meal volume, and meal temperature can cause physiological changes in the gastrointestinal tract in ways that affect drug transit time, intestinal dissolution, drug permeability, and systemic availability. In general, meals higher in total calorie and fat content are more likely to affect GI physiology, thereby impacting drug bioavailability. The methods provided herein can further include administering a plurality of foods to the subject, e.g., less than 2 hours (e.g., less than 1.5 hours, 1 hour, or 0.5 hours) before or after administration of the bile acid or pharma- ceutically acceptable salt thereof and / or phenylbutyrate compound. EXAMPLES
[0174] Additional aspects are disclosed in further detail in the following examples, which are provided by way of illustration and are not intended to limit the scope of this disclosure or the claims appended hereto.
[0175] Example 1 Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyric Acid (PB) and Tauroursodeoxycholic Acid (TUDCA), in the Treatment of AD 1. Overview Principle of AMX0035 AMX0035 was tested in the acute pre-plaque Tg2576 mouse model. As shown in Figure 1, AMX0035 treatment significantly reduced soluble amyloid-β, especially Aβ42.
[0176] 1.1 Research purpose The study aimed to demonstrate proof of concept for AMX0035 as a safe and effective treatment for adult subjects with AD. The primary objectives of the study were to: To compare the safety and tolerability of a fixed-dose combination of AMX0035 (TUDCA / PB combination) versus placebo in subjects with MCI (probable or moderate due to AD) or dementia due to AD over a treatment period of approximately 24 weeks; To determine the effect of AMX0035 treatment on AD progression as measured by global statistical tests (GSTs).
[0177] The secondary objectives of the study are: To determine the treatment effect of AMX0035 on global and regional brain atrophy as assessed by volumetric magnetic resonance imaging (vMRI); To measure the effects of treatment on functional MRI measures, including resting-state BOLD connectivity; To evaluate the effect of AMX0035 on clinical symptoms as measured by ADAS-Cog, DSRS, FAQ and additional clinical outcomes; To evaluate the effects of AMX0035 on measures of neuropsychiatric symptoms as assessed by the Neuropsychiatric Inventory Questionnaire (NPI-Q)
[0178] The exploratory objectives of the study were to: Neuronal synaptic dysfunction, mitochondrial redox and amyloid-β assessed in cerebrospinal fluid (CSF) of all volunteers 1-42 To measure the effects of AMX0035 on biochemical markers of tau and neuroinflammation.
[0179] The primary evaluand was treatment effect measured by change from baseline in estimated GST (composed of Mild / Moderate AD Composite Scale (MADCOMS), FAQ, and hippocampal volume) at 24 weeks versus placebo in individuals with MCI (probable or moderate due to AD) or dementia due to AD. The study population for the primary evaluand was the intention-to-treat population.
[0180] 1.2 Research outcome measures 1.2.1 Primary outcome measures The study's primary outcome measures included the safety and tolerability of AMX0035 in Alzheimer's disease.
[0181] Adverse events (AEs), symptoms, physical examination, neurological examination, and laboratory parameters were prospectively collected to monitor safety and tolerability of the study drug. Safety and tolerability were assessed according to procedures outlined in the "Study Schedule" section.
[0182] 1.2.2 Secondary outcome measures Secondary outcome measures included neurophysiological biomarker assessments as well as cognitive and symptom-based measures. The effect of AMX0035 on cognition (ADAS-Cog and MoCA), function (DSRS and FAQ) and neuropsychiatric symptoms (NPI-Q) ratios were evaluated. Additionally, the effect of AMX0035 was assessed by multi-sequence MRI consisting of T1 (specifically the hippocampus as the primary vMRI outcome) for treatment-related changes, T2 FLAIR for regional volumetric analysis, T2 FLAIR for evaluation of lesions and white matter hyperintensities, and resting-state BOLD for measuring functional connectivity of the posterior and anterior default mode networks. Safety outcomes, specifically ARIA-E and ARIA-H, were monitored by T2 FLAIR and susceptibility weighted imaging (SWI).
[0183] 1.2.3 Exploratory outcome measures To assess drug target engagement of PB and TUDCA, a select panel of biomarkers in CSF was analyzed to measure the effect of AMX0035 on pharmacodynamic and pathophysiological targets relevant to AD.
[0184] Biomarker endpoints To determine the effect of AMX0035 treatment on: 1. Whole Brain Volume 2. Ventricular volume 3. Functional MRI measurements including resting-state BOLD connectivity 4. Cerebrospinal fluid (CSF) and plasma biochemistry markers including: Signature Alzheimer's Analyte: Amyloid β 1-42 , amyloid beta 1-40 , total tau, phosphorylated tau (pTau)181 Markers of neuronal synaptic dysfunction Markers of metabolism and oxidative stress Markers of vascular injury Markers of neuroinflammation
[0185] Specifically, we aimed to detect 1) Aβ, a “core” AD biomarker, in CSF. 1-42 , Aβ 1-40 , total tau and phosphorylated tau (pTau); 2) neurofilament light chain (NfL) and neurogranin (Ng) as markers of neuronal damage; 3) pyruvate / lactate and 8-hydroxy-2'-deoxyguanosine (8-OHdG) as indicators of mitochondrial function and redox environment; and 5) YKL-40, MCP-1 and IL-6 were assayed as biomarkers of inflammation in AD.
[0186] Alzheimer's disease is defined by the presence of abundant amyloid plaques and neurofibrillary tangles in the neuronal cortex. These pathological lesions consist primarily of Aβ and tau, and extensive research has now established that CSF measurements of these two proteins are sensitive and specific diagnostic markers for AD. Moreover, these markers can be used as prognostic biomarkers for the progression of cognitive decline in MCI.
[0187] Neurofilament light chain is a putative marker of subcortical large axon degeneration and has been shown to be elevated in subjects with AD and MCI (Zetterberg, Henrik, et al. "Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression." JAMA Neurology 73.1 (2016): 60-67). Furthermore, levels of NfL in CSF have been found to be associated with more rapid AD disease progression.CSF NfL levels are considered a biomarker of nonspecific axonal degeneration and have been implicated in a number of conditions including inflammatory diseases (Constantinescu, Radu, et al. "Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies." Journal of Neuroimmunology 306 (2017): 25-30), Creutzfeldt-Jakob disease (van Eijk, Jeroen JJ, et al. "CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease." Journal of Alzheimer's Disease 21.2 (2010): 569-576;Steinacker, Petra, et al. "Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease." Scientific Reports 6 (2016)), and progressive supranuclear palsy (Jabbari, Edwin, Henrik Zetterberg, and Huw R. Morris. "Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers." J Neurol Neurosurg Psychiatry (2017): jnnp-2017), and has been shown to be elevated in subjects with ALS and vascular dementia.
[0188] YKL-40 is a secreted glycoprotein that is considered to be a biological marker of active gliosis and neuroinflammation. Therefore, the level of YKL-40 in CSF is evaluated as a biomarker of neuroinflammation. YKL-40 is produced by astrocytes and is significantly elevated in subjects with MCI and mild AD (Craig-Schapiro, Rebecaa, et al. "YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease." Biological psychiatry 68.10 (2010): 903-912). However, CSF YKL-40 levels are a non-specific marker of neuroinflammation and have been shown to be elevated in subjects with multiple sclerosis (Comabella, Manuel, et al. “Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.” Brain 133.4 (2010): 1082-1093) and traumatic brain injury (Bonneh-Barkay, Dafna, et al. “YKL-40 expression in traumatic brain injury: an initial analysis.” Journal of Neurotrauma 27.7 (2010): 1215-1223). In the absence of a proven disease-modifying drug for comparison, it is unclear whether YKL-40 can be used to measure disease modification by pharmaceutical interventions such as AMX0035. However, elevated CSF YKL-40 did not correlate with other promising biomarkers of AD, specifically CSF NfL, T-tau and Aβ. 1-42Related to (Janelidze, Shorena, et al. “Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease.” Annals of Clinical and Translational Neurology 3.1 (2016): 12-20 and Melah, Kelsey E., et al. “Cerebrospinal fluid markers of Alzheimer’s disease pathology and microglia activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer’s disease.” Journal of Alzheimer’s Disease 50.3 (2016): 873-886).
[0189] Neurogranin (Ng) is a calmodulin-binding postsynaptic protein that is thought to be exclusively expressed in the brain and particularly enriched in dendritic spines (Hayashi, Yasunori. "Long-term potentiation: two pathways meet at neurogranin." The EMBO Journal 28.19 (2009): 2859-2860). Ng has been hypothesized to play a role in long-term potentiation and memory consolidation (Zhong, Ling, et al. "Increased prefrontal cortex neurogranin enhances plasticity and extinction learning." Journal of Neuroscience 35.19 (2015): 7503-7508). CSF Ng levels are elevated in AD and correlate with levels of "core" AD CSF biomarkers (Janelidze, Shorena, et al. "Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease." Annals of Clinical and Translational Neurology 3.1 (2016): 12-20 and Portelius, Erik, et al. "Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease." Brain 138.11 (2015): 3373-3385).
[0190] Each study subject had a CSF sample collected any time from the screening visit up to 7 days prior to the baseline visit and at the Week 24 / Early Discontinuation visit. CSF was collected and aliquoted into polypropylene tubes using standard protocols and stored at -80°C for subsequent analysis.
[0191] Figure 3 shows the general trends of different biomarkers of AD.
[0192] 2.Research design 2.1 Overall study design and planning During the enrollment period, approximately 140 subjects were screened, and approximately 100 of these subjects were randomized from approximately 10 AD-specialized clinical centers in the United States. These subjects were randomly assigned in a 3:2 ratio to receive twice-daily oral sachets of the active combination of TUDCA / PB or placebo. Treatment duration was approximately 24 weeks. Subjects received study drug or placebo twice-daily. Visits were conducted at screening, baseline measurements, and at weeks 6, 12, 18, and 24. Subjects who dropped out of the study were asked to attend an early discontinuation visit approximately 14 days after their last dose of study drug. The overall study workflow is shown in Figure 2 (note that Figure 2 is generalized; final randomization was N=95 (n=51 PB / TURSO and n=44 placebo)).
[0193] All visit slots were consecutive calendar days and were calculated from the day the participant started study treatment (day 0 was the baseline visit and first day of treatment), except for the final follow-up phone call, which was calculated from the last dose of study medication.
[0194] 2.2 Duration of Research Subjects continued to receive their randomized, placebo-controlled, double-blind treatment until the Week 24 visit. Each subject participated in the study for approximately 8 months, including screening and follow-up visits. In some cases, the Week 24 visit was delayed due to COVID-19 restrictions, and study treatment was extended until Week 40 / Day 280. Thus, in some cases, subjects may participate in the study for up to approximately 11 months.
[0195] 3. Study Enrollment and Withdrawal 3.1 Inclusion and Exclusion Criteria 3.1.1 Selection Criteria: 1) Men and women aged 55 to 89 2) A diagnosis of "probable Alzheimer's disease" or "mild cognitive impairment" with primarily amnesic symptoms (deficits in learning and recall of recently learned information) with the presence of documented biomarkers (amyloid PET, AD biomarkers for CFS, FDG-PET, or vMRI) supporting that the syndrome may be due to AD pathology. 3) MoCA score ≥ 8 4) Ability to read and write English sufficiently to complete all study procedures. 5) Geriatric Depression Scale <7 6) Willing and able to complete all evaluations and study procedures 7) Not pregnant, lactating, or of childbearing potential (women are >2 years postmenopausal or surgically sterilized) 8) Study partners who are willing to accompany patients to clinic visits, complete partner study forms, and have contact with subjects at least 2 days per week. 9) No known hypersensitivity to tauroursodeoxycholic acid or phenylbutyric acid 10) If receiving a cholinesterase inhibitor (e.g., donepezil) and / or memantine, treatment must have been initiated ≥3 months (84 days) prior to baseline and the medication regimen must have been stable for ≥6 weeks (42 days) prior to baseline. The investigator expects baseline medication regimen to remain unchanged throughout study participation.
[0196] 3.1.2 Exclusion criteria 1) Any CNS disease other than AD, such as clinical stroke, brain tumor, normal pressure hydrocephalus, multiple sclerosis, significant head trauma with persistent neurological agnosia or complaints, Parkinson's disease, frontotemporal dementia, or other neurodegenerative diseases. 2) Abnormal liver function defined as AST and / or ALT >3 times the upper limit of normal 3) Renal insufficiency defined as serum creatinine >1.5 times the upper limit of normal 4) Recent (<1 year) cholecystectomy or the presence of post-cholecystectomy syndrome or bile duct obstruction 5) A clinically significant and unstable medical condition (other than AD) that, in the opinion of the site's investigator, poses a risk to the participant if he or she were to participate in the study. 6) Any contraindication to undergoing an MRI study, such as: a. Cardiac pacemaker or pacemaker wire B. Metal particles in the body C. Vascular clip on head d. Artificial heart valve e. Severe claustrophobia that interferes with the ability to participate in the imaging study, or MRI findings of one or more of the following: a. 5 or more incidental microbleeds b. Incidental lacunar infarction with attributable signs or symptoms and with a history of stroke b. Incidental meningioma with attributable signs or symptoms C. Newly recognized meningiomas 7) Any severe active or chronic psychiatric illness that has not stabilized or is not adequately controlled within 1 year prior to baseline (e.g., depression, bipolar disorder, obsessive-compulsive disorder, schizophrenia) 8) Any significant neurodevelopmental disorder 9) Current suicidal ideation or history of suicide attempt within 5 years of baseline, or significant change from screening and baseline C-SSRS as determined by the site investigator 10) History of alcohol or other substance abuse or dependence within the past two years 11) Any significant systemic illness or medical condition that, in the judgment of the site's investigator, may affect safety or compliance with the study. 12) Laboratory abnormalities of B12, TSH, or other common laboratory parameters that may contribute to cognitive dysfunction 13) Current use of medications with psychotropic properties that may adversely affect cognition (e.g., anticholinergics, centrally acting antihistamines, antipsychotics, sedative-hypnotics, anxiolytics) 14) Any clinical trials evaluating the treatment of AD are prohibited beginning 3 months (90 days) prior to the baseline visit and continuing throughout the study. 15) Use of other investigational drugs within 1 month (28 days) prior to the baseline visit and for the duration of the study
[0197] · Figures 4-8 and Table 1 show the baseline characteristics of the enrolled participants. Figures 4A and 4B are an overview of the enrolled participants. As shown in Figure 5, there were no significant differences in baseline characteristics between the groups. Figure 6 shows the cognitive scores of the enrolled patients measured by the different tests. As can be seen, the PB / TURSO group had more patients with significant cognitive impairment, but a similar functional status (ADAS-Cog14 total score, MOCA and MADCOMS, all P<0.01). Figure 7 shows the baseline levels of CSF biomarkers. Figure 8 shows the ApoE status (the PB / TURSO group had a numerically higher proportion of apolipoprotein E4 carriers compared to the placebo group (77.1% vs. 61.4%, respectively; P=0.12)).
[0198] [Table 1]
[0199] 3.2 Treatment allocation procedure Each subject who met all eligibility criteria was randomized to receive either AMX0035 (3 g PB and 1 g TUDCA) or placebo, two sachets per day, for 24 weeks of treatment. Subjects were instructed to take only one sachet per day during the first week of the study and to increase to two sachets per day at the week 1 visit.
[0200] 3.3 Reasons for withdrawal Subjects discontinued participation in the study if: Any clinical adverse event (AE), laboratory abnormality, intercurrent illness, or other medical condition or situation occurs such that continued participation in the study is not in the subject's best interest. Subject met any exclusion criteria (newly occurring or previously unrecognized). Subjects were free to withdraw from the study at any time if they requested. An overview of subjects who were excluded, withdrew or discontinued early is shown in Figure 9.
[0201] 4. Treatment to be performed 4.1 Treatment 4.1.1 Description of the Test Product AMX0035 is a combination therapy consisting of two active pharmaceutical ingredients, sodium phenylacetate (PB) and tauroursodeoxycholic acid (TUDCA).
[0202] Phenylacetic acid is a compound approved in the United States for urea cycle disorders and is commercially available in the United States as Buphenyl®. A USP monograph exists for this material. The drug substance PB is produced under cGMP conditions. The manufacture and control of PBA is described in Drug Master File No. 019569. Specifications for PB are identical to those in the European Pharmacopoeia. The chemical structure of PB is shown below.
[0203] Chemical structure of PB: [ka]
[0204] The drug substance, TUDCA, is currently marketed under the trade names Tudcabil® and Taurolite®. TUDCA is indicated for the treatment of cholesterol gallstones. TUDCA is used to treat cholestatic liver disease, including primary cirrhosis, pediatric familial intrahepatic cholestasis, primary sclerosing cholangitis, and cholestasis due to cystic fibrosis. The chemical structure of TUDCA is shown below.
[0205] Chemical structure of TUDCA: [ka]
[0206] Powder filled sachets were used as the AMX0035 drug product. The drug product was filled into aluminum foil lined sachets under cGMP conditions.
[0207] The sachet contains the two active investigational ingredients and excipients.
[0208] 4.1.2 Placebo A placebo was used to maintain blinding of medication. Placebo sachets for this study were matched in size, color and appearance to the corresponding AMX0035 sachets. Administration of placebo was the same as for subjects in the treatment groups.
[0209] 4.2 Product Storage and Stability All investigational drugs were kept at 15-25°C. Subjects were required to store the kits containing the sachets at room temperature away from moisture. Stability was assessed for each individual active ingredient under both ICH criteria and accelerated conditions and they were found to be stable over a period of 5 years. Drug products underwent stability testing periodically over the course of the study to ensure that the products were not deteriorating.
[0210] 4.3 Dosing, Preparation, and Administration of Investigational Intervention / Investigational Product Subjects were instructed to open a sachet of AMX0035 and add it to a cup or other container (see "Subject Instructions" below for details). Subjects were then instructed to add approximately 8 oz. (1 cup) of room temperature water, stir until the powder is nearly dissolved, and consume the beverage completely. It is normal for a small amount of powder to remain undissolved. Subjects were instructed to consume the powder within 1 hour after adding it to the water. Subjects may consume other beverages after consuming the study drug; however, subjects should not mix the study drug with any liquid other than water.
[0211] Instructions for subjects The following was verbally instructed to patients at the baseline visit by medical personnel: Try the Listerine® products (Pocket Pack® and Pocket Mist®) for demonstration purposes. Warn patients that the study drug has a bitter taste but that there are ways (see below) to make it more palatable. Tear open a sachet of the study drug, add it to a cup or other container, add approximately 8 oz. (1 cup) of room temperature water, and stir vigorously. The study drug may require significant stirring or gentle trituration to dissolve. · The remedy should be taken within one hour of mixing with water. The following may be done to reduce unpleasant tastes and make the drug more palatable: Use Listerine Pocket Packs® (strips) or Listerine Pocket Mist® (spray) immediately before and / or after taking the medication. Use liberally to coat the mouth. This has been found to significantly mask the bitter taste. ○ Eat a snack or meal after taking your medication. Drink milk immediately after the drug to remove the taste from your mouth. ○ Avoid taking fruit juice at the same time as medication as this may further impair the flavor. Mixing the investigational drug with liquids other than water should be avoided.
[0212] 4.3.1 Feeding tube study drug administration For subjects with a gastrostomy or nasogastric (feeding) tube, the study drug may be dissolved in water as outlined in the Treatment Assignment Procedure section and the study drug may be administered via the feeding tube.
[0213] 4.4 Changes to Study Intervention / Product for Subjects 4.4.1 Discontinuation of medication Reasons for discontinuation of study drug may include AEs, recommendation of the medical monitor or SI, sponsor termination, protocol deviations, loss to follow-up, subject request, or death. All serious adverse events (SAEs) occurring in subjects who discontinue prematurely must be recorded and reported within 24 hours of being noticed.
[0214] Subjects who decided to permanently discontinue study drug (early study termination) and not remain in the intent-to-treat (ITT) portion of the study were encouraged to attend a final safety / early termination visit and participate in follow-up telephone calls as outlined in the "Handling Withdrawals" section. All subjects who discontinued study drug early and chose to remain in the ITT portion of the study were encouraged to attend drug-free study visits until the time of the final follow-up telephone call.
[0215] 4.5 Prior and Concomitant Therapies Any clinical trials with small molecules being used in or evaluating the treatment of AD are prohibited for the study period beginning 3 months (84 days) prior to the baseline visit. Any clinical trials with immunotherapy are prohibited for the study period beginning 1 year (365 days) prior to the baseline visit.
[0216] 4.5.1 Prohibited medications and contraindications Prohibited Medicines Prohibited medicines include, but are not limited to: HDAC inhibitors, including: Valproate Vorinostat (Zolinza) Romidepsin Tushidinostat Panobinostat Lithium Butyrate ○ Suramin Probenecid Bile acid sequestrants, including: Cholestyramine and Cholestyramine Lite ○ Questran and Questran Lite ○ Welcall Colestid and flavored colestid ○ Prevalite (trademark)
[0217] Antacids: Antacids containing aluminum hydroxide or smectite (aluminum oxide) should not be taken within 2 hours of AMX0035 administration as they will inhibit the absorption of TUDCA. Antacids include: Alamug Alumina and magnesia Antacids, antacid M and antacid suspensions Gen-Alox · Kudrox · MAH · Maalox HRF and Maalox TC Magnalox Madroxal Mylanta and Mylanta Ultimate Ri-Mox · Rulox
[0218] Aricept, Exelon, Razadyne, Namenda - If these medications are being administered, treatment must have been initiated ≥3 months (84 days) prior to baseline and the dosing regimen must have been stable for ≥6 weeks (42 days) prior to baseline.
[0219] 5. Research Plan 5.1 Screening visit The following procedures were performed at the visit to determine the subject's eligibility for the study. Completion of the evaluations and parameters took approximately 3-4 hours: Obtain written informed consent from subjects ○ Evaluate inclusion and exclusion criteria to determine subject eligibility Obtain medical history and demographics ○ Review and record concomitant medications and therapies Obtain AD diagnosis history, medical history, and demographic information Assess and record adverse events (AEs) after subjects sign the Informed Consent Form (ICF) ○ Measure vital signs including height and weight (blood pressure, heart and respiratory rate, temperature) ○ Perform a physical and neurological examination ○ Perform a 12-lead ECG (electrocardiogram) ○ Administer the Montreal Cognitive Assessment (MoCA) ○ Administer the screening version of the C-SSRS questionnaire ○ Administer the Geriatric Depression Scale Administer the Neuropsychiatric Inventory Questionnaire (NPI-Q) ○ Undergo an MRI scan (completed any time between screening and up to 7 days prior to the baseline visit) ○ Take blood samples for: ○ Clinical laboratory evaluation, including blood test (CBC with differential) Complete Chemistry Panel, Liver Function Tests ○ Collect a urine sample for urinalysis Lumbar puncture will be performed to obtain CSF for biomarker analysis (completed any time between the screening visit and up to 7 days prior to the baseline visit, pre-treatment) ○ Schedule a baseline visit
[0220] 5.1.1 Screening failure Any subject who signed the consent form was considered enrolled in the study. If a subject failed screening, at least the following information was obtained and entered into the electronic data capture (EDC) system: ○ Inclusion / exclusion criteria ○ Demographics Reasons for Screening Failure
[0221] 5.2 Baseline visit This visit occurred within 28+5 days of the screening visit. The following steps were performed, which took approximately 3-4 hours: ○ Check if eligibility criteria are still met Randomize subjects ○ Review and record concomitant medications and therapies ○ Review and record adverse events ○ Measure vital signs (blood pressure, heart rate, respiratory rate, body temperature) ○ Implement DSRS ○ Implement FAQs o Administer the Neuropsychiatric Inventory Questionnaire (NPI-Q) if not administered at screening ○ Implement ADAS-Cog ○ Implement the C-SSRS questionnaire after the last visit ○ Take blood samples for: Biomarkers Genetic analysis o Study drug is administered first. Medical personnel will advise subjects on proper delivery. Dispense a 6-week supply of the study drug
[0222] 5.3 First week phone call This visit occurred 7±1 days after the baseline visit. The following steps were performed, which took approximately 15 minutes: ○ Review and record adverse events ○ Ask about compliance and management of study medication Inform subjects about the increase from 1 sachet per day to 2 sachet per day
[0223] 5.4 Sixth week visit This visit occurred 42 ± 14 days after the baseline visit. The following procedures were performed and took approximately 30 minutes to 1 hour. Whenever possible, the Week 6 visit was conducted remotely. If completed remotely, the next in-person visit was conducted to collect any unused study drug and determine compliance. If permitted by local regulations and the local IRB, this visit was conducted at the subject's residence or preferred location: ○ Review and record concomitant medications and therapies ○ Review and record adverse events ○ Conduct MoCA ○ Administer the C-SSRS questionnaire (after the last visit) ○ Ask about compliance and management of study medication o Collect any unused study drug (and empty study drug sachets, if necessary). Dispense a 6-week supply of the study drug ○ Schedule your next study visit
[0224] 5.5 12th week visit This visit occurred 84 ± 28 days after the baseline visit.
[0225] It was preferred that the Week 12 visit be completed at a site where the participant was physically present. If it was not possible to complete an in-person Week 12 visit at a site, the following safety assessments were completed by Week 16 / Day 112 for subjects remaining on study drug. Sites were permitted to implement alternative arrangements for completing these assessments in accordance with institutional and IRB policies: ECG Safety Laboratory Tests: Hematology (complete blood count with differential), complete chemistry panel, liver function tests and urinalysis Vital signs C-SSRS
[0226] If completed remotely, any unused study medication was collected at the next in-person visit and adherence was determined.
[0227] The following steps were performed, which took approximately 2-3 hours: ○ Measure vital signs (blood pressure, heart rate, respiratory rate, temperature) ○ Review and record concomitant medications and therapies ○ Review and record adverse events ○ Ask about compliance and management of study medication ○ Implement ADAS-Cog ○ Implement DSRS ○ Implement FAQs Administer the Neuropsychiatric Inventory Questionnaire (NPI-Q) ○ Administer the C-SSRS questionnaire (after the last visit) ○ Perform a 12-lead ECG (electrocardiogram) ○ Blood is drawn for: Routine safety laboratory tests (chemical and hematological evaluations) Biomarkers Pharmacokinetics (PK) ○ Collect a urine sample for urinalysis o Collect any unused study drug (and empty study drug sachets, if necessary). Dispense a 6-week supply of the study drug ○ Schedule your next study visit
[0228] 5.6 18th week visit This visit occurred 126 ± 14 days after the baseline visit. The following procedures were performed and took approximately 30 minutes to 1 hour. Whenever possible, the Week 18 visit was conducted remotely. If completed remotely, the next in-person visit was conducted to collect any unused study drug and determine compliance. If permitted by local regulations and the local IRB, this visit was conducted at the subject's residence or preferred location: ○ Review and record concomitant medications and therapies ○ Review and record adverse events ○ Conduct MoCA ○ Administer the C-SSRS questionnaire (after the last visit) o Collect any unused study drug (and empty study drug sachets, if necessary). ○ Ask about compliance and management of study medication Dispense a 6-week supply of the study drug ○ Schedule your next study visit
[0229] 5.7 24th week final study visit / early discontinuation visit This visit occurred 168 ± 28 days after the baseline visit.
[0230] Every reasonable effort was made to complete the week 24 or early discontinuation visit at a site where the participant was physically present. However, if COVID-19-related restrictions (e.g., site closures, travel restrictions) made an in-person clinic visit impossible within the designated window, any assessments that could be performed remotely were completed as unscheduled visits within the week 24 window. The actual week 24 visit along with all assessments indicated in the SOA may be postponed for up to 12 weeks, extending treatment. The maximum duration for which a subject may receive IP is 40 weeks. Safety checks (i.e., ECG, safety laboratory tests, vital signs, and C-SSRS) had to be completed at least every 16 weeks / 112 days. If a safety assessment was performed and the week 24 visit was postponed, the assessment was recorded as an unscheduled visit.
[0231] When possible, an early discontinuation visit was performed within 14 days of the last dose of IP (i.e., last IP dose + 14 days). MRI and lumbar puncture were performed as soon as practicable and, when possible, within 60 days of the last IP dose (i.e., last IP dose + 60 days). The following steps were performed, which took 3-4 hours: ○ Measure vital signs including weight (blood pressure, heart and respiratory rate, temperature) ○ Review and record concomitant medications and therapies ○ Review and record adverse events ○ Perform a physical and neurological examination ○ Ask about compliance and management of study medication ○ Implement ADAS-Cog ○ Implement DSRS ○ Implement FAQs Administer the Neuropsychiatric Inventory Questionnaire (NPI-Q) ○ Conduct MoCA ○ Take an MRI scan o Lumbar puncture will be performed to obtain CSF for biomarker analysis (may be obtained up to 7 days prior to this visit; if the Early Discontinuation visit occurs up to 7 days after initiating study drug, there is no need to terminate the LP) ○ Administer the C-SSRS questionnaire (after the last visit) ○ Perform a 12-lead ECG ○ Blood is drawn for: Routine safety laboratory tests (chemical and hematological evaluations) Biomarkers ○ PK (not performed for subjects who completed the early discontinuation visit) ○ Collect a urine sample for urinalysis o Collect any unused study drug (and empty study drug sachets, if necessary). ○ Ask about compliance and management of study medication ○ Schedule a final follow-up call if necessary
[0232] 5.7.1 Final follow-up call Follow-up telephone calls occurred after the week 24 visit and within 14 ± 5 days of the subject's last dose of study drug. For participants who discontinued treatment early, a final follow-up telephone call was not required if the early discontinuation visit occurred 14 ± 5 days after the last dose of study drug.
[0233] The following took approximately 15 minutes: ○ Review and record concomitant medications and therapies Assess and record AEs, including those specified in 9.2.3
[0234] 5.8 Protocol Deviations A protocol deviation was a failure to follow the clinical trial protocol, Good Clinical Practice (GCP). This could be by either the subject, the SI, or the study site staff. If a deviation occurred, the site would develop corrective actions with the coordination team and implement them promptly.
[0235] All protocol deviations were addressed in the subject source documents, sent to the local IRB according to their guidelines, and entered into the protocol deviation log in the EDC system.
[0236] 5.9 Omitted Visits and Procedures Visits and any procedures not performed (not attempted) for reasons other than illness, trauma, or progressive physical disability (i.e., the subject was physically unable to perform the test) were reported as protocol deviations. Multiple omitted study procedures due to COVID-19 that did not affect data integrity or patient safety were recorded and combined into one minor protocol deviation.
[0237] Procedures or visits not performed due to illness, injury, or disability, including attempted but unsuccessful procedures (i.e., blood samples could not be obtained after multiple attempts, or weight could not be measured because the subject was immobile), were not reported as protocol deviations.
[0238] Compliance with study medication that was outside the limits outlined in the study operating manual was reported as a protocol deviation.
[0239] Details and specific instructions regarding protocol deviations, including any exceptions to this standard procedure, will be found in the study operations manual.
[0240] 6. Clinical evaluation and outcome measures 6.1 Clinical variables Assessments were conducted at designated time points throughout the study for clinical evaluation. In addition to the assessments assessed below, subjects provided information about their demographics, medical and AD diagnosis history, and concomitant medication use.
[0241] 6.1.1 Vital signs, height and weight Subjects were placed in a sitting position for several minutes and then vital signs were obtained. Vital signs, including blood pressure, heart rate, respiratory rate, and temperature, were assessed at screening, baseline, Week 12, and Week 24 / early discontinuation visits. Height was collected at the screening visit only. Weight was collected when physical examinations were performed at screening and Week 24 / early discontinuation visits.
[0242] If a subject is unable to attend a site visit to have vitals taken due to COVID-19, other arrangements for taking vitals may be made as permitted per institutional and local IRB policies.
[0243] 6.1.2 Clinical Laboratory Evaluation The following laboratory tests were performed for safety at Screening, Week 12, and Week 24 / Early Discontinuation visits: Blood test with differential panel: Complete blood count with differential (hematocrit, hemoglobin, total platelet count, RBC index, total RBC, total WBC and differential WBC) Blood Chemistry Panel / Liver Function Tests (LFT): Alanine aminotransferase (ALT (SGPT)), Aspartate aminotransferase (AST (SGOT)), Albumin, Alkaline phosphatase (ALP), Bicarbonate, Blood Urea Nitrogen, Calcium, Chloride, Creatinine, Glucose, Magnesium, Phosphate, Potassium, Sodium, Total Bilirubin and Total Protein Urine analysis: Albumin, appearance, bilirubin, blood, color, glucose, ketones, nitrate, pH, protein, specific gravity, urobilinogen and WBC screening ○ B12 and TSH, which may contribute to cognitive dysfunction, were assessed only at the screening visit as routine laboratory assessments.
[0244] All subjects underwent safety laboratory tests at designated visits outlined in the protocol. These samples were analyzed at a central laboratory. The SI may order additional tests throughout the study if deemed necessary to further evaluate adverse events (AEs) or if there is any suspicion that the subject may be pregnant.
[0245] If a subject is unable to visit the site where samples will be collected due to COVID-19, other arrangements for sample collection and analysis may be made as permitted in accordance with institutional and local IRB policies (e.g., samples may be analyzed at the site or in a third-party laboratory).
[0246] 6.1.3 Blood and urine samples Subjects will provide additional blood samples for genetic analysis at baseline and for biomarkers at the baseline, week 12, and week 24 / early discontinuation visits. All samples were anonymized and labeled with a code that did not contain any identifying information. Samples are for research purposes only. Genetic information may be analyzed but was not provided to subjects.
[0247] There was no scheduled date for the samples to be destroyed. Samples were stored for the study until they were used, damaged, spoiled, or otherwise unsuitable for analysis. Subjects had the option to decline participation in this portion of the study at any time by withdrawing consent for sample use. However, samples that may have already been used could not be destroyed.
[0248] Additionally, the central laboratory stored transport blood samples for pharmacokinetic analysis. The central laboratory facility prepared kits for all sites detailing the sampling protocol.
[0249] 6.1.4 12-lead electrocardiogram (ECG) Standard 12-lead ECGs were performed at screening, week 12, and week 24 / early discontinuation visits. Traces were reviewed by a central ECG reader, and copies of traces were kept at the clinic site as part of the source documents. The central ECG reader provided each site with standard ECG equipment and training. A board-certified cardiologist at the central ECG reader reviewed all ECGs.
[0250] If a subject was unable to attend a site visit for an ECG due to COVID-19, arrangements were made for the ECG to be completed elsewhere using equipment not provided by the central reader as permitted per institutional and local IRB policies.
[0251] 6.1.5 Physical and Neurological Examination Physical and neurological examinations were performed at Screening and at the Week 24 / Early Discontinuation Visit. The following systems were examined: general appearance, head, eyes, ears, nose, throat, neck, chest, heart, abdomen, extremities, edema, peripheral vascular, skin and appendages, musculoskeletal, central nervous system, and back.
[0252] 6.1.6 Geriatric Depression Scale (GDS) The Geriatric Depression Scale (short form) was administered at the screening visit only (see below for the scale). The GDS is a questionnaire designed to identify and quantify the presence of depression in older adults. The scale consists of 15 yes / no questions related to how the subject felt over the past week. The GDS includes items where positive and negative answers indicate depressive symptoms. One point is awarded for each relevant appropriate answer, for a total possible score of 15. A total score of 0-5 was considered normal, whereas a score of 6-15 was considered indicative of depression. A GDS score of less than 7 had to be selected for the study.
[0253] Geriatric Depression Scale Choose the answer that best describes how you have felt over the past week. 1. I am basically satisfied with my life. Yes / no 2. Many activities and interests are reduced. yes / no 3. You feel like your life is empty. yes / no 4. I often feel bored. yes / no 5. I am usually in a good mood. Yes / no 6. I'm worried that something bad will happen. yes / no 7. I feel happy most of the time. Yes / no 8. I often feel powerless. yes / no 9. Prefer staying at home to going out and doing new things. yes / no 10. First and foremost, I feel like I have problems with my memory. yes / no 11. I think it's wonderful to be alive now. Yes / no 12. I feel like there is little value in being myself. yes / no 13. I feel full of energy. Yes / no 14. I feel like my situation is hopeless. yes / no 15. I think most people are happier than I am. yes / no
[0254] Answers in bold indicate depression. Each answer in bold is worth 1 point.
[0255] A score >5 suggests depression. A score ≥ 10 almost always indicates depression. A score >5 indicates a need for comprehensive follow-up evaluation.
[0256] Source: http: / / www.stanford.edu / ~yesavage / GDS.html This scale is in the public domain.
[0257] The Hartford Institute for Geriatric Nursing acknowledges the outstanding contributions made to the field of geriatric psychiatric nursing and the original author of Try This, Lenore Kurlowicz, PhD, RN, CS, FAAN, who passed away in 2007.
[0258] 6.1.7 Columbia Suicide Severity Rating Scale (C-SSRS) The US FDA has published the Columbia Classification Algorithm for Suicide Assessment (C-CASA) 40We recommend the use of a suicidal ideation assessment instrument that corresponds to the Columbia-Suicide Severity Rating Scale (C-SSRS). The Columbia-Suicide Severity Rating Scale (C-CASA) was developed to aid in the coding of suicidal ideation data accumulated during the conduct of antidepressant clinical trials. 23 was utilized in this study. The C-SSRS contains a series of questions designed to detect potential suicidal thoughts and behaviors.
[0259] The screening version of the C-SSRS was administered at the screening visit. This version was used to assess suicidal ideation over the specified time periods. The since-last visit version of the C-SSRS was administered at baseline, week 6, week 12, and week 24 / early discontinuation visits. This version of the scale assessed suicidal ideation since the subject's last visit.
[0260] 6.1.8 Adverse Events Adverse events (AEs) were recorded at each study visit, including the screening visit where the informed consent form was signed by the subject, and at all study visits, including the final follow-up phone call 14 days (± 5 days) after the last dose of study drug. Information about adverse effects of study drug and intercurrent events was determined at each visit by direct questioning of the subject, review of concomitant medications, and vital sign results. Figure 10 shows an overview of adverse events in the intention-to-treat population. As shown in the figure, there are no new safety concerns. The PB / TURSO group had a significantly higher rate of discontinuations versus placebo (20% [10 / 51] vs. 5% [2 / 44]) and reduced drug compliance versus placebo (71% vs. 93%).
[0261] 6.2 Outcome Measurement Comprehensive statistical testing The GST allows for the assessment of global change in disease state / trajectory by standardizing and then combining measurements. The GST was a combination of three endpoints of change from baseline to the end of the study (MADCOMS, FAQ, and total hippocampal brain volume). The GST was calculated for each subject as the mean score across the three component endpoints. This mean score was analyzed as the primary efficacy outcome variable.
[0262] MADCOMS ADAS-Cog14 does not specifically target mild / moderate stage AD. The Mild / Moderate AD Composite Scale (MADCOMS) was pre-optimized for two separate groups: mild AD (baseline MMSE 20-26) and moderate AD (baseline MMSE 14-19). A weighted composite value was derived from the individual items of ADAS-Cog, MMSE and CDR using PLS regression (S. Hendrix ADPD 2021).
[0263] Moderate MADCOM= Comprehension x 0.36390157 + Paraphrasing x 0.10931155 + Ideation x 0.42535667 + Object Naming x 0.65626894 + Word Recognition x 0.05159097 + Word Recall x 1.06988506 + Oral Language x 0.3019936 + Home Life and Hobbies x 0.66529282 + Memory x 0.12277257 - Place Orientation x 0.23001218 - Spelling Backwards x 0.07980965 - Language and Performance x 0.18954955 Mild MADCOM= Paraphrasing x 0.39065568 + Word Recall x 1.14084544 + Oral Language x 1.09895590 + Personal Care x 0.60865765 + Community Activities x 0.15706995 + Judgment x 1.4092009-Time Orientation x 0.275966227
[0264] The DSRS (equivalent to the CDR) and MoCA (equivalent to the MMSE) were collected in the current study. Equivalent DSRS and MoCA items were scaled to MMSE or CDR test ranges and used to create the MADCOMS.
[0265] [Table A]
[0266] [Table B]
[0267] DSRS values were converted to the CDR scale by dividing the sum of the DSRS questions that make up the equivalent CDR domain score by the maximum score for this question. Memory, orientation, judgment and problem solving, community activities, and home life and hobbies are multiplied by 4 to create five categories that are assigned a rank value of 0, 0.5, 1, 2, or 3. Personal care scores are multiplied by 3 to create four categories that are assigned a rank value of 0, 1, 2, or 3.
[0268] 6.2.1 Functional Activity Questionnaire (FAQ) The FAQ is a brief informant-administered rating scale used to determine a subject's level of functional independence in performing instrumental activities of daily living (IADLs); repeated assessments are useful for monitoring performance in these areas over time. 47 (See below for scale). The FAQ total score (0-30) reflects the sum of ordinal ratings (0=fully independent, 1=doing it on one's own, with some difficulty, 2=needing assistance, 3=dependence) across 10 items assessing a range of functional activities (i.e. preparing a balanced meal, financial skills, and shopping), with higher scores indicating higher levels of dependency. For activities that an individual would not normally perform, a score of 1 was assigned if the informant believed the subject would not be able to complete the task upon request, or a score of 0 if the informant believed the subject could perform the task as required. Overall, the FAQ is a sensitive marker of functional impairment among individuals with a range of dementia severity. 43 It has been shown to distinguish mild cognitive impairment from early Alzheimer's disease with 80% sensitivity and 87% specificity. 49 The FAQ has demonstrated high reliability (greater than 0.90), takes approximately 5 minutes to complete, and requires limited rater training to administer. 47 FAQs were administered at baseline, week 12, and week 24 / early discontinuation visits.
[0269] Functional activity questionnaire implementation Informants are asked to rate the patient's performance using the following scoring system: Depends=3 Needs assistance = 2 · Difficult but do it yourself = 1 · Normal=0 · I've never done [the activity] before, but I could do it now = 0 · Never done it before and still difficult to do = 1 Write checks, pay bills, and balance checkbooks Organize your tax records, business activities or documents Going shopping for clothes, daily necessities, or food alone Play games that require skill and pursue hobbies Boil water, make coffee, and turn off the stove after use. Prepare a balanced diet Keep up with recent events Concentrate on, understand, and discuss TV, books, and magazines Remembers appointments, family events, holidays, and medications Arrange for a long distance trip, driving, or bus ride Total score:
[0270] evaluation Total score (0–30). A cut-point of 9 (≥3 activities dependent) is recommended to indicate functional impairment and possible cognitive impairment. Pfeffer RI et al. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37(3):323-329.
[0271] 6.2.2 Dementia Severity Rating Scale (DSRS) The DSRS is a brief, 12-item informant-administered questionnaire that assesses the functional ability of subjects. 44The DSRS is a multiple-choice questionnaire designed to comprehensively characterize daily activities affected by neurodegenerative disease (see below for questionnaire). It has strong concurrent validity and contains material that parallels that covered in the Clinical Dementia Rating Scale (CDR), a commonly used dementia staging instrument. 46 The DSRS is a highly reliable scale, with intraclass correlations >90% for interrater reliability and Cronbach's alpha >0.70 for internal consistency. 48 , which was shown to accurately distinguish cognitively healthy individuals from subjects with dementia of various severity. 44、45 Furthermore, the DSRS allows for a wide range of scores (total scores 0–54) that enhances its sensitivity for detecting incremental changes in functional ability over time, making it suitable for quantifying a wide range of functional impairments without being hindered by floor effects seen in more advanced disease. 50 The DSRS takes approximately 5 minutes to administer, requires minimal rater training, and can be administered over the telephone to subjects if necessary. The DSRS was administered at baseline, week 12, and week 24 / early discontinuation visits.
[0272] Participant Name: date: Name of the person filling out the form: Please circle the most appropriate answer.
[0273] Do you live with the participant? No Yes How often will you contact participants? Less than 1 day per week / 2 days per week / 3-4 days per week / 5 days or more per week Relationship with participants Self, spouse, siblings, children, other family members, friends, etc. For each item, please circle the number that best describes you. This is a general format, so the statements do not have to be exact. Please circle the answer that you think applies most of the time. Please circle only one number per item and be sure to answer all questions.
[0274] memory 0 Memory normal. 1 I sometimes forget things I said a while ago. This doesn't cause much of a problem. 2 Mild and consistent forgetfulness. Can remember recent events, but often forgets parts of them. 3 Moderate memory loss. Loss of recent events is severe. You may not remember what you just said. Problems with daily activities. 4. Virtual memory loss. Quickly forgetting recent or newly learned things. Can only remember things that are old. 5. I can't remember basic facts like what day it is, when I had my last meal, or what my next meal will be. 6. I can't remember even the most basic things.
[0275] Speech and Language 0 Normal ability to speak and understand others. I can't think of a single word sometimes, but I can still carry on a conversation. 2. Often forgets words. Sometimes uses inappropriate words. Has some problems expressing ideas and responding. 3 Usually answers questions using sentences but rarely initiates conversations. 4 Can answer questions but replies are often difficult to understand or do not make sense. Can usually follow simple instructions. 5 Speech is often incomprehensible. Can't answer questions or follow instructions. 6 In most cases, they do not respond.
[0276] Family Recognition 0 Normal - Able to recognise people and have a general idea of who they are. 1. They may recognise grandchildren, cousins or other relatives they don't see often, but may not remember what their relationship is. 2. Does not recognize family members with whom he or she does not often meet. Often has confusion about how family members, such as grandchildren, nephews, or nieces, are related to him or her. 3 Occasionally does not recognise close family members or others seen frequently. May not recognise children, brothers or sisters whom they do not see regularly. 4. Frequently does not recognize spouse or caregiver. 5. Not recognizing or being aware of the existence of others.
[0277] Time orientation 0 Awareness of time and day of the week is normal. 1 Occasional confusion about what time it is or what day it is, but not severe enough to interfere with daily activities. 2. Frequently get confused about time. 3. Almost always confused about time. 4 He seems completely unaware of the time.
[0278] Orientation to place 0 Normal awareness of where you are in new places. 1 I sometimes lose my sense of direction in new places. 2. I frequently get disoriented in new places. 3. I get disoriented even in familiar places. I sometimes forget that I'm already at home. 4 I am almost always confused about the location.
[0279] Ability to make decisions 0 Normal - Able to make decisions as before. 1 I have very little difficulty making decisions that arise in everyday life. 2 Somewhat difficult. When things get complicated or plans change, it becomes confusing. 3. I rarely make any important decisions. I get confused easily. 4 Often times, they don't understand what's going on.
[0280] Social and Community Activities 0 Normal - Interacts with people as before. 1 The problem is minor and not very significant, but the behavior is clearly different from past years. 2 Able to still participate in community activities without assistance; may appear normal to people who do not know the subject. 3 Often has difficulty socializing outside the home without help from a caregiver. Can participate in quiet activities at home with friends. Problems are obvious to anyone observing. 4. Can no longer participate in activities at home that involve other people in any practical way. Can only associate with primary caregiver. 5 Little or no response to primary caregiver.
[0281] Home Activities and Responsibilities 0 Normal. No impairment in ability to work around the home. 1 Has some problems with activities at home. May have more difficulty managing money (paying bills) and keeping things in order. Still able to shop, cook and clean. Still able to watch TV or read the newspaper with interest and understanding. 2. Makes mistakes with simple tasks like shopping, cooking or cleaning. Loses interest in the newspaper, TV or radio. Often cannot keep up with long conversations on a single topic. 3. Unable to shop, cook or clean without much help. Does not understand the newspaper or TV. Cannot keep up with a conversation. 4. Home-based activities are no longer possible.
[0282] Personal Care - Cleanliness 0 Normal. Take care of yourself as you always have. 1. I sometimes forget to wash my face, shave, or comb my hair, or I wear the wrong types of clothes. I'm not as clean as I used to be. 2. Needs help with dressing, washing, and grooming. 3 Total reliance on help for personal care.
[0283] meal 0 Normal, does not need help eating offered food. 1. May need help cutting food or have difficulty with some meals, but generally can feed himself / herself. 2 Generally able to feed himself / herself, but may need some help. May lose interest in meals. 3. Needs to be fed. May have difficulty swallowing.
[0284] Bladder and bowel control 0 Normal - No problems with bladder or bowel control except for physical problems. 1 Infrequent loss of urination control (less than once a month). 2 Occasional inability to control urination (about once a week or less). 3 Frequent inability to control urination (more than once a week). 4. General inability to control urination and frequent inability to control bowel movements.
[0285] Ability to move from place to place 0 Normal, able to move around on one's own (may have physical problems requiring a cane or walker). 1. Sometimes gets confused, especially when driving or using public transport in a new place. Can walk alone. 2. Unable to drive or use public transport alone, even in familiar areas. Unable to travel short distances alone. May become lost if travelling far from home. 3. Cannot be left alone outdoors. Able to move around the house without becoming lost or disoriented. 4. Becoming disoriented in the house and needing help getting around. 5 Spends most of the time in bed or a chair. May be able to take a few steps with help, but has no sense of direction. 6 Always in bed. Unable to sit or stand.
[0286] author Dr. Christopher M Clark, Alzheimer's Disease Core Center Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
[0287] 6.2.3 Cognitive assessment Cognitive testing included the ADAS-Cog and Montreal Cognitive Assessment (MoCA) assessments.
[0288] ADAS-Cog The ADAS-Cog has been validated and is widely used as the primary cognitive outcome measure in AD pharmacotherapy studies. It is a psychometric instrument that assesses memory (immediate or delayed word recall, word recognition), attention (digit erasure), reasoning (following commands), language (naming, comprehension), orientation, conceptual performance (putting a letter in an envelope) and constructive performance (copying a geometric structure), as well as executive function (completion of a maze). Scoring ranges from 0 to 90, with higher scores indicating greater impairment. The test was administered by experienced raters at each site at baseline, week 12, and week 24 / early discontinuation visits. The ADAS-Cog was the primary cognitive outcome measure in this study.
[0289] If the ADAS-Cog was administered remotely, it was completed to the extent possible given the available technology. Failure to complete the ADAS-Cog remotely was recorded as a minor deviation.
[0290] MoCA The Montreal Cognitive Assessment (MoCA) is a questionnaire commonly used in clinical trials and research settings to measure the level of cognitive impairment. The MoCA measures five areas of cognitive function: orientation, visuospatial, attention and calculation, recall, and language. The MoCA takes approximately 10 minutes to complete. The test was administered by experienced raters at each site at screening, week 6, week 18, and week 24 / early discontinuation visits. See below for worksheet.
[0291] Three available versions of the MoCA test were administered by experienced raters at each site. Subjects received one version of the MoCA at the screening visit unless they had received the same MoCA version clinically within the previous 3 months. A different version of the MoCA was used at each subsequent visit until Week 24 or the early discontinuation visit (if applicable). The MoCA version used at a study visit was accurately recorded in the source documents and in the EDC for each visit.
[0292] Rescreening: Subjects were rescreened if screening failed due to a MoCA score outside the required selection range at the screening visit; a minimum of 1 month must have elapsed since the initial MoCA assessment. If a subject's MoCA score was <10, treatments or interventions that may have influenced the subject's cognitive status (in the opinion of SI) had to be changed. Subjects who proceeded to rescreening were assessed using a different MoCA version (7.1, 7.2 or 7.3) than that used at the initial screening visit, and subjects were rescreened only once.
[0293] If the MoCA was administered remotely, it should be completed whenever possible given the available technology. Failure to complete the MoCA remotely was recorded as a minor deviation.
[0294] [Table C]
[0295] 6.2.4 Neuropsychiatric Inventory Questionnaire (NPI-Q) The Neuropsychiatric Inventory (NPI) measures behavioral symptoms related to dementia and was used to assess changes in ethical status. There are several versions of the NPI, including the NPI-Questionnaire (NPI-Q), NPI-Clinician (NPI-C) and NPI-Nursing Home (NPI-NH). All test 12 subdomains of behavioral functioning, including hallucinations, delusions, agitation, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, abnormal motor activity, feeding disorders and changes in nocturnal behavior. The NPI-Q was completed by trained raters via an interview with the subject's research partner. The NPI-Q has been well validated and has been used widely in clinical trials for AD. The NPI-Q was administered at screening or baseline, week 12 and week 24 / early discontinuation visits.
[0296] 6.2.5 Lumbar puncture for CSF biomarker levels We assessed cerebrospinal fluid (CSF) biomarkers related to cellular processes and pathways involved in Alzheimer's disease and the mechanism of action of AMX0035. Biomarker analysis included Aβ 1-42 , total tau, phosphorylated tau, NfL, YKL-40, neurogranin, MCP-1, IL-6, and the mitochondrial redox markers pyruvate, lactate, and 8-OHdG.CSF samples were collected prior to AMX0035 treatment, any time from the screening visit up to 7 days prior to the baseline visit, and after 24 weeks of treatment at the final study visit or early discontinuation visit.
[0297] Subjects collected early morning fasting CSF samples any time from screening up to 7 days prior to the baseline visit (pre-dose), and at the Week 24 and / or early discontinuation visits. If the early discontinuation visit occurred within 7 days of study drug initiation (baseline visit), the LP was not required to be completed. Lumbar punctures (LP) were performed by experienced physicians. A standard protocol utilizing sterile conditions, local lidocaine anesthesia, and the preferred use of a 24-gauge Sproat needle was used, which minimized the occurrence of headaches after LP. Approximately 15-20 cc of CSF was collected for CSF biomarker assays as well as routine chemistry analyses (protein, glucose) and cell counts.
[0298] 6.2.6 Neuroimaging MRI Scans: In accordance with secondary study objectives, all subjects who underwent 3T structural and functional MRI completed assessments of treatment effects on brain volume, cerebral perfusion pressure and brain connectivity at any time from screening up to 7 days prior to the baseline visit, as well as at the 24-week and / or early discontinuation visits. Each scan session lasted approximately 35 minutes and included the following MR pulse sequences: high-resolution T1-weighted multi-echo MPRAGE for volumetric analysis, a task-free blood oxygen level-dependent (BOLD) sequence to measure resting-state neuronal connectivity, diffusion tensor imaging (DTI), susceptibility-weighted imaging (SWI) and T2-weighted fluid-suppressed inversion recovery (FLAIR) sequences to quantify white matter structural connectivity. Radiologists at each site provided clinical reads. For volumetric analysis, high-resolution T1-weighted images underwent reconstruction and volume segmentation using the Freesurfer image analysis suite. All imaging and biomarker processing and assessments were performed in a blinded fashion.
[0299] Volumetric analysis includes: Total gray matter volume Total left and right hippocampal volume · Parahippocampal gyrus volume Ventricular and choroid plexus volumes · Average cortical thickness
[0300] White matter analysis includes: Number of white matter lesions White matter lesion volume
[0301] CSF and plasma biomarkers Characteristic Alzheimer's Disease Marker - Amyloid β 1-42 , amyloid beta 1-40 , total tau, phosphorylated (p)-tau181 Alzheimer's disease is defined by the presence of large amounts of amyloid plaques and neurofibrillary tangles in the neuronal cortex. These pathological lesions consist mainly of specific Aβ species and tau, and extensive studies have established that CSF measurements of these proteins are sensitive and specific diagnostic markers for AD (Blennow K, Mattsson N, Schoell M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015;36:297-309. https: / / doi.org / https: / / doi.org / 10.1016 / j.tips.2015.03.002). Furthermore, these markers may be used as prognostic biomarkers for the progression of cognitive decline in MCI and AD.
[0302] Aβ 1-42 / Aβ 1-40 ratio Aβ 1-42 / Aβ 1-40 The ratio is an important marker in Alzheimer's disease and is decreased in the CSF of patients with Alzheimer's disease. 1-42 / Aβ 1-40 was shown to be a more reliable indicator of AD than other representative AD biomarkers. 1-42 / Aβ 1-40It has also been suggested that the ratio can be used to distinguish types of dementia. For example, Hansson, O., Lehmann, S., Otto, M. et al. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42 / 40 ratio in the diagnosis of Alzheimer's Disease. Alz Res Therapy 11, 34 (2019). https: / / doi.org / 10.1186 / s13195-019-0485-0 and James D. Doecke, Virginia. Perez-Grijalba, Noelia Fandos, Christopher Fowler, Victor L. Villemagne, Colin L. Masters, Pedro Pesini, Manuel Sarasa, for the AIBL Research Group, “Total Aβ42 / Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis,” Neurology Apr 2020, 94 (15) e1580-e1591; DOI: See 10.1212 / WNL.0000000000009240, which are incorporated herein by reference.
[0303] Neuroinflammation A panel of neuroinflammatory biomarkers was evaluated, including but not limited to YKL-40, MCP-1, IL-6, GFAP, etc. This biomarker panel reflects activation of both innate and / or adaptive immunity, allowing broad insight into the effects of AMX0035 in targeting all components of neuroinflammation.
[0304] Neurodegeneration – Neurofilament light chain (NfL), Neurogranin (Ng) Alterations in neurofilament light chains are putative markers of subcortical large axon degeneration and have been shown to be elevated in subjects with AD and MCI (Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med 2016;8:1184-96. https: / / doi.org / https: / / doi.org / 10.15252 / emmm.201606540). Furthermore, CSF levels of NfL have been found to be associated with more rapid AD disease progression.CSF NfL levels are considered a biomarker of nonspecific axonal degeneration and have been shown to be important in a variety of conditions, including inflammatory diseases (Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med 2016;8:1184-96. https: / / doi.org / https: / / doi.org / 10.15252 / emmm.201606540), Creutzfeldt-Jakob disease (Constantinescu R, Krysl D, Bergquist F, Andren K, Malmestroem C, Asztely F, et al. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. Eur J Neurol 2016;23:796-806. https: / / doi.org / https: / / doi.org / 10.1111 / ene.12942), progressive supranuclear palsy (Hall S, Oehrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and / or Parkinsonian Disorders. Arch Neurol 2012;69:1445-52. https: / / doi.org / 10.1001 / archneurol.2012.1654), ALS and vascular dementia.
[0305] Neurogranin (Ng) is a calmodulin-binding postsynaptic protein that appears to be exclusively expressed in the brain and particularly enriched in dendritic spines (Petersen A, Gerges NZ. Neurogranin regulates CaM dynamics at dendritic spines. Sci Rep 2015;5:11135. https: / / doi.org / 10.1038 / srep11135). Ng has been hypothesized to play a role in long-term potentiation and memory consolidation (Portelius E, Zetterberg H, Skilbaeck T, Toernqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain 2015;138:3373-85. https: / / doi.org / 10.1093 / brain / awv267). CSF Ng levels are elevated in AD and correlate with levels of "core" AD CSF biomarkers (Liu W, Lin H, He X, Chen L, Dai Y, Jia W, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment. Transl Psychiatry 2020;10:125. https: / / doi.org / 10.1038 / s41398-020-0801-2).
[0306] Oxidative Stress - 8-Hydroxy-2-deoxyguanosine (8-OHdG) 8-OHdG is a biomarker of oxidative DNA damage shown to be elevated in AD and potentially correlates positively with disease duration (Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and / or oxidative DNA damage contributes to the neurodegenerative process. J Neurol 2010;257:399-404. https: / / doi.org / 10.1007 / s00415-009-5333-x). This molecule was used to assess DNA damage.
[0307] Metabolism – leptin, soluble insulin receptor (sIR), 24-hydroxycholesterol (24-OHC) The soluble insulin receptor is a metabolically essential component for glucose detection and uptake. Levels of sIR are thought to be elevated as a sign of insulin resistance (Gerena Y, Menendez-Delmestre R, Skolasky RL, Hechavarria RM, Perez S, Hilera C, et al. Soluble insulin receptor as a source of insulin resistance and cognitive impairment in HIV-seropositive women. J Neurovirol 2015;21:113-9. https: / / doi.org / 10.1007 / s13365-014-0310-2). Elevated levels of sIR were associated with cognitive dysfunction (Gerena Y, Menendez-Delmestre R, Skolasky RL, Hechavarria RM, Perez S, Hilera C, et al. Soluble insulin receptor as a source of insulin resistance and cognitive impairment in HIV-seropositive women. J Neurovirol 2015;21:113-9. https: / / doi.org / 10.1007 / s13365-014-0310-2).
[0308] 24-OHC is a brain cholesterol metabolite that is measurable in CSF and blood (Hughes TM, Rosano C, Evans RW, Kuller LH. Brain cholesterol metabolism, oxysterols, and dementia. J Alzheimers Dis 2013;33:891-911. https: / / doi.org / 10.3233 / JAD-2012-121585). The majority of brain cholesterol is stored in myelin. Breakdown and degradation of myelin is thought to lead to increased production of 24-OHC in the brain and elevated levels of 24-OHC in body fluids. Previous studies have found that levels of 24-OHC are higher in early compared to later stages of AD, suggesting that 24-OHC may be a useful marker for early stage dementia (Papassotiropoulos A, Luetjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000;11:1959-62. https: / / doi.org / 10.1097 / 00001756-200006260-00030).
[0309] Neurovascular injury – MMP-10 MMP-10 is a biomarker of neurovascular injury. MMP10 is highly produced in injured neurons compared to healthy brain tissue (Cuadrado E, Rosell A, Penalba A, Slevin M, Alvarez-Sabin J, Ortega-Aznar A, et al. Vascular MMP-9 / TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res 2009;8:3191-7. https: / / doi.org / 10.1021 / pr801012x). Furthermore, elevated levels of MMP10 in CFS were associated with levels of tau and p-tau in individuals with Alzheimer's disease (Duits FH, Hernandez-Guillamon M, Montaner J, Goos JDC, Montanola A, Wattjes MP, et al. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. J Alzheimers Dis 2015;48:711-20. https: / / doi.org / 10.3233 / JAD-143186).
[0310] Additional biomarkers Additional biomarker panels focused on neurovascular injury and the potential involvement of histone deacetylation will be performed on CSF and plasma.
[0311] An extensive proteomic panel was investigated in a hypothesis-generating manner, and studies are currently planned with protein biomarker panels that utilize proximity extension and next-generation sequencing to provide highly multiplexed immunoassays.
[0312] 6.2.7 Pharmacokinetics Plasma concentrations of TUDCA and PB were assessed at weeks 12 and 24 (approximately simultaneously with CSF samples if collected on the same day). The times of administration of the two drugs and the time of the samples were noted on the eCRF. PK samples were not collected at the early discontinuation visit if the subject discontinued study drug >48 hours prior to the visit.
[0313] 6.2.8 Training and Validation All assessors were certified by the study PI to perform cognitive and psychiatric outcome assessments. When possible, it was strongly preferred that a single assessor perform all measurements with a given instrument throughout the study.
[0314] 7. Safety and Adverse Events The adverse events (AEs) and reporting procedures provided in this protocol will comply with all applicable U.S. Food and Drug Administration (FDA) regulations and International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines. Site investigators will closely monitor each subject throughout the study for possible adverse events. All AEs were recorded on a CRF specifically designed for this purpose. It is also important to report all AEs, whether serious or nonserious, especially those that result in permanent discontinuation of the investigational product being studied.
[0315] 7.1 Definitions of AE, Suspected Adverse Drug Reaction, and SAE 7.1.1 Adverse Events and Suspected Adverse Drug Reactions An adverse event (AE) is any untoward and unintended sign (including, for example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the study or use of a drug product or device, whether or not considered related to the drug product or device.
[0316] Adverse drug reactions (ADRs) are any noxious unintended responses to a drug product related to any dose. The expression "response to a drug product" means that there is at least a reasonable possibility of a causal relationship between the drug product and the adverse event, i.e., the causal relationship cannot be ruled out. Thus, some AEs may be classified as suspected ADRs if a causal relationship to the drug product is suspected.
[0317] Examples of adverse events include a new condition, a worsening of a pre-existing condition, a clinically significant abnormal sign on physical exam (i.e., skin rash, peripheral edema, etc.), or a clinically significant abnormal test result (i.e., laboratory value or vital signs), excluding results of outcome measures that are not recorded as adverse events in the study (outcome measure results are collected but analyzed separately). Stable chronic conditions that were present before the start of the study and do not worsen during the study (i.e., diabetes, arthritis) are not considered adverse events. Chronic conditions that occur more frequently (intermittent conditions) or are more severe are considered to have worsened and are recorded as adverse events. Adverse events are generally detected in two ways: Clinical - Symptoms reported by the subject or signs detected on physical examination. Ancillary tests - Abnormalities in vital signs, laboratory tests, and other diagnostic procedures (other than outcome measures; outcome measure results are not captured as AEs)
[0318] For the purposes of this study, any clinically notable progression / deterioration in cognition, behavior, or functional ability was recorded as an AE.
[0319] The following measures of disease progression, even if worsening, will not be recorded as AEs (these are recorded and analyzed separately): ADAS-Cog, DSRS, and FAQ.
[0320] If identifiable at the time the AE Log is completed, the specific disease or syndrome, rather than the individual associated signs and symptoms, should be identified by the site investigator and recorded in the AE Log. However, if an observed or reported sign, symptom, or clinically significant laboratory abnormality is not considered by the site investigator to be a component of a specific disease or syndrome, it should be recorded as a separate AE in the AE Log. Clinically significant laboratory abnormalities, such as those requiring intervention, will be identified as such by the SI.
[0321] Subjects were monitored for AEs from the time the subject prepared and signed the consent form until the end of participation in the study (after death, withdrawal of consent, loss to follow-up, early termination of the study for other reasons, or completion of the entire study). Any treatment AEs still present at the end of treatment (including early discontinuation) should be monitored until resolution or until the AE is declared a chronic condition.
[0322] An unexpected adverse event is any AE where the specificity or severity of the AE is inconsistent with the current Investigator Brochure. A suspected unexpected adverse drug reaction is any unexpected adverse event that, in the opinion of the SI or sponsor, has a reasonable possibility of being related to the investigational product.
[0323] 7.1.2 Serious Adverse Events A serious adverse event (SAE) is defined as an adverse event that meets any of the following criteria: 1. Leads to death. 2. Life threatening: i.e., poses an imminent risk of death if the event occurs. This seriousness criterion applies if the subject, in the opinion of the site investigator or sponsor, is at imminent risk of death from the AE if it occurs, but does not apply if the AE would hypothetically have caused death if it were more severe. 3. Requires hospitalization or extension of existing hospitalization. a. Hospitalization for elective surgery or routinely scheduled procedures is not an SAE under this standard because an elective or scheduled “surgery” or “treatment” is not an indecent medical occurrence. 4. Causes a persistent or significant disability or incapacity. a. This seriousness criterion is met if the “disability” attributable to the reported AE substantially destroys the subject's ability to perform normal life functions. 5. Requires medical or surgical intervention to prevent permanent impairment of a bodily function or permanent damage to a bodily structure. 6. A significant medical event that may not result in death, be life threatening, or require hospitalization may also be considered an SAE if, based on sound medical judgment, it may endanger the subject and require medical or surgical intervention to prevent one of the outcomes enumerated in this definition. Examples of such medical events include blood dyscrasia or convulsions that do not result in hospital admission, or the development of drug dependence or abuse.
[0324] Hospital admission in the absence of a worsening treatment-emergent clinical adverse event may meet the criteria for "seriousness" but is not considered an SAE because it is not an adverse experience. Examples of this include social hospitalization (subjects who are hospitalized for other non-medical reasons, such as living far from the hospital or not having a place to sleep).
[0325] A suspected serious adverse drug reaction is an SAE that, in the opinion of the SI or sponsor, is reasonably likely to be related to the investigational product. The SI is responsible for classifying the adverse event as serious or non-serious.
[0326] 7.2 Assessment and Recording of Adverse Events Site investigators closely monitor each subject throughout the study for possible AEs. All AEs were recorded in source document templates and eCRFs specifically designed for this purpose. All AEs were reported to the EDC system and compiled into reports that were regularly reviewed by the medical monitor, who promptly reviews all information related to the safety of the investigational product, including all serious adverse events (SAEs). Particular attention was paid to AEs, whether serious or non-serious, that led to permanent discontinuation of the investigational product being studied.
[0327] 7.2.1 Evaluation of Adverse Events At each visit (including the telephone interview), subjects were asked if they had had any problems or symptoms since their last visit to determine the occurrence of adverse events. If a subject reported an adverse event, the site investigator would review further to determine: 1.Type of Event 2. Date of onset and recovery (duration) 3. Severity (mild, moderate, severe) 4. Severity (whether the event meets the above definition of an SAE) 5. Causality, relationship to investigational product and disease 6. Actions Taken Regarding Investigational Products 7. Outcomes
[0328] 7.2.2 Relationship of Adverse Events to Investigational Products The relationship of an AE to the investigational product should be identified by the site investigator using the following definitions: 1. Unrelated: Concomitant illness, accident or event that has no reasonable connection to the treatment. 2. Unlikely: The reaction has little or no temporal sequence from administration of the investigational product and / or another etiology is likely to exist. 3. Possibly Related: The reaction follows a reasonable temporal sequence from administration of the investigational product and follows the known pattern of response to the suspected investigational product; the reaction may have been caused by the investigational product or may have been caused by the subject's clinical condition or by other treatment modalities administered to the subject. (Suspected ADR) 4. Probably Related: The reaction follows a reasonable temporal sequence from administration of the investigational product; is confirmed by discontinuation of the investigational product or by rechallenge; and cannot be reasonably explained by known features of the subject's clinical condition. (Suspected ADR) 5. Clearly Related: Response follows a reasonable temporal sequence from administration of investigational product; follows known or expected pattern of response to investigational product; is confirmed by improvement upon discontinuation or reduction of investigational product dosing and reappearance of response upon repeated exposure. (Suspected ADR)
[0329] 7.2.3 Adverse events in previous human experience with each individual ingredient TUDCA and PB were evaluated separately in multiple patient populations. The most commonly reported adverse events were: TUDCA: A small number of subjects receiving TUDCA experienced mild diarrhea and abdominal pain. ○ Skin rash and vomiting have been observed in rare cases. PB: Menstrual irregularities, loss of appetite, sweaty body odor and unpleasant taste. Less common side effects include nausea, vomiting, heartburn, stomach pain, gastritis, headache and skin rash. Rare cases of peptic ulcers, rectal bleeding, constipation, pancreatitis and renal tubular acidosis have been reported. ○ Hypoalbuminemia, metabolic acidosis, alkalosis, hyperchloremia, hyperuricemia, hypokalemia, hypophosphatemia, hyperphosphatemia and hypernatremia were observed.
[0330] 7.2.4 Recording of Adverse Events All clinical adverse events will be recorded in the Adverse Event (AE) Log in the subject's study binder. Sites must complete the AE Log and enter the AE information into the EDC system within 48 hours of the site learning of a new AE or receiving an update on an existing AE.
[0331] Serious adverse events (SAEs) must be reported to the MGH Coordinating Center within 24 hours of the institution learning of the SAE.
[0332] Entries in the AE log (and in the EDC) included: name and severity of the event, date of onset, date of resolution, relationship to investigational product, actions taken, and the primary outcome of the event.
[0333] 7.3 Adverse Events and Serious Adverse Events - Reportable Events The following are considered reportable events and must be reported to the MGH Coordinating Center within 24 hours of the facility being notified of the event: Any event that meets the above criteria for a serious adverse event (SAE) ○ Medication changes (administration management) Postponement, reduction or rechallenge of investigational products Discontinuation of investigational product
[0334] 8. Data Safety Monitoring and Statistical Analysis Plan 8.1 Medical Monitoring A medical monitor independent of the conduct of the study was identified by the sponsor. The medical monitor's responsibilities included periodic evaluation of the frequency, severity, and type of AEs and SAEs reported at all sites in the study. The medical monitor was a physician with expertise in Alzheimer's disease and common chronic medical (e.g., renal and cardiac) conditions in this elderly patient population, and prior experience in the conduct of clinical trials (study design, safety monitoring, and recruitment). All AEs were collected and reported in an electronic data capture (EDC) system and compiled into bimonthly blinded reports that were regularly reviewed by the medical monitor. In some cases, any serious adverse events possibly or definitely related to the study drug (i.e., suspected unexpected serious adverse drug reactions or SUSARs) and any deaths were considered events of interest and reported in real time (within one business day of the Coordinating Center (CC) becoming aware of them) to the medical monitor and members of the PSC. The medical monitor approved the format and content of the periodic safety reports. The Medical Monitor will promptly review all information regarding the safety of the investigational product, including all serious adverse events (SAEs) and AEs that are rare in Alzheimer's disease. Particular attention will be paid to AEs, whether serious or non-serious, that result in permanent discontinuation of the investigational product being studied. The Medical Monitor may request to receive more frequent AE reports. The Medical Monitor will communicate its recommendations to the PSC.
[0335] 8.2 Protocol Steering Committee The Protocol Steering Committee (PSC) is composed of the study's principal investigator (who serves as SC Chair), a study biostatistician, an independent investigator member with expertise in Alzheimer's disease and medical (e.g. renal and cardiac) conditions and priorities (study recruitment and drug procurement) relevant to the study, and the Sponsor's Deputy Medical Director. The PSC is responsible for designing the study protocol and analytic plan and oversees the clinical trial from protocol development through study analysis and publication.
[0336] 8.3 Statistical methods Complete details of the efficacy and safety analysis are provided in the "Efficacy Analysis" section.
[0337] 8.3.1 Sample size determination A sample size of approximately 100 randomized subjects was selected based on feasibility, not solely on statistical considerations. Subjects were randomized in a 3:2 (active vs. placebo) ratio. A comprehensive test statistic was used to maximize the study power for evaluation of efficacy endpoints. The comprehensive test statistic was a combination of three endpoints (univariate components) of change from baseline to end of study, including: ○ Recognition ○ Activities of daily living (ADL) Total hippocampal brain volume
[0338] A comprehensive test statistic is calculated for each subject as the average percentile score between the above three component endpoints for each subject of the study.This average percentile score is then analyzed as the primary efficacy outcome variable.For power calculation, the comprehensive test statistic may be characterized based on the expected effect size of each of the three component endpoints and the correlation between each of the three pairs of component endpoints.
[0339] Even when the component univariate endpoints have unequal treatment effect sizes that favor an effective treatment, the use of a global test statistic can handle cases of correlated univariate endpoints and provide substantially more power than the use of a univariate test statistic. Based on historical analysis, assume that the correlation between the cognition and ADL component endpoints is 0.4, and the correlation between the total hippocampal volume component endpoint and each of the other two component endpoints (i.e., the cognitive component endpoint and the ADL component endpoint) is 0.2. Using 50% statistical power and the assumed effect size as inputs, we can obtain an "expected p-value" for the two selected combinations of component endpoints for the composite value. This is done in two stages, the first for the combination of ADAS-Cog and ADL component endpoints, with expected p-values of 0.09409 and 0.20184, respectively, and the expected p-value for the two components is 0.077583. The expected p-values of the two components are then combined with the expected p-value of total hippocampal brain volume (0.20184) to obtain an expected p-value of 0.049756 for the global test statistic.
[0340] Each of the three component scales may have a different sensitivity for detecting change over time. Sensitivity is quantified using the mean-to-standard deviation ratio (MSDR), calculated by dividing the mean of the change scores from baseline by the standard deviation of the change scores from baseline. For change from baseline to 6 months, assume MSDR values of 0.8, 0.6, and 0.6 for ADAS-Cog, ADL, and total hippocampal brain volume, respectively. Assume a value of 60% for the proportion of placebo effect (i.e., the decline for the active treatment group is only 40% of the decline for the placebo group). This corresponds to effect size (assumed treatment difference divided by common standard deviation) values of 0.48 for cognitive endpoints, 0.36 for ADL endpoints, and 0.36 for total hippocampal brain volume. Using these expected p-values and the assumed correlation between each pair of these three endpoints, as described above, the expected p-value of the global test statistic is 0.049756.
[0341] Using 100 randomized subjects (assuming that no subjects drop out and that there are 100 completers or that imputation adequately accounts for subject dropout), 50% power, and a 1:1 randomization ratio, we obtain an effect size of 0.566 (corresponding to the use of a global test statistic); this shows that, based on these assumptions, the use of a global test statistic is equivalent to the use of single component test statistics with an effect size of 0.566 (rather than the assumed effect sizes of 0.48 for ADAS-Cog, 0.36 for ADL, and 0.36 for total hippocampal volume). Another way to interpret this is how the use of a global test statistic, corresponding to an assumed effect size of 0.566 for the single component endpoints, and the use of α=0.05, results in a power of approximately 50% (50.1%). Thus, when the individual components of the global test statistic are in the same direction (and favor the active treatment group over placebo), the use of a global test statistic generally provides higher power than the use of the single components.
[0342] Although the power calculation (see Table 2 below) indicates a power of 80% for an assumed placebo effect percentage value of 85%, a placebo effect percentage value of around 50% or 60% is still clinically relevant and a promising indicator for moving forward into new research. As noted above, a placebo effect percentage value of 60% corresponds to a global test statistic p-value of about 0.05 (0.049756, two-sided), an effect size of 0.566, and a power of about 50%. A global test statistic p-value of 0.10 (two-sided) is an observed trend that still suggests a signal that moving forward into new research is appropriate. This corresponds to a placebo effect percentage value of just under 50%; a placebo effect percentage value of 50% corresponds to a global test statistic p-value of about 0.095 (0.09477, two-sided) at the two-sided α=0.05 level, an effect size of 0.479, and a power of about 38%.
[0343] [Table 2]
[0344] Some additional examples of comprehensive test statistics based on various assumed placebo effect percentage values and corresponding effect sizes (and using the pairwise correlations of 0.4, 0.2, and 0.2 described above) are provided below along with the examples described above. (Note that a placebo effect percentage value of 0% means that the active treatment is attenuated to the same extent as the placebo, a value of 50% means that the active treatment is attenuated to half that of the placebo, and a value of 100% means that the active treatment is not attenuated at all over the 6 month treatment period.)
[0345] 8.3.2 Unblinding of the Study After database lock, the responsible statistician requested treatment codes, unblinded the study, and performed the statistical analyses.
[0346] 8.3.3 Safety endpoints 8.3.3.1 Safety endpoints The primary safety outcome was the occurrence of treatment-emergent grade II to IV adverse events.
[0347] Other safety endpoints included: Occurrence and severity of treatment-emergent adverse events (AEs) Clinical testing Vital signs Physical Examination ○ ECG Use of concomitant medications in the treatment of AE ○ C-SSRS
[0348] 8.3.3.2 Primary Efficacy Endpoint The primary efficacy endpoint was the global test statistic (GST) of change from baseline through 24 weeks, as described in the "Sample Size Determination" section. Briefly, the GST combines correlated univariate components (MADCOMS, FAQ, and total hippocampal volume) and provides greater power to detect treatment effects than any of the univariate components alone. Correlations of 0.4 between cognition and the FAQ component and 0.2 between hippocampal volume and each of the other two components were assumed based on historical analysis.
[0349] 8.3.3.3 Secondary Efficacy Endpoints Changes in the following assessments from Screening and / or Baseline to each post-baseline visit listed below based on the activity schedule (see Table 3 below) between the AMX0035 and placebo treatment arms in the ITT population: Cognitive outcome component for comprehensive test statistics (baseline, week 12, and week 24) ADL endpoint components for comprehensive test statistics (baseline, week 12, and week 24) Total hippocampal brain volume (screening / baseline and week 24) Additional volumetric MRI brain volume parameters (screening / baseline and week 24) ADAS-Cog (baseline, week 12 and week 24) FAQ (Baseline, Week 12 and Week 24) DSRS (baseline, week 12 and week 24) NPI-Q (screening / baseline, week 12 and week 24) MoCA (screening, weeks 6, 18 and 24)
[0350] [Table 3]
[0351] 1 The baseline visit may be completed any time after screening as long as all eligibility criteria are met, or may occur within 28+5 days after the screening visit. 2 Randomization should occur at the Baseline Visit. Randomization involves entering the subject's kit number into the electronic data capture system. 3 Vital signs included systolic and diastolic blood pressure in mmHg, respiratory rate / min, heart rate / min and temperature. 4Height will be recorded once at the screening visit. 5 A standard neurological examination is performed on all subjects. 6 Safety laboratory tests will include blood tests (CBC with differential), complete chemistry panel, liver function tests, B12 and TSH (at screening visit only), and urinalysis. 7 The NPI-Q test may be administered at either the screening or baseline visit. 8 The MRI evaluation may be completed any time from screening up to 7 days prior to the baseline visit, with a clinical readout performed on-site. 9 The first dose of study medication will be administered in the clinic after all baseline visit procedures are completed. 10 Subjects will be informed of the increase from 1 sachet per day to 2 sachet per day. 11 The screening version of the C-SSRS will be completed at the screening visit only. The post-last version of the C-SSRS will be completed at all other visits. 12 The initial LP may be completed any time from screening up to 7 days prior to the baseline visit. 13 A single PK plasma sample will be collected (concurrent with the lumbar puncture) at Visits 12 and 24. If a subject discontinues study drug more than 48 hours prior to a visit, a PK sample will not be collected for subjects who complete the Early Discontinuation Visit. 14 A final follow-up telephone call should occur 14 ± 5 days after the participant's last dose of study drug. For participants who discontinue treatment early, a final follow-up telephone call is not necessary if the early discontinuation visit occurs 14 ± 5 days after the last dose of study drug. 15 Whenever possible, the Week 6 and Week 18 visits may be conducted remotely. If visits are conducted remotely, medication management / compliance will occur at the next in-person clinic visit. 16The Week 12 visit is preferably completed at a site where the participant is physically present. If it is not possible to complete an in-person Week 12 visit at a site, the following safety evaluations must be completed by Week 16 / Day 112 for subjects who remain on study drug. Sites may have alternative arrangements for completing these evaluations in accordance with institutional and IRB policies. Safety Laboratory Tests: Blood tests (differential complete blood count), complete chemistry panel, liver function tests and urinalysis Vital signs 17 The week 24 visit window is day 168 ± 28 days. However, if COVID-19 related restrictions (e.g., facility closures, travel restrictions) make it impossible to have an in-person clinic visit within the specified window, any assessments that can be done remotely should be completed as unscheduled visits within the week 24 window. The actual week 24 visit along with all assessments indicated in the SOA may be postponed for up to 12 weeks, extending treatment. The maximum duration for which a subject may receive IP is 40 weeks. Safety checks (i.e., ECG, safety laboratory tests, vital signs, and C-SSRS) must be completed at least every 16 weeks / 112 days. If a safety assessment is performed and therefore the week 24 visit may be postponed, the assessment should be recorded as an unscheduled visit. 18 If possible, an early discontinuation visit should occur within 14 days after the last dose of IP (i.e., last dose of IP + 14 days). MRI and lumbar puncture may be performed as soon as practicable and, if possible, within 60 days after the last dose of IP (i.e., last dose of IP + 60 days).
[0352] The derivation of the cognitive and ADL endpoint components for the global test statistic was designed to optimize sensitivity in the MCI and mild-to-moderate AD populations by using scales specific to these two populations, respectively (including some overlapping tests and some tests that differentiate each population). The method for combining scores per scale (i.e., cognitive and ADL endpoint components) between the two populations is described in the "Global Test Statistic" section.
[0353] Repeated measures mixed-effects models were used to calculate differences at 12 and 24 weeks with baseline assessments as covariates.
[0354] Secondary efficacy outcomes were assessed using MMRM. Missing data at week 24 were imputed using pattern mixture models (PMM) sensitivity analyses described in the "Missing Data" section for each of the three component efficacy outcomes (based on cognition, ADL, and total hippocampal brain volume) used to calculate the global test statistic.
[0355] 8.3.3.4 Volumetric MRI Observational case analysis of differences in vMRI changes over 24 weeks. Ventricular and hippocampal volumes were measured. Brain MRI imaging was performed to measure brain atrophy over time. Imaging was performed using cross-sectional techniques for baseline and 24 week samples, and longitudinal techniques for baseline and 24 week pairs. Results of vMRI studies suggest that AD atrophy patterns can be reliably detected and tracked over time. MRI-derived hippocampal volumes correlate with histological hippocampal volumes and the extent of neuronal loss and AD pathology. Longitudinal MRI measurements of regional and whole brain volume changes are a useful complement to cognitive measurements in that they are not affected by transient symptomatic improvements, and longitudinal MRI measurements can provide an early indicator of the ability of a test drug to reach the central nervous system and have an effect on AD-related atrophy.
[0356] 8.3.3.5 CSF Observational case analysis of differences in CSF biomarker changes over 24 weeks
[0357] 8.3.4 Analysis Population The safety population included all randomized subjects who received at least one dose of study drug. Subjects in the safety population were analyzed based on the treatment they actually received, not necessarily the treatment to which they were randomized.
[0358] The intention-to-treat (ITT) approach was used to define the primary efficacy analysis population. For a given endpoint, all randomized subjects who received any study drug, had a baseline assessment, and had at least one post-baseline efficacy assessment for the primary efficacy endpoint were included in the ITT population. Subjects in the ITT population who moved between treatment groups during the study were analyzed based on the treatment to which they were randomized, not necessarily the treatment they actually received.
[0359] 8.3.5 Safety Analysis A safety population was used for the analysis of each safety endpoint. All concomitant medications were tabulated according to drug class and preferred term using the WHO dictionary. Safety data were summarized by treatment group. Treatment AEs were coded and graded using the MedDRA grading criteria. Treatment groups were compared for the occurrence of each adverse event and the occurrence of grade II / IV adverse events. Withdrawals, laboratory abnormalities, vital signs, and use of concomitant medications for the treatment of AEs were evaluated to characterize the safety profile of the PB and TUDCA combination. Compliance data were determined by visit and by treatment group. Time to subject refusal was compared between treatment groups to determine good tolerability. This was achieved using survival analysis methods that allowed for informative censoring due to death. Descriptive statistics describing the change from baseline to the final evaluation visit for key laboratory parameters and vital signs are also provided.
[0360] 8.3.5.1 Adverse Events Adverse events (AEs) occurring after initiation of study drug at baseline were summarized narratively for the safety population. All AEs were coded according to system organ class (SOC) and preferred term (PT) using the Medical Dictionary for Clinical Practice (MedDRA). Summary tables showing the number of subjects and the percentage within each category were generated for each type of adverse event and its relationship to study treatment (study treatment related); ○ All events Serious events ○ Death Events leading to withdrawal ○ Severe events
[0361] Treatment AEs were coded and graded using MedDRA grading criteria. Treatment groups were compared for the occurrence of each adverse event and for the occurrence of grade II / IV adverse events. The total number of adverse events was compared between groups using Fisher's exact test. Any treatment AEs still present at the end of treatment (including early discontinuation) should be monitored until resolution or until the AE is declared a chronic condition. AEs were monitored until they became chronic or fully resolved.
[0362] 8.3.5.2 Clinical Laboratory Parameters Laboratory parameters were summarized by visit. Descriptive statistics describing the change from baseline to the final evaluation visit for key laboratory parameters and vital signs are also provided. The frequency of high and low values relative to the normal range was displayed as shift tables comparing each treatment visit with the baseline visit by time point and treatment group. Laboratory abnormalities were compared between groups using Fisher's exact test.
[0363] 8.3.5.3 Other safety parameters Vital signs were summarized between groups by visit using descriptive statistics at each outcome visit and at the end of the study. Physical examination findings and subject numbers were summarized as total number and percentage of subjects by predefined categories on the eCRF at the final visit. Changes from baseline at the final visit were summarized in shift tables comparing baseline and final visit results. Concomitant medications were summarized by treatment group, drug class, and preferred term. Changes in C-SSRS scores from baseline to each postbaseline visit were summarized between active and placebo treatment groups.
[0364] 8.3.6 Efficacy Analysis Analyses of primary and secondary efficacy endpoints were performed in the ITT population (LZCF and non-LZCF).
[0365] The primary efficacy analysis was based on the use of the global test statistic described in the "Sample Size Determination" section. The null hypothesis was that there was no difference between the treatment groups, and the corresponding alternative hypothesis was that treatment with AMX0035 results in a statistically significant difference (favoring the active treatment group) in the global test statistic score compared to the placebo group at week 24 in the ITT population. As described in the "Sample Size Determination" section, the global test statistic p-value was calculated using the p-values of the three individual components (corresponding to the change from baseline to week 24 in cognitive outcome measures, ADL outcome measures, and total hippocampal brain volume) and the three pairwise correlation values between the three outcome measures.
[0366] The primary efficacy analysis with a comprehensive test statistic was based on the use of the pattern mixture model (PMM) approach described in the "Missing Data" section to impute any missing data for the three component endpoints (i.e., cognitive endpoints, ADL endpoints, and total hippocampal brain volume) at week 24. Secondary analyses with a comprehensive test statistic were based on the use of observed cases.
[0367] The GST was calculated for each subject as the average z-score across the three component endpoints (described above under the "Determining Sample Size" section) for each subject in the study. This average score was then analyzed as the primary efficacy outcome variable.
[0368] Individual items of the GST containing right-censored data were imputed using LZCF. Intermittent missing data were imputed using linear imputation. Linear imputation or z-scores were calculated for each data collection time point in the study (baseline, weeks 6, 12, 18, and 24). Let Z be the imputed z-score, x is the last observation at time point t1, and μ and δ are the mean and standard deviation of the next time point (t2) where data are missing. Z t2 =(x t1 -μ t2 ) / δ t2
[0369] Imputed z-scores for group means and standard deviations at each time point preserve the slopes for each group better and are more robust to differences in dropout rates between treatments. For individuals missing all postbaseline data, the population baseline z-scores were used to calculate the LZCF by treatment group. After the LZCF was calculated for individual-level items, the GST was calculated for each individual. Imputation of the LZCF was constrained by the range of possible scores for each measure.
[0370] Composite covariates were calculated for the primary efficacy variable (GST) and adjusted for baseline covariates and baseline covariates interacting with time and included in the model. To calculate composite covariates, the change score (GST) is regressed on time. The residuals are regressed on the covariates listed below. The individual composite coefficients for each covariate are multiplied by the individual covariate values and summed. Composite values of the separate covariates are calculated for the baseline covariates and baseline covariates interacting with time.
[0371] CFB was analyzed by comparing the change between treatment groups using a mixed model for repeated measures (MMRM), which compares the estimated change from baseline between treatments for each primary endpoint. This analysis evaluates whether there was a difference in estimated CFB between the active and placebo groups.
[0372] The MMRM with the primary outcome CFB value as the response variable included the following covariates and fixed effects: Baseline composite covariates only: · Age (covariate); Baseline ADAS-Cog Baseline MOCA Baseline FAQ Baseline DSRS Baseline hippocampal volume · AD / dementia status (fixed effect); AD drug combinations · years of education (fixed effect split into ≤12 years and >12 years); · Gender (fixed effect); · APOE ε4 status (fixed effect, positive or negative); · Time composite covariate only; · Time · age * time Baseline ADAS-Cog * time Baseline MOCA * time Baseline FAQ * time Baseline DSRS * time Baseline hippocampal volume * time AD / dementia conditions * time; AD drug combinations * time Years of education * time (fixed effect split into ≤12 years and >12 years); · Gender * time; APOEε4 status * time (positive or negative); Time (continuous time) Time by treatment interaction (time * treatment); · Baseline laboratory scores for efficacy parameters (covariates); · Center (random effect);
[0373] The covariate structure for repeated measures in this model was unstructured (UN). If the UN did not converge to a model, the MMRM model was simplified to allow convergence as described in the following section. Variance components were used as the covariance structure for the center random effect in the model.
[0374] Any efficacy outcomes that did not converge using the specified primary model were re-run with a first-order heterogeneous autoregressive (ARH[1]) covariance structure, then a compound symmetry (CS) followed by a variance components (VC) structure if ARH(1) did not converge. The covariance structure for the center random effect was VC.
[0375] Least squares means were estimated at each visit for the primary outcome. LS means for the outcome were interpreted as the predicted CFB of the primary outcome at 24-week estimates derived from the model within each group. Least squares means and standard errors were estimated from the mixed models at all time points (12 and 24 weeks) and presented for all analyses. In addition, treatment differences, p-values, 95% confidence intervals for the differences, effect sizes, 95% confidence intervals for the effect sizes, and effect sizes based on Cohen's D were presented for each comparison. Effect sizes were calculated by taking the difference in LSMEANS and dividing by the standard deviation (i.e., the standard error of the estimated difference multiplied by the degrees of freedom squared). The following formula shows how effect sizes and Cohen's D effect sizes were calculated. In the following formula, p represents placebo group, t represents post-treatment, SE represents standard error, and df represents degrees of freedom:
number
[0376] Cohen's D was calculated using the following formula:
number
number
[0377] The number of subjects with observed efficacy outcomes, mean, standard deviation, median, 25th percentile (Q1), 75th percentile (Q3), minimum and maximum will all be reported, with estimates from the MMRM outlined in this section (Tables 14.2.1 through 14.2.16).
[0378] Covariate and categorical interaction analysis The following variables were evaluated for primary efficacy variables and their interactions with time using the MMRM described above: Baseline score (the outcome being analyzed) Baseline MoCA score ApoEε4 (carrier / non-carrier; discrete) ApoEε4 (number of E4 alleles; discrete)
[0379] Estimates for continuous variables were derived at the first and third quartiles.
[0380] MMRM without imputation was performed as a sensitivity analysis. The same MMRM parameters were used as above. Additionally, MMRM was performed for the primary analysis using MRI quantitative data generated in a longitudinal manner.
[0381] FIG. 11 shows the calculated GST for the intent-to-treat LZCF population.
[0382] Analyses of secondary efficacy endpoints were performed using repeated measures mixed models (MMRM). The mixed model analysis compares the estimated change from baseline (CFB) or change from screening (if applicable) between active treatment and placebo in all efficacy outcome scores at each scheduled post-baseline visit. Separate repeated measures longitudinal models were used for each efficacy endpoint. This analysis evaluates whether there is a difference in the estimated CFB values between treatment groups. Using SAS PROC MIXED, MMRM models were fitted with the CFB of each efficacy outcome (e.g., ADAS-Cog total score) as the response variable, as well as certain covariates and fixed effects as specified in the "Blinding" section. See, for example, Figures 12A and 12B.
[0383] PK analysis PK was analyzed using the ITT population. Descriptive statistics were provided for the AMX0035 and placebo treatment groups. Additionally, correlations between exposure values and clinical outcomes may be assessed by correlation with concentration data, when available, and summary of outcome data for upper and lower PK tertiles.
[0384] PK concentration data collected before each dose may be used in concentration-response relationship analyses to assess correlation with each outcome reflecting the primary analysis, but substituting PK concentrations for treatment variables. Analyses may be performed for each PK collection time point separately and using the higher of both PK time points.
[0385] Descriptive statistics for continuous variables include number of subjects (n), mean, standard deviation (SD), median, minimum, maximum, first and third quartiles unless otherwise stated. Frequencies and percentages were calculated for categorical variables. Percentages were calculated within each treatment group for nonmissing observations.
[0386] Subgroup analyses (e.g., based on subgroups defined by sex, age, baseline MoCA score) were performed in the ITT population.
[0387] Exploratory analysis Exploratory endpoints and biomarkers were also assessed using MMRM as described above.
[0388] Biomarker data were filtered out for values with large coefficients of variation. Additionally, biomarker analyses were separated into two distinct subgroups based on the predicted mechanism of AMX0035: clinically relevant markers and markers of target engagement, with hierarchical analyses within each subgroup.
[0389] Markers of target engagement assessed in CSF include: 8-OHdG All Tau Neurogranin MMP-10 FABP3 NfL Clinically relevant markers assessed in CSF include: Amyloid beta 1-42 Amyloid beta 1-40 P-Tau 181 24-OHC YKL-40 · GFAP MCP-1 · IL-6, IL-7, IL-8, IL-15, IL-16, MDC, MIP-1β Leptin sIR Biomarkers of target engagement were assessed along with pharmacokinetics in CSF and plasma. See, e.g., Figures 13-15 and Table 4. As shown in the figures and tables, total tau and phosphorylated tau, both of which are elevated in AD, were significantly reduced in patients treated with AMX0035 compared to the placebo group (see, e.g., Figure 13 and Table 4). Treatment reduced CSF tau and p-tau181 by approximately 10% over the 24-week study. Patients treated with AMX0035 had significantly lower Aβ 1-42 and Aβ 1-40AMX0035 treated patients showed a significant increase in the ratio of t-tau and p-tau in CSF to placebo in the PB / TURSO group over 24 weeks (third graph in FIG. 14). 8-OHdG was significantly increased in AMX0035 treated patients (FIG. 15 and Table 4). Overall, the following was found: changes in core AD biomarkers were found to be significant, with reductions in CSF t-tau and p-tau and Aβ in the PB / TURSO group over 24 weeks versus the placebo group. 1-42 / Aβ 1-40 Fatty acid binding protein 3 (FABP3) was significantly decreased in the PB / TURSO group compared to the placebo group. Neurogranin was also significantly decreased in the PB / TURSO group compared to the placebo group. In addition, inflammatory markers, including YKL-40 and IL-15, were decreased in the PB / TURSO group compared to the placebo group.
[0390] [Table 4]
[0391] In addition to CSF and plasma biomarker analyses, exploratory evaluations of MRI data were performed. These analyses included analysis of resting-state functional MRI (rsfMRI) of gray and white matter. In particular, the following analyses were performed: Total brain volume Ventricular volume · Average cortical thickness Total white matter volume White matter lesion volume Posterior cingulate default mode network (DMN) connectivity Biomarkers were further analyzed in an exploratory fashion to assess collinear changes and pathway enrichment.
[0392] Overall, a total of 95 participants were randomized (PB / TURSO, n=51; placebo, n=44). The mean age of participants was 70.7 years; approximately 80% of participants were receiving concomitant acetylcholinesterase inhibitors and 42% were receiving concomitant memantine. Mean (SD) cognitive assessment scores indicated significantly higher baseline levels of cognitive impairment among participants randomized to PB / TURSO versus placebo (ADAS-Cog14 total score, MOCA, and MADCOMS, all P<0.01). The PB / TURSO group had a numerically higher proportion of apolipoprotein E ε4 carriers compared with the placebo group (77.1% vs. 61.4%, respectively; P=0.12). Baseline values of all other measures were similar between groups. Treatment-emergent adverse events (TEAEs) were reported by 34 (67%) participants in the PB / TURSO group and 26 (59%) participants in the placebo group, with gastrointestinal events (mainly diarrhea) accounting for the greatest proportion of TEAEs in the PB / TURSO group (39% vs. 14%). Ten of 51 participants (20%) in the PB / TURSO group and two of 44 participants (5%) in the placebo group discontinued the study. No significant differences between groups were observed for primary and secondary endpoints. Significant changes in core AD biomarkers were found, with reductions in CSF t-tau (p=0.0005) and p-tau (p=0.0008) and Aβ levels over 24 weeks in the PB / TURSO group versus the placebo group. 1-42 / Aβ 1-40 (p=0.0017) increased.
[0393] 8.4 Missing Data Subjects who dropped out had all available post-baseline data included in the analysis. In addition, some subjects may have had missing data due to visits completed remotely during the COVID-19 pandemic. The repeated measures mixed model is based on the missing at random (MAR) assumption and is designed to handle right-censored data for subjects who dropped out of the study. An additional analysis was performed as a sensitivity analysis of this study and was a pattern mixed model (PMM) method based on z-scores. PMM uses the MAR assumption and this sensitivity analysis uses the subject's last observation and the z-score of that observation as the imputed value, assuming a similar progression pattern for subjects in the same treatment group who completed each visit. At each subsequent visit, values were imputed to have the same z-score for the treatment group mean and standard deviation for the subjects for those who completed at that visit. The initial analysis is intended to estimate the treatment effect in the future if all subjects continued treatment. After imputation for the sensitivity analysis, the estimated change from baseline between the active and placebo groups was evaluated by fitting an analysis of covariance (ANCOVA) model.
[0394] 8.5 Stopping rules The Study PI will review the safety data throughout the study and may stop the study for safety. Any death will lead to an expedited review by the Medical Monitor and Overall Study PI. Two or more of the same SAEs deemed by the site investigator to be possibly or definitely related to the study drug will lead to an expedited review by the Medical Monitor and Study PI.
[0395] References 1. Zhou, Wenbo, et al. "Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease." Journal of Biological Chemistry 286.17 (2011): 14941-14951. 2. Wright, Jerry M., et al. "Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins." Physiological Genomics 16.2 (2004): 204-211. 3. Cuadrado-Tejedor, Mar, et al. "Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer s disease-like phenotype of a commonly used mouse model." Current Pharmaceutical Design 19.28 (2013): 5076-5084. 4. Ricobaraza, Ana, et al. "Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease." Hippocampus 22.5 (2012): 1040-1050. 5. Wiley, Jesse C., Christina Pettan‐Brewer, and Warren C. Ladiges. "Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice." Aging Cell 10.3 (2011): 418-428. 6. Ricobaraza, Ana, et al. "Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model." Neuropsychopharmacology 34.7 (2009): 1721. 7. Ryu, Hoon, et al. "Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice." Journal of Neurochemistry 93.5 (2005): 1087-1098. 8. Gardian, Gabriella, et al. "Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease." Journal of Biological Chemistry 280.1 (2005): 556-563. 9. Corbett, Grant T., Avik Roy, and Kalipada Pahan. "Sodium phenylbutyrate enhances Astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB)." Journal of Biological Chemistry 288.12 (2013): 8299-8312. 10. Rodrigues, Cecilia MP, et al. "Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria." Biochemistry 42.10 (2003): 3070-3080. 11. Lo, Adrian C., et al. "Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP / PS1 mice." Neurobiology of disease 50 (2013): 21-29. 12. Dionisio, Pedro A., et al. "Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP / PS1 mice after disease onset." Neurobiology of aging 36.1 (2015): 228-240. 13. Nunes, Ana F., et al. "TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP / PS1 mice." Molecular neurobiology 45.3 (2012): 440-454. 14. Rodrigues, Cecilia MP, et al. "Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats." Proceedings of the National Academy of Sciences 100.10 (2003): 6087-6092. 15. Castro-Caldas, M., et al. "Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease." Molecular neurobiology 46.2 (2012): 475-486. 16. Zhang, Yong-Jie, et al. "Aggregation-prone c9FTD / ALS poly (GA) RAN-translated proteins cause neurotoxicity by inducing ER stress." Acta Neuropathologica 128.4 (2014): 505-524. 17. Cudkowicz, Merit E., et al. "Phase 2 study of sodium phenylbutyrate in ALS." Amyotrophic Lateral Sclerosis 10.2 (2009): 99-106. 18. Borovecki, F., et al. "Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease." Proceedings of the National Academy of Sciences of the United States of America 102.31 (2005): 11023-11028. 19. Hogarth, Penelope, Luca Lovrecic, and Dimitri Krainc. "Sodium phenylbutyrate in Huntington's disease: A dose‐finding study." Movement Disorders 22.13 (2007): 1962-1964. 20. Elia, A., et al. "Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis." European Journal of Neurology 23.1 (2016): 45-52. 21. Min, Ju-Hong, et al. "Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial." Journal of Korean Medical Science 27.2 (2012): 200-206. 22. Buphenyl Package Insert URL: http: / / www.horizonpharma.com / wp-content / uploads / 2016 / 04 / BUPHENYL_PI_April_2016.pdf 23. Gilbert, Jill, et al. "A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies." Clinical Cancer Research 7.8 (2001): 2292-2300. 24. Gore, Steven D., et al. "Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia." Clinical Cancer Research 8.4 (2002): 963-970. 25. Wey, Hsiao-Ying, et al. "Insights into neuroepigenetics through human histone deacetylase PET imaging." Science Translational Medicine 8.351 (2016): 351ra106-351ra106. 26. Zetterberg, Henrik, et al. "Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression." JAMA Neurology 73.1 (2016): 60-67. 27. Constantinescu, Radu, et al. "Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies." Journal of Neuroimmunology 306 (2017): 25-30. 28. van Eijk, Jeroen JJ, et al. "CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease." Journal of Alzheimer's Disease 21.2 (2010): 569-576. 29. Steinacker, Petra, et al. "Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease." Scientific Reports 6 (2016). 30. Jabbari, Edwin, Henrik Zetterberg, and Huw R. Morris. "Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers." J Neurol Neurosurg Psychiatry (2017): jnnp-2017. 31. Craig-Schapiro, Rebecaa, et al. “YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease.” Biological psychiatry 68.10 (2010): 903-912. 32. Comabella, Manuel, et al. “Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.” Brain 133.4 (2010): 1082-1093. 33. Bonneh-Barkay, Dafna, et al. “YKL-40 expression in traumatic brain injury: an initial analysis.” Journal of Neurotrauma 27.7 (2010): 1215-1223. 34. Janelidze, Shorena, et al. “Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease.” Annals of Clinical and Translational Neurology 3.1 (2016): 12-20. 35. Melah, Kelsey E., et al. “Cerebrospinal fluid markers of Alzheimer’s disease pathology and microglia activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer’s disease.” Journal of Alzheimer’s Disease 50.3 (2016): 873-886. 36. Hayashi, Yasunori. "Long-term potentiation: two pathways meet at neurogranin." The EMBO Journal 28.19 (2009): 2859-2860. 37. Zhong, Ling, et al. "Increased prefrontal cortex neurogranin enhances plasticity and extinction learning." Journal of Neuroscience 35.19 (2015): 7503-7508. 38. Portelius, Erik, et al. "Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease." Brain 138.11 (2015): 3373-3385. 39. Posner K, (et.al), Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s Pediatric Suicidal Risk Analysis of Antidepressants, Am J Psychiatry, 2007, 164:1035-1043. 40. September 2010 US FDA Draft Guidance for Industry Suicidality: Prospective Assessment of Occurrence in Clinical Trials 41. TUDCA in new onset diabetes. Clinicaltrials.gov identifier NCT02218619. 42. TUDCA and PB: effect on ER stress and metabolism. Clinicaltrial.gov identifier. NCT00771901. 43. Castilla-Rilo, J., Lopez-Arrieta, J., Bermejo-Pareja, F., Ruiz, M., Sanchez-Sanchez, F., & Trincado, R. (2007). Instrumental activities of daily living in the screening of dementia in population studies: a systematic review and meta-analysis. Int J Geriatr Psychiatry, 22(9), 829-836. doi:10.1002 / gps.1747 44. Clark, C. M., & Ewbank, D. C. (1996). Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord, 10(1), 31-39. 45. Mitchell, J. C., Dick, M. B., Wood, A. E., Tapp, A. M., & Ziegler, R. (2015). The utility of the Dementia Severity Rating Scale in differentiating mild cognitive impairment and Alzheimer disease from controls. Alzheimer Dis Assoc Disord, 29(3), 222-228. doi:10.1097 / WAD.0000000000000057 46. Moelter, S. T., Glenn, M. A., Xie, S. X., Chittams, J., Clark, C. M., Watson, M., & Arnold, S. E. (2015). The Dementia Severity Rating Scale predicts clinical dementia rating sum of boxes scores. Alzheimer Dis Assoc Disord, 29(2), 158-160. doi:10.1097 / WAD.0000000000000031 47. Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Jr., Chance, J. M., & Filos, S. (1982). Measurement of functional activities in older adults in the community. J Gerontol, 37(3), 323-329. 48. Rikkert, M. G., Tona, K. D., Janssen, L., Burns, A., Lobo, A., Robert, P., . . . Waldemar, G. (2011). Validity, reliability, and feasibility of clinical staging scales in dementia: a systematic review. Am J Alzheimers Dis Other Demen, 26(5), 357-365. doi:10.1177 / 1533317511418954 49. Teng, E., Becker, BW, Woo, E., Knopman, DS, Cummings, JL, & Lu, PH (2010). Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from mild very Alzheimer disease. Alzheimer Dis Assoc Disord, 24(4), 348-353. doi:10.1097 / WAD.0b013e3181e2fc84 50. Xie, SX, Ewbank, DC, Chittams, J., Karlawish, JH, Arnold, SE, & Clark, CM (2009). Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale. Alzheimer Dis Assoc Disord, 23(3), 268-274. doi:10.1097 / WAD.0b013e318194a324
[0396] Other Aspects Although the present invention has been described in conjunction with its detailed description, it should be understood that the above description is illustrative and not limiting of the scope of the invention, which is defined by the claims. The following are numbered embodiments that further illustrate, but do not limit, the scope of the invention.
[0397] 1. A method for treating at least one symptom of AD in a human subject, the method comprising administering to the human subject about 10 mg / kg to about 50 mg / kg of body weight of a bile acid or a pharma- ceutically acceptable salt thereof, and about 10 mg / kg to about 400 mg / kg of body weight of a phenylbutyrate compound, wherein the human subject (a) carrying one or more copies of the APOE ε4 allele; (b) a total tau cerebrospinal fluid (CSF) level of about 300 pg / mL or greater; or (c) CSF levels of phosphorylated tau are greater than or equal to approximately 70 pg / mL; thereby treating at least one symptom of AD in said human subject. method. 2. The method of claim 1, wherein the method includes a step of determining whether the human subject has at least one of the characteristics (a) to (c) prior to administration. 3. The method of embodiment 1, wherein the human subject has a total tau cerebrospinal fluid (CSF) level of about 300 pg / mL or greater. 4. The method of embodiment 1, wherein the human subject has a CSF level of phosphorylated tau of about 70 pg / mL or greater. 5. A method of slowing AD disease progression in a human subject having one or more symptoms of AD, the method comprising: 1. A method comprising administering to the subject about 10 mg / kg to about 50 mg / kg of body weight of a bile acid or a pharma- ceutically acceptable salt thereof, and about 10 mg / kg to about 400 mg / kg of body weight of a phenylbutyrate compound, thereby slowing progression of AD disease in the human subject. 6. A method for increasing survival time of a human subject having one or more symptoms of AD, the method comprising: 16. A method comprising administering to the subject about 10 mg / kg to about 50 mg / kg of body weight of a bile acid or a pharma- ceutically acceptable salt thereof, and about 10 mg / kg to about 400 mg / kg of body weight of a phenylbutyrate compound, thereby increasing survival time of the human subject. 7. In a human subject having one or more symptoms of AD, the present inventio...
Claims
1. 1. A method of treating at least one symptom of progressive supranuclear palsy (PSP), the method comprising administering to a subject a pharma- ceutical effective amount of a combination of TURSO and sodium phenylbutyrate.
2. 1. A method of treating at least one symptom of Alzheimer's disease (AD) in a human subject, the method comprising administering to the human subject a pharma- ceutical effective amount of a combination of TURSO and sodium phenylbutyrate; The human subject (a) carrying one or more copies of the APOE ε4 allele; (b) a total tau cerebrospinal fluid (CSF) level of about 300 pg / mL or greater; or (c) a CSF level of phosphorylated tau is greater than or equal to about 70 pg / mL; method.
3. The method of claim 2, wherein the method comprises, prior to administration, a step of determining whether the human subject has at least one of characteristics (a) to (c).
4. 3. The method of claim 2, wherein the human subject has a total CSF level of tau of about 300 pg / mL or greater.
5. 3. The method of claim 2, wherein the CSF level of phosphorylated tau in the human subject is greater than or equal to about 70 pg / mL.
6. 1. A method of slowing the progression of Alzheimer's disease (AD) in a human subject having one or more symptoms of AD, the method comprising administering to the subject a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
7. 1. A method of increasing survival time of a human subject having one or more symptoms of Alzheimer's disease, said method comprising administering to said subject a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
8. In a human subject having one or more symptoms of Alzheimer's disease, the present invention provides a method for reducing CSF total tau levels, reducing CSF phosphorylated tau levels, and reducing CSF Aβ levels. 1-42 / Aβ 1-40 16. A method for increasing CSF 8-OHDG levels or increasing CSF 8-OHDG levels, said method comprising administering to said subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate.
9. 9. The method of claim 8, wherein the phosphorylated tau is phosphorylated tau 181.
10. 1. A method for treating and / or preventing a tauopathy in a human subject, the method comprising administering to the human subject a pharma- ceutical effective amount of a combination of TURSO and sodium phenylbutyrate.
11. 11. The method of claim 10, wherein the subject has a baseline CSF total tau level of about 300 pg / mL or greater.
12. 11. The method of claim 10, wherein the tauopathy is progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD-TAU), corticobasal degeneration, Pick's disease, argyrophilic grain disease, postencephalitic parkinsonism, chronic traumatic encephalopathy, primary age-related tauopathy, stroke, traumatic brain injury, or Alzheimer's disease.
13. 11. The method of claim 10, wherein the tauopathy is progressive supranuclear palsy.
14. 1. A method for treating and / or preventing a condition associated with amyloidosis in a human subject, said method comprising administering to said human subject a pharma- ceutical effective amount of a combination of TURSO and sodium phenylbutyrate.
15. A method comprising administering to a human subject at risk of developing Alzheimer's disease a pharma- tically effective amount of a combination of TURSO and sodium phenylbutyrate.
16. 16. The method of claim 15, wherein the subject is determined to be at risk for developing Alzheimer's disease by assessing the level of a biomarker in a biological sample obtained from the subject.
17. 17. The method of claim 16, wherein the biomarker is total tau or phosphorylated tau.
18. 17. The method of claim 16, wherein the biological sample is CSF.
19. The method of claim 15, wherein the subject carries one or more copies of the APOE ε4 allele.
20. 16. The method of claim 15, wherein the subject carries one or more mutations in at least one gene selected from the group consisting of APP, PSEN1, and PSEN2.
21. 1. A method of reducing CSF FABP3, neurogranin, YKL-40 or IL-15 levels in a human subject having one or more symptoms of Alzheimer's disease, the method comprising administering to the subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate.
22. 1. A method for treating at least one symptom of a neurodegenerative disease characterized by elevated levels of total tau or phosphorylated tau, the method comprising administering to a subject a pharma- ceutical effective amount of a combination of TURSO and sodium phenylbutyrate.
23. 1. A method for treating at least one symptom of a neurodegenerative disease characterized by elevated levels of YKL-40, said method comprising administering to said subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate.
24. 24. The method of claim 22 or 23, wherein the neurodegenerative disease is Alzheimer's disease.
25. 24. The method of claim 22 or 23, wherein the neurodegenerative disease is PSP.
26. The neurodegenerative diseases include cerebral amyloid angiopathy, corticobasal degeneration, Creutzfeldt-Jakob disease, dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17, frontotemporal lobar degeneration (FTLD-TAU), corticobasal degeneration, Pick's disease, argyrophilic grain disease, postencephalitic parkinsonism, chronic traumatic encephalopathy, primary age-related tauopathy, stroke, traumatic brain injury, and the like.
24. The method of claim 22 or 23, wherein the condition is selected from the group consisting of cerebral atrophy, Gerstmann-Straussler-Scheinker disease, Hallervorden-Spatz disease, inclusion body myositis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C, non-Guam motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, subacute sclerosing panencephalitis, neurofibrillary tangle-isolated dementia, multi-infarct dementia, and ischemic stroke.
27. 1. A method of decreasing CSF YKL-40 levels, decreasing Ptpn1 levels, or increasing CSF 33 kDa tau / 55 kDa tau in a human subject having one or more symptoms of PSP, the method comprising administering to the subject a pharmacologic effective amount of a combination of TURSO and sodium phenylbutyrate.
28. 28. The method of any one of claims 1-27, wherein the TURSO and the sodium phenylbutyrate are administered once daily or twice daily.
29. 29. The method of any one of claims 1-28, wherein TURSO is administered to the subject at a dose of about 5 mg / kg to about 100 mg / kg.
30. 30. The method of any one of claims 1-29, wherein sodium phenylbutyrate is administered to the subject at a dose of about 10 mg / kg to about 400 mg / kg.
31. 31. The method of any one of claims 1-30, wherein the TURSO is administered from about 0.5 to about 5 g per day.
32. 32. The method of any one of claims 1-31, wherein the sodium phenylbutyrate is administered from about 0.5 g to about 10 g per day.
33. 33. The method of any one of claims 1-32, comprising administering to the subject 1 g TURSO and 3 g sodium phenylbutyrate once daily or twice daily.
34. 34. The method of any one of claims 1-33, comprising administering to the subject 1 gram of TURSO once per day and 3 grams of sodium phenylbutyrate once per day for about 14 days or more, followed by administering to the subject about 1 gram of TURSO twice per day and 3 grams of sodium phenylbutyrate twice per day.
35. 35. The method of any one of claims 1 to 34, wherein the TURSO and the sodium phenylbutyrate are administered orally.
36. 36. The method of any one of claims 1 to 35, wherein the TURSO and the sodium phenylbutyrate are formulated as a single powder.
37. The method of any one of claims 1 to 36, further comprising administering to the subject one or more additional therapeutic agents.
38. 38. The method of claim 37, wherein the therapeutic agent is tacrine, rivastigmine, galantamine, donepezil or memantine.
39. 39. The method of any one of claims 1 to 38, further comprising administering to the human subject a plurality of foods comprising solid or liquid foods.
40. The method of any one of claims 1 to 39, wherein the human subject is about 18 years of age or older.
